2024

GLOBAL QUALITY P4P (FOR PCPs)

Pay for Performance (P4P) Program Technical Guide



Contact: QualityPrograms@iehp.org

Published: April 5, 2024

| Program Overview | 1 |
|--|----|
| Program Terms and Conditions | 4 |
| Performance Measures | 6 |
| Scoring Methodology | 8 |
| Payment Methodology | 9 |
| Reporting Timeline | 11 |
| Quality Incentive Payout Timeline | 12 |
| 2024 PCP Global Quality P4P Program Measures- Appendix 1 | 13 |
| Core Measures Overview- Appendix 2 | |
| Asthma Medication Ratio (AMR) | 16 |
| Colorectal Cancer Screening (COL) | 18 |
| Controlling High Blood Pressure (CBP) | 22 |
| Diabetes Care- Blood Pressure Control <140/90 (BPD) | 32 |
| Glycemic Status Assessment for Patients with Diabetes (GSD) | 34 |
| Diabetes Care- Kidney Health Evaluation (KED) | 36 |
| Adult Influenza Vaccine | 41 |
| Adult Zoster Vaccine | 43 |
| Adult Pneumococcal Vaccine | 44 |
| Adult Td/Tdap Vaccine | 45 |
| Post Discharge Follow-Up | 46 |
| Statin Therapy Received for Patients with Cardiovascular Disease (SPC) | 55 |
| Statin Therapy Received for Patients with Diabetes (SPD) | 56 |
| Substance Use Assessment in Primary Care | 57 |
| Antidepressant Medication Management (AMM) | |
| Screening for Clinical Depression in Primary Care | 61 |
| Social Determinants of Health Screening Rate | |
| Social Determinants of Health Identification Rate | |
| Social Need Screening and Intervention (SNS-E) | |
| Breast Cancer Screening (BCS) | |
| Cervical Cancer Screening (CCS) | |
| Chlamydia Screening in Women (CHL) | |
| Child and Adolescent Well-Care Visits (WCV) | 85 |



TABLE OF CONTENTS (CONTINUED)

| Childhood Immunizations (CIS) – Combo 10 | 87 |
|--|-----|
| Lead Screening in Children (LSC) | 90 |
| Developmental Screening | 91 |
| Immunizations for Adolescents (IMA) – Combo 2 | 92 |
| Substance Use Assessment in Primary Care for Adolescents | 94 |
| Well-Child Visits in the First 15 Months of Life (W30) | 95 |
| Well-Child Visits in the First 30 Months of Life (W30) | 96 |
| Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents (WCC) | 98 |
| Initial Health Appointment (IHA) | 100 |
| After Hours Availability On-Call Physician Access | 106 |
| After Hours Availability Emergency Calls | 106 |
| Appointment Availability- Urgent Visits | 107 |
| Appointment Availability- Routine Visits | 107 |
| Access to Care Needed Right Away | 108 |
| Coordination of Care | 108 |
| Medical Assistance with Smoking and Tobacco Use Cessation (MSC)- Advising Smokers to Quit | 109 |
| Rating of Personal Doctor | |
| Potentially Avoidable Emergency Department (ED) Visits | |
| 2024 PCP Global Quality P4P Process Measures - Appendix 3 | 112 |
| Process Measure Overview - Appendix 4 | |
| Manifest MedEx (MX) Connectivity | 113 |
| Provider Diversity Equity Inclusion Survey | 115 |
| 2024 PCP Global Quality Bonus Bundles - Appendix 5 | 116 |
| 2024 PCP Global Quality P4P Quality Bonus Services - Appendix 6 | 119 |
| Quality Bonus Services Overview - Appendix 7 | 119 |
| 2024 PCP Global Quality P4P Penalty Measures - Appendix 8 | 127 |
| Penalty Measures Overview – Appendix 9 | |
| PCP Encounter Data Rate | 128 |
| Customer Service Grievance | 128 |
| Historical Data Form - Appendix 10 | 130 |
| Member Satisfaction Survey - Appendix 11 | 131 |



This program guide provides an overview of the 2024 Global Quality Pay for Performance (GQ P4P) Program for Primary Care Providers (PCPs). In this ninth year of the program, IEHP has made enhancements based on feedback from Providers in an effort to continually improve program effectiveness. The IEHP GQ P4P Program for PCPs is designed to reward PCPs for high performance and year-over-year improvement in key quality performance measures. This program guide is designed as an easy reference for Physicians and their staff to understand the GQ P4P Program.

This year's GQ P4P Program continues to provide financial rewards to PCPs for improving health care quality across multiple domains and measures. The 2024 Global Quality P4P Program includes core measures, process measures and penalty "risk" measures.

IEHP also encourages all PCPs to attend IEHP Provider P4P meetings that are held throughout the year to support your efforts to maximize earnings in this program.

If you would like more information about IEHP's GQ P4P Program or best practices to help improve quality scores and outcomes, visit our Secure Provider Portal at *www.iehp.org*, email the Quality Team at *QualityPrograms@iehp.org* or call the IEHP Provider Relations Team at (909) 890-2054.

✓ What's New?

Seven measures were Added

Core Measures

- Adult Pneumococcal Vaccine
- Adult Td/Tdap Vaccine
- Adult Zoster Vaccine
- Lead Screening for Children
- Social Need Screening and Intervention

Process Measures

• Health Equity: Provider Diversity Equity Inclusion Survey

Penalty Measures

• Customer Service Grievance

Two measures were Revised

- Manifest MedEx (MX) Connectivity
- Screening for Clinical Depression in Primary Care

Two measures were Retired

- Timely Response to Provider Directory
- Provider Grievance Response Rate

Eligibility and Participation

To be eligible for incentive payments in the 2024 GQ P4P Program, PCPs must meet the following criteria:

- Have at least 200 Medi-Cal Members (including Covered California) assigned as of July 2024.
- Have at least 20 Members in the denominator as of December 2024 for each quality measure to qualify for scoring.
- Have at least three quality measures that meet minimum denominator requirements in order for a global quality score to be calculated.
- Provider must be connected to CAIR2 (must enter immunizations into the registry and use to look up prior immunizations given to assigned patients) by July 1, 2024.

PCP enrollment into the GQ P4P program is automatic once the four criteria above have been met.

Minimum Data Requirements

Encounter Data

Encounter data is foundational to performance measurement and is essential to succeed in the GQ P4P Program. Complete, timely and accurate encounter data should be submitted through normal reporting channels for all services rendered to IEHP Members. Please use the appropriate codes listed in <u>Appendix 2</u> to meet measure requirements.

Lab Results

Data from lab results data is also foundational to Program performance measurement. Providers should ensure they submit complete lab results data for services rendered to IEHP Members. Work with your IPA to ensure you are using the appropriate lab vendors for IEHP Members, and submitting lab results data to IEHP.

Lab results that are performed in the office (e.g., point of care HbA1c testing, urine tests, etc.) should be coded and submitted through your encounter data.

Immunizations

To maximize performance in immunization-based measures, **IEHP requires all Providers to report all immunizations via the California Immunization Registry (CAIR2)**. For more information on how to register for CAIR2, please visit http://cairweb.org/. IEHP works closely with CAIR to ensure data sharing to support the GQ P4P program.

✓ Provider P4P Research Inquiries

All Provider research inquiries, related to the data collected to measure P4P metrics, must be submitted in an excel worksheet. The following information must be included in the research inquiry to support the description of the dispute: Provider Name, Provider NPI, Member Name, Member ID, Measure Name, DOS, Procedure Code/ICD-10 code, and any other information that would be helpful to research the inquiry.

Program Terms and Conditions

- Good Standing: A Provider currently contracted with Plan for the delivery of services, not pursuing any litigation or arbitration or has a pending claim pursuant to the California Government Tort Claim Act (Cal. Gov. Code Sections 810, et seq.) filed against Plan at the time of program application or at the time additional funds may be payable, and has demonstrated the intent, in Plan's sole determination, to continue to work together with Plan on addressing community and Member issues. Additionally, at the direction of the CEO or their designee, Plan may determine that a Provider is not in good standing based on relevant quality, payment, or other business concerns.
- Participation in IEHP's GQ P4P Program, as well as acceptance of incentive payments, does not in any way modify or supersede any terms or conditions of any agreement between IEHP and Providers or IPAs, whether that agreement is entered into prior to or subsequent to the date of this communication.
- There is no guarantee of future funding for, or payment under, any IEHP Provider incentive program. The IEHP GQ P4P Program and/or its terms and conditions may be modified or terminated at any time, with or without notice, at IEHP's sole discretion.
- Criteria for calculating incentive payments are subject to change at any time, with or without notice, at IEHP's sole discretion.
- In consideration of IEHP's offering of the IEHP GQ P4P Program, participants agree to fully and forever release and discharge IEHP from any and all claims, demands, causes of action, and suits, of any nature, pertaining to or arising from the offering by IEHP of the IEHP GQ P4P Program.
- The determination of IEHP regarding performance scoring and payments under the IEHP GQ P4P Program is final.
- As a condition of receiving payment under the IEHP GQ P4P Program, Providers and IPAs
 must be active and contracted with IEHP and have active assigned Members at the time
 of payment.
- Providers will not charge IEHP for medical records for HEDIS, Risk Adjustment, and other health plan operational activities.

▼ Financial Overview

Providers are eligible to receive financial rewards for performance excellence and for performance improvement. Financial rewards are based on a tiered system, providing increasing financial rewards as Providers reach each level of higher performance. The 2024 GQ P4P Program incentive pool is \$148 million for PCPs. Incentive dollars for the 2024 performance period will be distributed via a monthly Per Member Per Month (PMPM) Quality Payment beginning in July 2025 and continuing through June 2026. Based on PCP performance, payment methodologies may be adjusted to ensure that the 2024 program year costs do not exceed this \$148 million pool for the PCP Program.



CORE MEASURES

✓ Performance Measures

<u>Appendix 1</u> provides a list of the 42 measures in the 2024 GQ P4P Core Program and includes thresholds and benchmarks associated with respective Tier Goals. These measures are categorized into four domains: *Access, Clinical Quality, Behavioral Health Integration, Patient Experience*.

Most measures included in the *Clinical Quality Domain* primarily use standard Healthcare Effectiveness Data and Information Set (HEDIS*) process and outcomes measures that are based on the specifications published by the National Committee for Quality Assurance (NCQA). Non-HEDIS* measures that are included in the program come from the California Department of Health Care Services (DHCS) Medi-Cal Managed Care Quality Program and the Pharmacy Quality Alliance (PQA).

Clinical Quality Domain Measures:

- Asthma Medication Ratio
- Breast Cancer Screening
- Cervical Cancer Screening
- Child and Adolescent Well-Care Visits
- Childhood Immunization Combo 10
- Chlamydia Screening in Women
- Colorectal Cancer Screening
- Controlling High Blood Pressure
- Diabetes Care Blood Pressure Control <140/90
- Glycemic Status Assessment for Patients with Diabetes (GSD)
- Diabetes Care Kidney Health Evaluation
- Developmental Screening
- Lead Screening for Children
- Adult Influenza Vaccine
- Adult Pneumococcal Vaccine
- Adult Td/Tdap Vaccine
- Adult Zoster Vaccine
- Immunizations for Adolescents Combo 2
- Initial Health Appointment
- Post Discharge Follow-Up
- Statin Therapy Received in Patients with Cardiovascular Disease and Diabetes
- Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
 - o Counseling for Physical Activity
 - o Counseling for Nutrition
 - o BMI Percentile

- Well-Child Visits in the First 15 Months of Life
- Well-Child Visits in the First 30 Months of Life

IEHP's HEDIS® measurement year 2024 data set and Managed Care Accountability Set (MCAS) will be used to evaluate Providers' year-end performance. These measure sets undergo an independent audit review prior to rate finalization.

The Initial Health Appointment (IHA) measure follows IEHP's IHA internal compliance monitoring methodology and is not a HEDIS® measure.

The Post Discharge Follow-Up measure is an IEHP-defined measure developed to support transitions of care needs of IEHP Members.

Access Domain Measures:

- After Hours Availability On-Call Physician Access
- After Hours Availability Emergency Calls
- Appointment Availability Urgent
- Appointment Availability Routine
- Potentially Avoidable Emergency Department (ED) Visits

The *Access* measures are based on the Department of Managed Health Care (DMHC) and NCQA requirements for monitoring access to care across the network. See <u>Appendix 2</u> for measure details.

Behavioral Health Integration Domain Measures:

Measures in this domain come from various measure stewards including: the National Quality Forum (NQF), HEDIS*, and the Department of Health Care Services (DHCS).

- Antidepressant Medication Management
- Screening for Clinical Depression in Primary Care
- Substance Use Assessment in Primary Care for Adolescents
- Substance Use Assessment in Primary Care
- Social Determinants of Health Screening
- Social Determinants of Health Identification Rate
- Social Need Screening and Intervention

Patient Experience Domain Measures:

Patient Experience Domain measures include Member Satisfaction Survey questions from the Consumer Assessment of Healthcare Providers and Systems (CAHPS*) survey that is published by the Agency for Healthcare Research and Quality (AHRQ). IEHP conducts a Member Satisfaction Survey that is a modified CAHPS survey and is the sole data source used for this measure domain. The IEHP Member Satisfaction Survey is conducted between June and December of each year. Surveys received from the 2024 Member Satisfaction Survey will be used to calculate the Patient Experience Domain measures. Below are the four areas included in the Patient Experience Domain for the 2024 program.

- Access to Care Needed Right Away
- Coordination of Care
- Medical Assistance with Smoking Cessation Advising Smokers to Quit
- Rating of Personal Doctor

Scoring Methodology

Payments within the core program will be awarded to PCPs based on individual performance in reaching established Quality Goals (e.g., Tier Goals for each measure).

In the *Clinical Quality Domain*, HEDIS® measure results are based on each measure's total eligible population assigned to the PCP. The eligible population is defined as the set of Members who meet the denominator criteria specified in each measure by NCQA. Members in the eligible population are attributed to the assigned PCP on each measure's anchor date, as defined within each measure. Members contribute to a PCP's measure denominator if continuous enrollment criteria are met at the health plan level. For each measure, the measure score reflects the proportion of the eligible population that complies with the numerator criteria. For measures that are based on the HEDIS methodology, IEHP will adhere to the most current HEDIS technical specifications (Volume 2) for determining both numerators and denominators.

In the Clinical Quality Domain, non-HEDIS measures include the Initial Health Appointment and the Post Discharge Follow-Up measure. Each measure was designed by IEHP using validated coding and technical specifications. The Initial Health Appointment Measure is based on DHCS requirements and includes new health plan Members who are assigned to the PCP during the measurement year and who remain enrolled with IEHP and the PCP through the end of the 120 day post-enrollment period. The Post Discharge Follow-Up measure is described in detail in Appendix 2.

In the *Access Domain*, PCP telephone handling for appointments and after hours access is assessed via Plan-conducted phone surveys. IEHP follows the DMHC Timely Access Standards Provider Appointment Availability Study methodology to assess PCP adherence to Appointment Availability Standards. IEHP follows the NCQA standards of assessing PCP adherence to After Hours access to care and call handling protocols.

In the *Patient Experience Domain*, monthly Member Satisfaction Survey measures are based on Members who meet eligibility criteria to receive a mailed survey between June and December of the measurement year. Members eligible to receive a Member Satisfaction Survey must have been continuously enrolled with IEHP for at least six months in the measurement year (2024) and must have had an office visit in the prior six months based on encounter data submitted to IEHP. Members who meet the survey eligibility criteria are randomly sampled to receive a survey. Survey measure results are attributed to the Member's assigned PCP based on the most recent encounter that qualified the Member to be eligible for the survey. A Member is eligible to receive only one survey per calendar year.

Payment Methodology

PCP performance for each quality measure will be given a point value (i.e., a Quality Score). Points are assigned based on the Tier Goal achieved (i.e., Tier 1 = one point, Tier 2 = two points, Tier 3 = three points) for each measure.

Providers who have at least three quality measures that meet the minimum denominator size (n = 20) will be considered for payment calculations. An overall weighted average of all eligible Quality Scores will determine the overall GQ Performance Score. Individual measure weights will be assigned as follows:

- Process measures (such as screenings) are given a weight of 1
- Patient experience measures are given a weight of 1.5
- Outcome and intermediate outcome measures (e.g., HbA1c, blood pressure control, and childhood immunizations) are given a weight of 3

Please reference Appendix 1 for a list of individual measure weights for the 2024 GQP4P measure set.

The following formula will be used to calculate the overall **GQ Performance Score**:

GQ Performance Score (i.e. overall weighted average) = Sum (measure tier* measure weight) / Sum of measure weights

GQ P4P Program payments will be awarded according to the following formula:

([Global Quality Performance Score] x [# Medi-Cal Average Member Months] x [GQ P4P Payment Multiplier] / [Total Medi-Cal Member Months]) + Bonus Bundles + Process Measures - Penalty Measures = GQ P4P PMPM Bonus


The GQ P4P payment multiplier will be determined based on Network performance and budget limits. The GQ P4P payment multiplier value displayed in the Interim Reports may not be the final value used in determining final Quality PMPM payment amounts.

PCP PMPM Quality Payment Methodology

From July 2025 – June 2026, PCPs will receive a monthly Quality PMPM payment based on their 2024 GQ P4P performance using the following formula:



PCP payment example: *PCP with monthly average of 2,500 Members (30,000 Member Months) and 2.0 GQ Quality Score*



^{*}Assuming stable membership volume and there is additional incentive for bonus bundles, or process measures, and no PCP penalty to be deducted from the Quality PMPM bonus.

Note: Members with Other Health Coverage will be removed from the measure denominators prior to the final payment calculation.

▼ Reporting Timeline


Below is a table describing the flow of encounter data to IEHP in support of the GQ P4P Program reporting.

| | P4P ENCOUNTER DATA REPORTING TIMELINE: | | | | | | |
|------------------|--|----------------------------------|--------------------|---------------------------|--------------------|--|--|
| Month of Service | Provider Encounters Due to IPA | IPA Encounters Due to IEHP | P4P Data Freeze | Dates of Service Assessed | Rosters Updated | | |
| January 2024 | 2/1/2024 | 2/15/2024 | 2/15/2024 | January 2024 | 3/10/2024 | | |
| January 2024 | 2/1/2024 | 3/1/2024 | 3/1/2024 | January 2024 | 3/25/2024 | | |
| January 2024 | 2/1/2024 | 3/15/2024 | 3/15/2024 | January 2024 | 4/10/2024 | | |
| January 2024 | 2/1/2024 | 4/1/2024 | 4/1/2024 | January 2024 | 4/25/2024 | | |
| January 2024 | 2/1/2024 | 4/15/2024 | 4/15/2024 | January 2024 | 5/10/2024 | | |
| January 2024 | 2/1/2024 | 5/1/2024 | 5/1/2024 | January 2024 | 5/25/2024 | | |
| January 2024 | 2/15/2024 | 5/15/2024 | 5/15/2024 | January 2024 | 6/10/2024 | | |
| February 2024 | 3/1/2024 | 6/1/2024 | 6/1/2024 | January - February 2024 | 6/25/2024 | | |
| February 2024 | 3/15/2024 | 6/15/2024 | 6/15/2024 | January - February 2024 | 7/10/2024 | | |
| March 2024 | 4/1/2024 | 7/1/2025 | 7/1/2025 | January - March 2024 | 7/25/2024 | | |
| March 2024 | 4/15/2024 | 7/15/2024 | 7/15/2024 | January - March 2024 | 8/10/2024 | | |
| April 2024 | 5/1/2024 | 8/1/2024 | 8/1/2024 | January - April 2024 | 8/25/2024 | | |
| April 2024 | 5/15/2024 | 8/15/2024 | 8/15/2024 | January - April 2024 | 9/10/2024 | | |
| May 2024 | 6/1/2024 | 9/1/2024 | 9/1/2024 | January - May 2024 | 9/25/2024 | | |
| May 2024 | 6/15/2024 | 9/15/2024 | 9/15/2024 | January - May 2024 | 10/10/2024 | | |
| June 2024 | 7/1/2024 | 10/1/2024 | 10/1/2024 | January - June 2024 | 10/25/2024 | | |
| June 2024 | 7/15/2024 | 10/15/2024 | 10/15/2024 | January - June 2024 | 11/10/2024 | | |
| July 2024 | 8/1/2024 | 11/1/2024 | 11/1/2024 | January - July 2024 | 11/25/2024 | | |
| July 2024 | 8/15/2024 | 11/15/2024 | 11/15/2024 | January - July 2024 | 12/10/2024 | | |
| August 2024 | 9/1/2024 | 12/1/2024 | 12/1/2024 | January - August 2024 | 12/25/2024 | | |
| August 2024 | 9/15/2024 | 12/15/2024 | 12/15/2024 | January - August 2024 | 1/10/2025 | | |
| September 2024 | 10/1/2024 | 1/1/2025 | 1/1/2025 | January - September 2024 | 1/25/2025 | | |
| September 2024 | 10/15/2024 | 1/15/2025 | 1/15/2025 | January - September 2024 | 2/10/2025 | | |
| October 2024 | 11/1/2024 | 2/1/2025 | 2/1/2025 | January - October 2024 | 2/25/2025 | | |
| October 2024 | 11/15/2024 | 2/15/2025 | 2/15/2025 | January - October 2024 | 3/10/2025 | | |
| November 2024 | 12/1/2024 | 3/1/2025 | 3/1/2025 | January - November 2024 | 3/25/2025 | | |
| November 2024 | 12/15/2024 | 3/15/2025 | 3/15/2025 | January - November 2024 | 4/10/2025 | | |
| December 2024 | 1/1/2025 | 4/1/2025 | 4/1/2025 | January - December 2024 | 4/25/2025 | | |
| December 2024 | 1/15/2025 | 4/15/2025 | 4/15/2025 | January - December 2024 | 5/10/2025 | | |
| December 2024 | 2/1/2025 | 5/1/2025 | 5/1/2025 | January - December 2024 | 5/25/2025 | | |

This timeline depicts the latest reporting dates based on IEHP's policies and procedures. However, Providers and IPAs are encouraged to report their encounter data as soon as possible to IEHP. All encounters received by IEHP are considered when calculating updated reports and rosters including those encounters that are reported earlier than the encounter data due date.

11

✓ Quality Incentive Payout Timeline:Provider Communication Timeline



Getting Help

Please direct questions and/or comments related to this program to the IEHP Provider Relations Team at (909) 890-2054 or IEHP's Quality Department at *QualityPrograms@iehp.org*.



APPENDIX 1: 2024 PCP Global Quality P4P

Program Measures

| 2024 GQ P4P PROGRAM MEASURE LIST: | | | | | | | |
|-----------------------------------|--|----------------------|---|---|---------------------|---------------------|-------------------|
| Domain | Measure Name | Population | Tier 1 | Tier 2 | Tier 3 ¹ | Tier 4 ² | Measure Weight |
| Clinical Quality | Asthma Medication Ratio | Adult | | | 71% | 76% | 3.0 |
| Clinical Quality | Colorectal Cancer Screening | Adult | | | 77% | 82% | 1.0 |
| Clinical Quality | Controlling Blood Pressure | Adult | | | 67% | 72% | 3.0 |
| Clinical Quality | Diabetes Care- Blood Pressure Control <140/90 | Adult | | If baseline is below 50th | 70% | 75% | 3.0 |
| Clinical Quality | Glycemic Status Assessment for Patients with Diabetes (GSD) | Adult | Improvement demonstrated | percentile: 20% reduction | 57% | 60% | 3.0 |
| Clinical Quality | Diabetes Care- Kidney Health Evaluation | Adult | by meeting the following | in non- compliance | 41% | 48% | 1.0 |
| Clinical Quality | Adult Influenza Vaccine | Adult | 2 conditions: 10% reduction | AND must meet the 50th | 18% | 21% | 1.0 |
| Clinical Quality | Adult Pneumococcal Vaccine | Adult | in non- | percentile | 39% | 61% | 1.0 |
| Clinical Quality | Adult Td/Tdap Vaccine | Adult | compliance | If baseline | 47% | 57% | 1.0 |
| Clinical Quality | Adult Zoster Vaccine | Adult | AND Improvement | is at or above 50th | 11% | 15% | 1.0 |
| Clinical Quality | Post Discharge Follow-Up | Adult | of at least 2% | percentile: | 70% | 80% | 1.0 |
| Clinical Quality | Statin Therapy Received for Patients with Cardiovascular Disease and Diabetes ³ | Adult | points | 75% | 79% | 1.0 | |
| Behavioral Health Integration | Substance Use in Primary Care Adolescents | Child | | | | 25% | 1.0 |
| Behavioral Health Integration | Antidepressant Medication Management | Adult and Adolescent | 57% | 66% | 1.0 | | |
| Behavioral Health Integration | Social Determinants of Health Screening ⁴ | Adult and Adolescent | | Monitoring | Only | | NA |
| Behavioral Health Integration | Social Need Screening and Intervention ⁴ | Adult and Adolescent | Monitoring Only | | | NA | |
| Behavioral Health Integration | Social Determinants of Health Identification Rate Adult and Adolescent 10% 15% | | 20% | 25% | 1.0 | | |
| Behavioral Health Integration | Screening for Clinical Depression in Primary Care | Adult and Adolescent | | If baseline is below 50th | 56% | 72% | 1.0 |
| Behavioral Health Integration | Substance Use Assessment in Primary Care | Adult | Improvement demonstrated | percentile: 20% reduction | 17% | 32% | 1.0 |
| Clinical Quality | Breast Cancer Screening | Women | by meeting | in non- | 58% | 63% | 1.0 |
| Clinical Quality | Cervical Cancer Screening | Women | the following | compliance | 62% | 66% | 1.0 |
| Clinical Quality | Chlamydia Screening in Women | Women | 2 conditions: 10% reduction in non- | AND must meet the 50th percentile | 63% | 67% | 1.0 |
| Clinical Quality | Child and Adolescent Well- Care Visits | Child | compliance AND | If baseline is at or | 55% | 61% | 1.0 |
| Clinical Quality | Childhood Immunizations - Combo 10† | Child | Improvement of at least 2% | above 50th percentile: | 38% | 45% | 3.0 |
| Clinical Quality | Developmental Screening | Child | points | Improvement | 39% | 46% | 1.0 |
| Clinical Quality | Immunizations for Adolescents - Combo 2 | Child | | of at least 2% points | 41% | 49% | 3.0 |

| 2024 GQ P4P PROGRAM MEASURE LIST: | | | | | | | |
|-----------------------------------|--|---|---|---|------------------|---------------------|-------------------|
| Domain | Measure Name | Population | Tier 1 | Tier 2 | Tier 3 1 | Tier 4 ² | Measure Weight |
| Clinical Quality | Lead Screening for Children | Child | | | 70% | 79% | 1.0 |
| Clinical Quality | Well-Child Visits First 15 Months of Life | Child | | | 63% | 68% | 1.0 |
| Clinical Quality | Well-Child Visits First 30 Months of Life | Child | | If baseline is below 50th | 71% | 78% | 1.0 |
| Clinical Quality | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents - Counseling for Physical Activity | Child | Improvement demonstrated by meeting the following 2 conditions: 10% reduction | percentile: 20% reduction in non- compliance AND must meet the 50th | 75% | 82% | 1.0 |
| Clinical Quality | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents - Counseling for Nutrition | Child | in non- compliance AND Improvement of at least 2% | percentile If baseline is at or above 50th percentile: | 77% | 83% | 1.0 |
| Clinical Quality | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents - BMI Percentile | ight Assessment and legling for Nutrition and al Activity for Children del Adolescents - BMI points Improvement of at least 2% points | | 85% | 90% | 1.0 | |
| Clinical Quality | Initial Health Appointment | All | | | 65% | 75% | 1.0 |
| Access | After Hours Availability - On- Call Physician Access | All | | | | | |
| Access | After Hours Availability - Life- Threatening Emergency Calls | All | NA | Pass 2 Access | Pass 3 Access | Pass 4 Access | 1.0 |
| Access | Appointment Availability- Urgent | All | | Measures | Measures | Measures | |
| Access | Appointment Availability- Routine | All | | | | | |
| Access | Potentially Avoidable ED Visits | All | ≤8.28% | NA | NA | NA | 1.0 |
| Patient Experience | Member Satisfaction Survey - Access to Care Needed Right Away | All | 82%* | 83%** | 87%*** | NA | 1.5 |
| Patient Experience | Member Satisfaction Survey - Coordination of Care | All | 85%* | 87%** | 89%*** | NA | 1.5 |
| Patient Experience | Member Satisfaction Survey – Medical Assistance with Smoking Cessation Advising Smokers to Quit | All | 73% [*] | 75%** | 80%*** | NA | 1.0 |
| Patient Experience | Member Satisfaction Survey - Rating of Personal Doctor | All | 83%* | 84%** | 87%*** | NA | 1.5 |

^{*} Tier 1 goals set at the 50th percentile as published in the 2023 (MY 2022) NCQA Quality Compass

The goals in Appendix 1 may be adjusted once measurement year (2023) national benchmarks are available (estimated 2024 Quarter 4). The goals are based on a combination of national and network performance and may be adjusted higher or lower based on network trends.

^{**} Tier 2 goals set at the 66th percentile as published in the 2023 (MY 2022) NCQA Quality Compass

^{***} Tier 3 goals set at the 90th percentile as published in the 2023 (MY 2022) NCQA Quality Compass

¹ Tier 3 goals set at the 75th percentile as published in the 2023 (MY 2022) NCQA Quality Compass, Colorectal Cancer Screening set as 75th percentile as published in the 2023 (MY 2022) NCQA Medicare Quality Compass

² Tier 4 goals set at the 90th percentile as published in the 2023 (MY 2022) NCQA Quality Compass, Colorectal Cancer Screening set as 90th percentile as published in the 2023 (MY 2022) NCQA Medicare Quality Compass

³ The Statin Therapy Received for Patients with Cardiovascular Disease and Diabetes measure is a combination of two measures (Statin Therapy Received for Patients with Cardiovascular Disease and Statin Therapy Received for Patients with Diabetes). The denominators and numerators for this combined measure will be calculated to produce one rate for this measure. The minimum denominator requirement for this measure is 10 eligible Members.

⁴ Reporting Only Measure. Not eligible for incentive dollars

[†] Tier 1: If baseline is at or above 50th percentile: Goal is the 50th percentile, Tier 2: If baseline is at or above 50th percentile: Goal is the 50th percentile plus 1%.

| | 2024 50TH PERCENTILE RATES | |
|-------------------|---|----------------------|
| Domain | Measure Name | 50th Percentile Rate |
| Clinical Quality | Asthma Medication Ratio | 66% |
| Clinical Quality | Colorectal Cancer Screening | 70% |
| Clinical Quality | Controlling Blood Pressure | 61% |
| Clinical Quality | Diabetes Care - Blood Pressure Control <140/90 | 64% |
| Clinical Quality | Glycemic Status Assessment for Patients with Diabetes (GSD) | 41% |
| Clinical Quality | Diabetes Care - Kidney Health Evaluation | 34% |
| Clinical Quality | Developmental Screening | 31% |
| Clinical Quality | Flu Vaccine in Adults | 14% |
| Clinical Quality | Adult Pneumococcal Vaccine | 26% |
| Clinical Quality | Adult Td/Tdap Vaccine | 34% |
| Clinical Quality | Adult Zoster Vaccine | 7% |
| Clinical Quality | Post Discharge Follow Up | 59% |
| Clinical Quality | Statin Therapy Received for Patients with Cardiovascular Disease and Diabetes | 73% |
| Behavioral Health | Social Determinants of Health Identification Rate | 15% |
| Behavioral Health | Screening for Clinical Depression in Primary Care | 31% |
| Behavioral Health | Substance Use Assessment in Primary Care | 10% |
| Behavioral Health | Substance Use in Primary Care Adolescents | 10% |
| Behavioral Health | alth Antidepressant Medication Management | |
| Clinical Quality | | |
| Clinical Quality | | |
| Clinical Quality | Chlamydia Screening in Women | 56% |
| Clinical Quality | Child and Adolescent Well-Care Visits | 48% |
| Clinical Quality | Childhood Immunizations - Combo 10 | 31% |
| Clinical Quality | Immunizations for Adolescents - Combo 2 | 34% |
| Clinical Quality | Lead Screening for Children | 63% |
| Clinical Quality | Well-Child Visits First 15 Months of Life | 58% |
| Clinical Quality | Well-Child Visits First 30 Months of Life | 67% |
| Clinical Quality | Weight Assessment and Counseling for Nutrition and Physical Activity | |
| Clinical Quality | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents -Counseling for Nutrition | 71% |
| Clinical Quality | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents -BMI Percentile | 80% |
| Clinical Quality | Initial Health Appointment | 52% |

The 50th percentile rates may be adjusted once measurement year 2023 national benchmarks are available (estimated 2024 Quarter 4). The 50th percentile goals are based on a combination of national and network performance and may be adjusted higher or lower based on network trends.



APPENDIX 2: Core Measures Overview

✓ Population: Adult

Asthma Medication Ratio (AMR)

Methodology: HEDIS®

Measure Description: The percentage of Members who are 5-64 years of age and identified as having persistent asthma, who had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Members who are 5-64 years of age as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) and the year prior to the measurement year (2023) with no more than one month gap in continuous enrollment with IEHP during the measurement year (2024) and no more than one month gap in continuous enrollment in the year prior to the measurement year (2023).

Denominator: Members 5-64 years of age who meet all criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had a medication ratio of 0.50 or greater during the measurement year (2024).

| ASTHMA CONTROLLER MEDICATIONS: | | | | | | |
|--------------------------------|------------------------|--|--|--|--|--|
| Description | Prescription | | | | | |
| Antibody inhibitors | Omalizumab | | | | | |
| Anti-interleukin-4 | Dupilumab | | | | | |
| Anti-interleukin-5 | Benralizumab | | | | | |
| Anti-interleukin-5 | Mepolizumab | | | | | |
| Anti-interleukin-5 | Reslizumab | | | | | |
| Inhaled steroid combinations | Budesonide-formoterol | | | | | |
| Inhaled steroid combinations | Fluticasone-salmeterol | | | | | |
| Inhaled steroid combinations | Fluticasone-vilanterol | | | | | |
| Inhaled steroid combinations | Formoterol-mometasone | | | | | |
| Inhaled corticosteroids | Beclomethasone | | | | | |
| Inhaled corticosteroids | Budesonide | | | | | |
| Inhaled corticosteroids | Ciclesonide | | | | | |
| Inhaled corticosteroids | Flunisolide | | | | | |
| Inhaled corticosteroids | Fluticasone | | | | | |
| Inhaled corticosteroids | Mometasone | | | | | |
| Leukotriene modifiers | Montelukast | | | | | |
| Leukotriene modifiers | Zafirlukast | | | | | |
| Leukotriene modifiers | Zileuton | | | | | |
| Methylxanthines | Theophylline | | | | | |

| ASTHMA RELIEVER MEDICATIONS: | | | | | | |
|---------------------------------------|--------------|--|--|--|--|--|
| Description Prescription | | | | | | |
| Short-acting, inhaled beta-2 agonists | Albuterol | | | | | |
| Short-acting, inhaled beta-2 agonists | Levalbuterol | | | | | |

Colorectal Cancer Screening (COL)

Methodology: HEDIS®

Measure Description: The percentage of Members who are 45-75 years of age who had an appropriate screening for colorectal cancer.

- Eligible population in this measure meets all of the following criteria:
 - 1. Members who are 46-75 years of age as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) and the year prior (2023) with no more than one gap in continuous enrollment with IEHP of up to 45 days during each year of the continuous enrollment period.

Denominator: Members who meet all the criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had one or more screenings for colorectal cancer. Any of the following meet criteria:

- Fecal occult blood test during the measurement year (2024).
- Flexible sigmoidoscopy during the measurement year (2024) or four years prior to the measurement year (2020).
- Colonoscopy during the measurement year (2024) or the nine years prior to the measurement year (2015).
- CT colonography during the measurement year (2024) or the four years prior to the measurement year (2020).
- Stool DNA with FIT test during the measurement year (2024) or two years prior to the measurement year (2022).

| | CODES TO IDENTIFY COLORECTAL CANCER SCREENING: | | | | | |
|--------------------------------|--|-------|--|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Colorectal Cancer Screening | СРТ | 44388 | Colonoscopy through stoma; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) | | | |
| Colorectal Cancer Screening | CPT | 44389 | Colonoscopy Through Stoma; With Biopsy, Single Or Multiple | | | |
| Colorectal Cancer Screening | СРТ | 44390 | Colonoscopy Through Stoma; With Removal Of Foreign Body(s) | | | |
| Colorectal Cancer Screening | CPT | 44391 | Colonoscopy Through Stoma; With Control Of Bleeding, Any Method | | | |
| Colorectal Cancer Screening | СРТ | 44392 | Colonoscopy Through Stoma; With Removal Of Tumor(s), Polyp(s), Or Other Lesion(s) By Hot Biopsy Forcep | | | |
| Colorectal Cancer Screening | СРТ | 44394 | Colonoscopy Through Stoma; With Removal Of Tumor(s), Polyp(s), Or Other Lesion(s) By Snare Technique | | | |
| Colorectal Cancer Screening | СРТ | 44401 | Colonoscopy Through Stoma; With Transendoscopic Stent Placement (includes Predilation) | | | |
| Colorectal Cancer Screening | СРТ | 44402 | Colonoscopy through stoma; with endoscopic stent placement (including pre- and post-dilation and guide wire passage, when performed) | | | |
| Colorectal Cancer Screening | СРТ | 44403 | Colonoscopy Through Stoma; With Endoscopic Mucosal Resection | | | |
| Colorectal Cancer Screening | СРТ | 44404 | Colonoscopy Through Stoma; With Directed Submucosal Injection(s), Any Substance | | | |
| Colorectal Cancer Screening | СРТ | 44405 | Colonoscopy through stoma; with transendoscopic balloon dilation | | | |
| Colorectal Cancer Screening | СРТ | 44406 | Colonoscopy through stoma; with endoscopic ultrasound examination, limited to the sigmoid, descending, transverse, or ascending colon and cecum and adjacent structures | | | |
| Colorectal Cancer Screening | СРТ | 44407 | Colonoscopy through stoma; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s), includes endoscopic ultrasound examination limited to the sigmoid, descending, transverse, or ascending colon and cecum and adjacent structures | | | |
| Colorectal Cancer Screening | СРТ | 44408 | Colonoscopy through stoma; with decompression (for pathologic distention) (e.g., volvulus, megacolon), including placement of decompression tube, when performed | | | |
| Colorectal Cancer Screening | СРТ | 45330 | Sigmoidoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) | | | |
| Colorectal Cancer Screening | СРТ | 45331 | Sigmoidoscopy, Flexible; With Biopsy, Single Or Multiple | | | |
| Colorectal Cancer Screening | СРТ | 45332 | Sigmoidoscopy, Flexible; With Removal Of Foreign Body(s) | | | |
| Colorectal Cancer Screening | СРТ | 45333 | Sigmoidoscopy, Flexible; With Removal Of Tumor(s), Polyp(s), Or Other Lesion(s) By Hot Biopsy Forceps | | | |
| Colorectal Cancer Screening | СРТ | 45334 | Sigmoidoscopy, Flexible; With Control Of Bleeding, Any Method | | | |
| Colorectal Cancer Screening | СРТ | 45335 | Sigmoidoscopy, Flexible; With Directed Submucosal Injection(s), Any Substance | | | |

| CODES TO IDENTIFY COLORECTAL CANCER SCREENING: | | | | | |
|--|--------------|-------|---|--|--|
| Service | Code Type | Code | Code Description | | |
| Colorectal Cancer Screening | СРТ | 45337 | Sigmoidoscopy, flexible; with decompression (for pathologic distention) (e.g., volvulus, megacolon), including placement of decompression tube, when performed | | |
| Colorectal Cancer Screening | СРТ | 45338 | Sigmoidoscopy, Flexible; With Removal Of Tumor(s), Polyp(s), Or Other Lesion(s) By Snare Technique | | |
| Colorectal Cancer Screening | CPT | 45340 | Sigmoidoscopy, Flexible; With Transendoscopic Balloon Dilation | | |
| Colorectal Cancer Screening | СРТ | 45341 | Sigmoidoscopy, Flexible; With Endoscopic Ultrasound Examination | | |
| Colorectal Cancer Screening | СРТ | 45342 | Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s) | | |
| Colorectal Cancer Screening | СРТ | 45346 | Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre-and post-dilation and guide wire passage, when performed) | | |
| Colorectal Cancer Screening | СРТ | 45347 | Sigmoidoscopy, flexible; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed) | | |
| Colorectal Cancer Screening | СРТ | 45349 | Sigmoidoscopy, Flexible; With Endoscopic Mucosal Resection | | |
| Colorectal Cancer Screening | СРТ | 45350 | Sigmoidoscopy, Flexible; With Band Ligation(s) (e.g., Hemorrhoids) | | |
| Colorectal Cancer Screening | СРТ | 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) | | |
| Colorectal Cancer Screening | CPT | 45379 | Colonoscopy, Flexible; With Removal Of Foreign Body(s) | | |
| Colorectal Cancer Screening | CPT | 45380 | Colonoscopy, Flexible; With Biopsy, Single Or Multiple | | |
| Colorectal Cancer Screening | СРТ | 45381 | Colonoscopy, Flexible; With Directed Submucosal Injection(s), Any Substance | | |
| Colorectal Cancer Screening | CPT | 45382 | Colonoscopy, Flexible; With Control Of Bleeding, Any Method | | |
| Colorectal Cancer Screening | СРТ | 45384 | Colonoscopy, Flexible; With Removal Of Tumor(s), Polyp(s), Or Other Lesion(s) By Hot Biopsy Forceps | | |
| Colorectal Cancer Screening | СРТ | 45385 | Colonoscopy, Flexible; With Removal Of Tumor(s), Polyp(s), Or Other Lesion(s) By Snare Technique | | |
| Colorectal Cancer Screening | CPT | 45386 | Colonoscopy, Flexible; With Transendoscopic Balloon Dilation | | |
| Colorectal Cancer Screening | СРТ | 45388 | Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre-and post-dilation and guide wire passage, when performed) | | |
| Colorectal Cancer Screening | СРТ | 45389 | Colonoscopy, flexible; with endoscopic stent placement (includes pre- and post-dilation and guide wire passage, when performed) | | |
| Colorectal Cancer Screening | СРТ | 45390 | Colonoscopy, Flexible; With Endoscopic Mucosal Resection | | |
| Colorectal Cancer Screening | СРТ | 45391 | Colonoscopy, flexible; with endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures | | |

| CODES TO IDENTIFY COLORECTAL CANCER SCREENING: | | | | | |
|--|--------------|-------|---|--|--|
| Service | Code Type | Code | Code Description | | |
| Colorectal Cancer Screening | СРТ | 45392 | Colonoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s), includes endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures | | |
| Colorectal Cancer Screening | СРТ | 45393 | Colonoscopy, flexible; with decompression (for pathologic distention) (e.g., volvulus, megacolon), including placement of decompression tube, when performed | | |
| Colorectal Cancer Screening | CPT | 45398 | Colonoscopy, Flexible; With Band Ligation(s) (e.g., Hemorrhoids) | | |
| Colorectal Cancer Screening | СРТ | 74261 | Computed tomographic (CT) colonography, diagnostic, including image postprocessing; without contrast material | | |
| Colorectal Cancer Screening | СРТ | 74262 | Computed tomographic (CT) colonography, diagnostic, including image postprocessing; with contrast material(s) including non-contrast images, if performed | | |
| Colorectal Cancer Screening | СРТ | 74263 | Computed Tomographic (ct) Colonography, Screening, Including Image Postprocessing | | |
| Colorectal Cancer Screening | СРТ | 81528 | Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result | | |
| Colorectal Cancer Screening | СРТ | 82270 | Blood, occult, by peroxidase activity (e.g., guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (i.e., patient was provided 3 cards or single triple card for consecutive collection) | | |
| Colorectal Cancer Screening | СРТ | 82274 | Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations | | |
| Colorectal Cancer Screening | HCPCS | G0104 | Colorectal Cancer Screening; Flexible Sigmoidoscopy | | |
| Colorectal Cancer Screening | HCPCS | G0105 | Colorectal Cancer Screening; Colonoscopy On Individual At High Risk | | |
| Colorectal Cancer Screening | HCPCS | G0121 | Colorectal Cancer Screening; Colonoscopy On Individual Not Meeting Criteria For High Risk | | |
| Colorectal Cancer Screening | HCPCS | G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, one to three simultaneous determinations | | |

^{*}These are the codes that IEHP will use to determine the numerator compliance for the Colorectal Cancer Screening measure. These codes would be submitted by the testing Provider, not the PCP.

Controlling High Blood Pressure (CBP)

Methodology: HEDIS®

Measure Description: The percentage of Members who are 18-85 years of age, with a diagnosis of hypertension (HTN), and whose blood pressure (BP) was controlled (<140/90 mm Hg) during the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Age 18-85 years of age as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in continuous enrollment with IEHP of up to 45 days during the measurement year (2024).
 - 3. Members who had at least two different visits with a hypertension diagnosis on or between January 1 of the year prior to the measurement year (2023) and June 30 of the measurement year (2024). Visit can be in any outpatient setting.

Denominator: All Members 18-85 years of age who meet all criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had a BP reading taken during the measurement year (2024), in any of the following settings: office visits, e-visits, telephone visits or online assessments. The most recent BP of the measurement year (2024) will be used to determine compliance for this measure. **Provider must bill one diastolic code, one systolic code and one visit type code.**

NOTE: The BP reading must be taken on or after the date of the second hypertension diagnosis.

| C | CODES TO IDENTIFY BLOOD PRESSURE SCREENING: | | | | | |
|-----------------------------|---|-------|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Blood Pressure Screening | CPT- CAT-II | 3079F | Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | | | |
| Blood Pressure Screening | CPT- CAT-II | 3080F | Most recent diastolic blood pressure greater than or equal to 90 mm Hg (HTN, CKD, CAD) (DM) | | | |
| Blood Pressure Screening | CPT- CAT-II | 3078F | Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | | | |
| Blood Pressure Screening | CPT- CAT-II | 3077F | Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | | | |
| Blood Pressure Screening | CPT- CAT-II | 3074F | Most recent systolic blood pressure less than 130 mm Hg (DM), (HTN, CKD, CAD) | | | |
| Blood Pressure Screening | CPT- CAT-II | 3075F | Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | | | |

| CODES TO IDENTIFY OFFICE VISITS: | | | | | | | |
|----------------------------------|--------------|-------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Office Visit | СРТ | 99202 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 15-29 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99203 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 30-44 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99204 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 45-59 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99205 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 60-74 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99211 | Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. | | | | |
| Office Visit | СРТ | 99212 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 10-19 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99213 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99214 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99215 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 40-54 minutes of total time is spent on the date of the encoun | | | | |
| Office Visit | СРТ | 99241 | Office consultation for a new or established patient, which requires these three key components: A problem-focused history; A problem-focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family. | | | | |

| | CODES TO IDENTIFY OFFICE VISITS: | | | | | | | |
|-----------------|----------------------------------|-------|--|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | | |
| Office Visit | СРТ | 99242 | Office consultation for a new or established patient, which requires these three key components: An expanded problem-focused history; An expanded problem-focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Typically, 30 minutes are spent face-to-face with the patient and/or family. | | | | | |
| Office Visit | СРТ | 99243 | Office consultation for a new or established patient, which requires these three key components: A detailed history; A detailed examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 40 minutes are spent face-to-face with the patient and/or family. | | | | | |
| Office Visit | СРТ | 99244 | Office consultation for a new or established patient, which requires these three key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/ or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent faceto-face with the patient and/or family. | | | | | |
| Office Visit | СРТ | 99245 | Office consultation for a new or established patient, which requires these three key components: A comprehensive history; A comprehensive examination; and Medica decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs Usually, the presenting problem(s) are of moderate to high severity. Typically, 80 minutes are spent face-to-face with the patient and/or family. | | | | | |
| Office Visit | СРТ | 99341 | Home visit for the evaluation and management of a new patient, which requires these three key components: A problem-focused history; A problem-focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Typically, 20 minutes are spent face-to-face with the patient and/or family. | | | | | |

| | CODES TO IDENTIFY OFFICE VISITS: | | | | | | |
|-----------------|----------------------------------|-------|---|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Office Visit | СРТ | 99342 | Home visit for the evaluation and management of a new patient, which requires these three key components: An expanded problem-focused history; An expanded problem-focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family. | | | | |
| Office Visit | СРТ | 99343 | Home visit for the evaluation and management of a new patient, which requires these three key components: A detailed history; A detailed examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent faceto-face with the patient and/or family. | | | | |
| Office Visit | СРТ | 99344 | Home visit for the evaluation and management of a new patient, which requires these three key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family. | | | | |
| Office Visit | СРТ | 99345 | Home visit for the evaluation and management of a new patient, which require these three key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health | | | | |
| Office Visit | СРТ | 99347 | Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A problem-focused interval history; A problem-focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family. | | | | |

| | CODES TO IDENTIFY OFFICE VISITS: | | | | | | | |
|-----------------|----------------------------------|-------|---|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | | |
| Office Visit | СРТ | 99348 | Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: An expanded problem-focused interval history; An expanded problem-focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 25 minutes are spent face-to-face with the patient and/or family. | | | | | |
| Office Visit | СРТ | 99349 | Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family. | | | | | |
| Office Visit | СРТ | 99350 | Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A comprehensive interval history; A comprehensive examination; Medical decision making of moderate to high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with | | | | | |
| Office Visit | СРТ | 99385 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years. | | | | | |
| Office Visit | СРТ | 99386 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years. | | | | | |
| Office Visit | СРТ | 99387 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older. | | | | | |
| Office Visit | СРТ | 99395 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years. | | | | | |

| | CODES TO IDENTIFY OFFICE VISITS: | | | | | | | |
|-----------------|----------------------------------|-------|---|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | | |
| Office Visit | СРТ | 99396 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years. | | | | | |
| Office Visit | СРТ | 99397 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older. | | | | | |
| Office Visit | CPT | 99401 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes. | | | | | |
| Office Visit | СРТ | 99402 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 30 minutes. | | | | | |
| Office Visit | CPT | 99403 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 45 minutes. | | | | | |
| Office Visit | CPT | 99404 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 60 minutes. | | | | | |
| Office Visit | СРТ | 99411 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately minutes. | | | | | |
| Office Visit | СРТ | 99412 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 60 minutes. | | | | | |
| Office Visit | CPT | 99429 | Unlisted preventive medicine service. | | | | | |
| Office Visit | СРТ | 99455 | Work-related or medical disability examination by the treating physician that includes: Completion of a medical history commensurate with the patient's condition; Performance of an examination commensurate with the patient's condition; Formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment; Development of future medical treatment plan; and Completion of necessary documentation/certificates and report. | | | | | |
| Office Visit | СРТ | 99456 | Work-related or medical disability examination by other than the treating physician that includes: Completion of a medical history commensurate with the patient's condition: Performance of an examination commensurate with the patient's condition: | | | | | |

| | CODES TO IDENTIFY OFFICE VISITS: | | | | | | | |
|-----------------|----------------------------------|-------|---|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | | |
| Office Visit | CPT | 99483 | Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination; Medical decision making of moderate or high complexity; Functional assessment (e.g., basic and instrumental activities of daily living), including decision-making capacity; Use of standardized instruments for staging of dementia (e.g., functional assessment staging test [FAST], clinical dementia rating [CDR]); Medication reconciliation and review for high-risk medications; Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s); Evaluation of safety (e.g., home), including motor vehicle operation; Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks; Development, updating or revision, or review of an Advance Care Plan; Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (e.g., rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 50 minutes are spent face-to-face with the patient and/or family or caregiver. | | | | | |
| Office Visit | HCPCS | G0071 | Payment for communication technology-based services for five minutes or more of a virtual (non-face-to-face) communication between a rural health clinic (RHC) or federally qualified health center (FOHC) practitioner and RHC or | | | | | |
| Office Visit | HCPCS | G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of Medicare enrollment. | | | | | |
| Office Visit | HCPCS G0438 | | Annual wellness visit; includes a personalized prevention plan of service (PPS), initial visit. | | | | | |
| Office Visit | HCPCS | G0439 | Annual wellness visit, includes a personalized prevention plan of service (PPS) subsequent visit. | | | | | |
| Office Visit | HCPCS | G0463 | Hospital outpatient clinic visit for assessment and management of a patient. | | | | | |
| Office Visit | HCPCS | T1015 | Clinic Visit/encounter, All-inclusive (t1015) | | | | | |

| | CODES TO IDENTIFY E-VISITS: | | | | | | |
|---------|-----------------------------|-------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| E-Visit | СРТ | 98970 | Qualified nonphysician health care professional online digital assessment and management, for an established patient, for up to seven days, cumulative time during the seven days; 5-10 minutes. | | | | |
| E-Visit | СРТ | 98971 | Qualified nonphysician health care professional online digital assessment and management, for an established patient, for up to seven days, cumulative time during the seven days; 11-20 minutes. | | | | |
| E-Visit | СРТ | 98972 | Qualified nonphysician health care professional online digital assessment and | | | | |
| E-Visit | СРТ | 99421 | Online digital evaluation and management service, for an established patient, for up to seven days, cumulative time during the seven days; 5-10 minutes. | | | | |
| E-Visit | СРТ | 99422 | Online digital evaluation and management service, for an established patient, fo up to seven days, cumulative time during the seven days; 11-20 minutes. | | | | |
| E-Visit | СРТ | 99423 | Online digital evaluation and management service for an established natient fo | | | | |
| E-Visit | HCPCS | G2010 | Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with | | | | |
| E-Visit | HCPCS | G2012 | Brief communication technology-based service, e.g., virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established nation, not originating | | | | |

| | CODES TO IDENTIFY TELEPHONE VISITS: | | | | | | |
|--------------------|-------------------------------------|-------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Telephone Visit | ne CPT 98966 | | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion. | | | | |
| Telephone Visit | - I (PI 19896/ | | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion. | | | | |
| Telephone Visit | СРТ | 98968 | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion. | | | | |
| Telephone Visit | - I (.PI I 99441 | | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion. | | | | |
| Telephone Visit | - I (PI 19944) | | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion. | | | | |
| Telephone Visit | СРТ | 99443 | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion. | | | | |

| | CODES TO IDENTIFY ONLINE ASSESSMENTS: | | | | | | | |
|------------------------|---|-------|---|--|--|--|--|--|
| Service Code Type Code | | Code | Code Description | | | | | |
| Online Assessment | СРТ | 98980 | Remote therapeutic monitoring treatment management services, physician or other qualified health care professional time in a calendar month requiring at least one interactive communication with the patient or caregiver during the calendar month; first 20 minutes | | | | | |
| Online Assessment | СРТ | 98981 | Remote therapeutic monitoring treatment management services, physician or other qualified health care professional time in a calendar month requiring at least one interactive communication with the patient or caregiver during the calendar month; each additional 20 minutes (List separately in addition to code for primary procedure) | | | | | |
| Online Assessment | CPT 99457 | | Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | | | | | |
| Online Assessment | СРТ | 99458 | Remote physiologic monitoring treatment management services, clini staff/physician/other qualified health care professional time in a calendary | | | | | |
| Online Assessment | . HCPCS 1 G2250 | | Remote assessment of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment | | | | | |
| Online Assessment | Brief communication technology-based service, e.g. virtual of a qualified health care professional who cannot report evaluation management services, provided to an established patient, no from a related service provided within the previous 7 days not service. | | Brief communication technology-based service, e.g. virtual check-in, by a qualified health care professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion | | | | | |
| Online Assessment | HCPCS | G2252 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related EM service provided within the previous 7 days nor leading to an EM service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | | | | | |

Diabetes Care- Blood Pressure Control <140/90 (BPD)

Summary of Changes to the Global Quality P4P Program Guide:

• Update to the exclusions

Methodology: HEDIS®

Measure Description: The percentage of Members who are 18-75 years of age and have a diagnosis of diabetes (type 1 and 2), whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Members who are 18-75 years as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in enrollment of up to 45 days.
 - 3. Members who meet any of the following criteria during the measurement year (2024) or the year prior to the measurement year (2023). Count services that occur over both years:
 - At least two outpatient visits, observation visits, telephone visits, e-visits or virtual check-ins, Emergency Department (ED) visits, nonacute inpatient encounters or nonacute inpatient discharges on different dates of service, with a diagnosis of diabetes. Visit type need not be the same for the two visits.
 - At least one acute inpatient encounter with a diagnosis of diabetes without telehealth.
 - Members who were dispensed insulin or hypoglycemics/antihyperglycemics during the measurement year (2024) or the year prior to the measurement year (2023).
 - At least one acute inpatient with a diagnosis of diabetes on the discharge claim. To identify an acute inpatient discharge:
 - Identify all acute and nonacute inpatient stays
 - Exclude nonacute inpatient stays
 - Identify the discharge date for the stay
- Members who meet any of the following criteria are excluded:
 - 1. Members in hospice.
 - 2. Members receiving palliative care.
 - 3. Members who expired an any time during the measurement year (2024).
 - 4. Members 66 years of age and older as of December 31 of measurement year (2024) with both frailty and advanced illness.

Denominator: Members who are 18-75 years of age who meet all criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had a Blood Pressure reading that was adequately controlled <140/90 mm Hg. The latest Blood Pressure reading will be used to determine compliance. If there are multiple BPs on the same date of service, the lowest systolic and lowest diastolic Blood Pressure reading on that date will be used as a representative Blood Pressure reading. **Provider must bill one diastolic code and one systolic code.**

| CODES TO IDENTIFY DIABETES CARE-BLOOD PRESSURE CONTROL: | | | | | | | |
|---|------------|-------|---|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Systolic Blood Pressure | CPT-CAT-II | 3074F | Most recent systolic blood pressure less than 130 mm Hg (DM), (HTN, CKD, CAD) | | | | |
| Systolic Blood Pressure | CPT-CAT-II | 3075F | Most recent systolic blood pressure 130-139 mm Hg (DM),(HTN, CKD, CAD) | | | | |
| Systolic Blood Pressure | CPT-CAT-II | 3077F | Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | | | | |
| Diastolic Blood Pressure | CPT-CAT-II | 3078F | Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | | | | |
| Diastolic Blood Pressure | CPT-CAT-II | 3079F | Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | | | | |
| Diastolic Blood Pressure | CPT-CAT-II | 3080F | Most recent diastolic blood pressure greater than or equal to 90 mm Hg (HTN, CKD, CAD) (DM) | | | | |

Glycemic Status Assessment for Patients with Diabetes (GSD)

Summary of Changes to the Global Quality P4P Program Guide:

- Update to the Measure Title
- Update to the Measure Description
- Update to the eligible population
- Update to the exclusions

Methodology: HEDIS®

Measure Description: The percentage of Members 18-75 years of age and have a diagnosis of diabetes (type 1 and type 2) who had the following:

- Glycemic Status (<8.0%) This includes diabetics whose <u>most recent</u> Glycemic Status (hemoglobin A1c or glucose management indicator [GMI]) during the measurement year (2024) has a value <8.0%.
 - The Member is <u>not</u> numerator compliant if the result for the <u>most recent</u> Glycemic Status Assessment is ≥8.0% or is missing a result, or if an Glycemic Status Assessment was not done during the measurement year (2024).
- The eligible population in this measure meets all of the following criteria:
 - 1. Members who are 18-75 years old as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP in the measurement year (2024) with no more than one gap of up to 45 days during the measurement year (2024).
 - 3. Members who meet any of the following criteria during the measurement year (2024) or the year prior to the measurement year (2023). Count services that occur over both years:
 - Members who had at least two diagnoses of diabetes on different days of service during the measurement year (2024) or the year prior to the measurement year (2023).
 - Members who were dispensed insulin or hypoglycemics/antihyperglycemics during the measurement year (2024) or the year prior to the measurement year (2023) and have at least one diagnosis of diabetes during the measurement year (2024) or the year prior to the measurement year (2023).

| | CODES TO IDENTIFY GLYCEMIC STATUS TESTS: | | | | | | |
|---------------------------|--|-------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Glycemic Status Result | CPT-CAT-II | 3046F | Most Recent Hemoglobin A1c Level Greater Than 9.0% (DM) | | | | |
| Glycemic Status Result | CPT-CAT-II | 3051F | Most Recent Hemoglobin A1c (HbA1c) Level Greater Than Or Equal To 7.0% And Less Than 8.0% | | | | |
| Glycemic Status Result | CPT-CAT-II | 3052F | Most Recent Hemoglobin A1c (HbA1c) Level Greater Than Or Equal To 8.0% And Less Than Or Equal To 9.0% | | | | |
| Glycemic Status Result | CPT-CAT-II | 3044F | Most Recent Hemoglobin A1c (HbA1c) Level Less Than 7.0% (DM) | | | | |

- Members who met any of the following criteria are excluded:
 - 1. Members in hospice.
 - 2. Members receiving palliative care.
 - 3. Members who expired at any time during the measurement year (2024).
 - 4. Members 66 years of age and older as of December 31 of measurement year (2024) with both frailty and advanced illness.

Denominator: Members 18-75 years of age who meet all the criteria for eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had the most recent glycemic status test result of <8 during the measurement year (2024).

Diabetes Care - Kidney Health Evaluation (KED)

Summary of Changes to the Global Quality P4P Program Guide:

- Update to the eligible population
- Update to the exclusions

Methodology: HEDIS®

Measure Description: The percentage of Members who are 18-85 years of age and have a diagnosis of diabetes (type 1 and 2), who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), during the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Members who are 18-85 years of age as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in continuous enrollment with IEHP of up to 45 days during the measurement year (2024).
 - 3. Members who meet any of the following criteria during the measurement year (2024) or the year prior to the measurement year (2023). Count services that occur over both years:
 - Members who had at least two diagnoses of diabetes on different days of service during the measurement year (2024) or the year prior to the measurement year (2023).
 - Members who were dispensed insulin or hypoglycemics/antihyperglycemics during the measurement year (2024) or the year prior to the measurement year (2023).
- Members who meet any of the following criteria are excluded:
 - 1. Members in hospice.
 - 2. Members with evidence of End-Stage Renal Disease (ESRD) any time in the Members history on or before December 31 of the measurement year (2024).
 - 3. Members receiving palliative care.
 - 4. Members who expired at any time during the measurement year (2024).
 - 5. Members who had dialysis any time during the member's history on or prior to December 31 of the measurement year (2024).
 - 6. Members 66 years of age and older as of December 31 of measurement year (2024) with both frailty and advanced illness.

Denominator: Members who are 18-85 years of age who meet all criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who received both an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR) during the measurement year (2024), on the same or different dates of service. **The following is required for compliance in this measure:**

- At least one estimated glomerular filtration rate (eGFR).
- At least one urine albumin-creatinine ratio (uACR):
 - o Quantitative urine albumin lab test <u>AND</u> urine creatinine lab test that are 4 days or less apart.

OR

o Urine albumin-creatinine ratio lab test.

| CODES | CODES TO IDENTIFY ESTIMATED GLOMERULAR FILTRATION RATE: | | | | | | | |
|--|---|-------|---|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | | |
| Estimated Glomerular Filtration Rate | СРТ | 80047 | Basic metabolic panel (Calcium, ionized) This panel must include the following: Calcium, ionized (82330) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520) | | | | | |
| Estimated Glomerular Filtration Rate | СРТ | 80048 | Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) | | | | | |
| Estimated Glomerular Filtration Rate | СРТ | 80050 | General health panel This panel must include the following: Comprehensive metabolic panel (80053) Blood count, complete (CBC), automated and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Thyroid stimulating hormone (TSH) (84443) | | | | | |
| Estimated Glomerular Filtration Rate | СРТ | 80053 | Comprehensive metabolic panel This panel must include the following: Albumin (82040) Bilirubin, total (82247) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphatase, alkaline (84075) Potassium (84132) Protein, total (84155) Sodium (84295) Transferase, alanine amino (ALT) (SGPT) (84460) Transferase, aspartate amino (AST) (SGOT) (84450) Urea nitrogen (BUN) (84520) | | | | | |
| Estimated Glomerular Filtration Rate | СРТ | 80069 | Renal function panel this panel must include the following: Albumin (82040) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphorus inorganic (phosphate) (84100) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) | | | | | |

| CODES | CODES TO IDENTIFY ESTIMATED GLOMERULAR FILTRATION RATE: | | | | | | | |
|--|---|---------|---|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | | |
| Estimated Glomerular Filtration Rate | СРТ | 82565 | Creatinine; Blood | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 50044-7 | Glomerular Filtration Rate/1.73 Sq M.predicted Among Females [volume Rate/area] In Serum, Plasma Or Blood By Creatinine-based Formula (mdrd) | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 50210-4 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood By Cystatin C-based Formula | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 50384-7 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood By Creatinine-based Formula (schwartz) | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 62238-1 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood By Creatinine-based Formula (ckd-epi) | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 69405-9 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 70969-1 | Glomerular Filtration Rate/1.73 Sq M.predicted Among Males [volume Rate/area] In Serum, Plasma Or Blood By Creatinine-based Formula (mdrd) | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 77147-7 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood By Creatinine-based Formula (mdrd) | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 94677-2 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood By Creatinine And Cystatin C-based Formula (ckd-epi) | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 98979-8 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood By Creatinine-based Formula (ckd-epi 2022) | | | | | |
| Estimated Glomerular Filtration Rate | LOINC | 98980-6 | Glomerular Filtration Rate/1.73 Sq M.predicted [volume Rate/area] In Serum, Plasma Or Blood By Creatinine And Cystatin C-based Formula (ckd-epi 2022) | | | | | |

| CODES | TO IDENT | IFY QUA | NTITATIVE URINE ALBUMIN LAB TEST: |
|-------------------------------|-----------|----------|--|
| Service | Code Type | Code | Code Description |
| Quantitative Urine Albumin | СРТ | 82043 | Albumin; Urine (e.g, Microalbumin), Quantitative |
| Quantitative Urine Albumin | LOINC | 100158-5 | Microalbumin [mass/volume] In Urine Collected For Unspecified Duration |
| Quantitative Urine Albumin | LOINC | 14957-5 | Microalbumin [mass/volume] In Urine |
| Quantitative Urine Albumin | LOINC | 1754-1 | Albumin [mass/volume] In Urine |
| Quantitative Urine Albumin | LOINC | 21059-1 | Albumin [mass/volume] In 24 Hour Urine |
| Quantitative Urine Albumin | LOINC | 30003-8 | Microalbumin [mass/volume] In 24 Hour Urine |
| Quantitative Urine Albumin | LOINC | 43605-5 | Microalbumin [mass/volume] In 4 Hour Urine |
| Quantitative Urine Albumin | LOINC | 53530-2 | Microalbumin [mass/volume] In 24 Hour Urine By Detection Limit <= 1.0 Mg/l |
| Quantitative Urine Albumin | LOINC | 53531-0 | Microalbumin [mass/volume] In Urine By Detection Limit <= 1.0 Mg/l |
| Quantitative Urine Albumin | LOINC | 57369-1 | Microalbumin [mass/volume] In 12 Hour Urine |
| Quantitative Urine Albumin | LOINC | 89999-7 | Microalbumin [mass/volume] In Urine By Detection Limit <= 3.0 Mg/l |

| (| CODES TO IDENTIFY URINE CREATININE LAB TEST: | | | | | |
|------------------|--|---------|--|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Urine Creatinine | CPT | 82570 | Creatinine; Other Source | | | |
| Urine Creatinine | LOINC | 20624-3 | Creatinine [mass/volume] In 24 Hour Urine | | | |
| Urine Creatinine | LOINC | 2161-8 | Creatinine [mass/volume] In Urine | | | |
| Urine Creatinine | LOINC | 35674-1 | Creatinine [mass/volume] In Urine Collected For Unspecified Duration | | | |
| Urine Creatinine | LOINC | 39982-4 | Creatinine [mass/volume] In Urine - baseline | | | |
| Urine Creatinine | LOINC | 57344-4 | Creatinine [mass/volume] In 2 Hour Urine | | | |
| Urine Creatinine | LOINC | 57346-9 | Creatinine [mass/volume] In 12 Hour Urine | | | |
| Urine Creatinine | LOINC | 58951-5 | Creatinine [mass/volume] In Urine2nd Specimen | | | |
| Urine Creatinine | LOINC | 58951-5 | Creatinine [mass/volume] In Urine2nd Specimen | | | |

| CODES T | O IDENTI | FY URIN | E ALBUMIN-CREATININE RATIO LAB TEST: |
|------------------------------------|-----------|---------|---|
| Service | Code Type | Code | Code Description |
| Urine Albumin- Creatinine Ratio | LOINC | 13705-9 | Albumin/creatinine [mass Ratio] In 24 Hour Urine |
| Urine Albumin- Creatinine Ratio | LOINC | 14958-3 | Microalbumin/creatinine [mass Ratio] In 24 Hour Urine |
| Urine Albumin- Creatinine Ratio | LOINC | 14959-1 | Microalbumin/creatinine [mass Ratio] In Urine |
| Urine Albumin- Creatinine Ratio | LOINC | 30000-4 | Microalbumin/creatinine [ratio] In Urine |
| Urine Albumin- Creatinine Ratio | LOINC | 44292-1 | Microalbumin/creatinine [mass Ratio] In 12 Hour Urine |
| Urine Albumin- Creatinine Ratio | LOINC | 59159-4 | Microalbumin/creatinine [ratio] In 24 Hour Urine |
| Urine Albumin- Creatinine Ratio | LOINC | 76401-9 | Albumin/creatinine [ratio] In 24 Hour Urine |
| Urine Albumin- Creatinine Ratio | LOINC | 77253-3 | Microalbumin/creatinine [ratio] In Urine By Detection Limit <= 1.0 Mg/l |
| Urine Albumin- Creatinine Ratio | LOINC | 77254-1 | Microalbumin/creatinine [ratio] In 24 Hour Urine By Detection Limit <= 1.0 Mg/l |
| Urine Albumin- Creatinine Ratio | LOINC | 89998-9 | Microalbumin/creatinine [ratio] In Urine By Detection Limit <= 3.0 Mg/l |
| Urine Albumin- Creatinine Ratio | LOINC | 9318-7 | Albumin/creatinine [mass Ratio] In Urine |

Methodology: IEHP – HEDIS Modified Measure

Measure Description: The percentage of Members 19 years of age and older, who received an influenza vaccine between July 1 of the year prior to the measurement year (2023) and June 30 of the measurement year (2024).

- The eligible population in this measure meets all of the following criteria:
 - Continuous enrollment with IEHP in the measurement year (2024) with no more than one gap of up to 45 days during the measurement year.

Denominator: Members 19 years of age or older who meet all criteria for the eligible population.

• Anchor Date: June 30, 2024

Numerator: Members in the denominator who received an influenza vaccine between July 1, 2023–June 30, 2024.

| | ADULT INFLUENZA VACCINE CODE SET: | | | | | |
|-------------|-----------------------------------|-------|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Flu Vaccine | СРТ | 90630 | Influenza Virus Vaccine, Quadrivalent (Iiv4), Split Virus, Preservative Free, For Intradermal Use | | | |
| Flu Vaccine | CPT | 90653 | Influenza Vaccine, Inactivated (Iiv), Subunit, Adjuvanted, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90654 | Influenza Virus Vaccine, Trivalent (Iiv3), Split Virus, Preservative Free, For Intradermal Use | | | |
| Flu Vaccine | СРТ | 90656 | Influenza Virus Vaccine, Trivalent (Iiv3), Split Virus, Preservative Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90658 | Influenza Virus Vaccine, Trivalent (Iiv3), Split Virus, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | CPT | 90660 | Influenza Virus Vaccine, Trivalent, Live (Laiv3), For Intranasal Use | | | |
| Flu Vaccine | СРТ | 90661 | Influenza Virus Vaccine, Trivalent (Cciiv3), Derived From Cell Cultures, Subunit, Preservative And Antibiotic Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90662 | Influenza Virus Vaccine (Iiv), Split Virus, Preservative Free, Enhanced Immunogenicity Via Increased Antigen Content, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90672 | Influenza Virus Vaccine, Quadrivalent, Live (Laiv4), For Intranasal Use | | | |
| Flu Vaccine | СРТ | 90673 | Influenza Virus Vaccine, Trivalent (Riv3), Derived From Recombinant Dna, Hemagglutinin (Ha) Protein Only, Preservative And Antibiotic Free, For Intramuscular Use | | | |

| | ADULT INFLUENZA VACCINE CODE SET: | | | | | |
|-------------|-----------------------------------|-------|--|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Flu Vaccine | СРТ | 90674 | Influenza Virus Vaccine, Quadrivalent (Cciiv4), Derived From Cell Cultures, Subunit, Preservative And Antibiotic Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90682 | Influenza Virus Vaccine, Quadrivalent (RIV4), Derived From Recombinant DNA, Hemagglutinin (HA) Protein Only, Preservative And Antibiotic Free, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90686 | Influenza Virus Vaccine, Quadrivalent (Iiv4), Split Virus, Preservative Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90688 | Influenza Virus Vaccine, Quadrivalent (Iiv4), Split Virus, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90689 | Influenza Virus Vaccine Quadrivalent (Iiv4), Inactivated, Adjuvanted, Preservative Free, 0.25 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90694 | Influenza Virus Vaccine, Quadrivalent (aIIV4), Inactivated, Adjuvanted, Preservative Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90756 | Influenza Virus Vaccine, Quadrivalent (Cciiv4), Derived From Cell Cultures, Subunit, Antibiotic Free, 0.5Ml Dosage, For Intramuscular Use | | | |

Adult Zoster Vaccine

Methodology: IEHP – HEDIS Modified Measure

Measure Description: The percentage of Members 50 years of age and older, who received the appropriate herpes zoster vaccine in the measurement year (2024).

- The eligible population in this measure meets all of the following criteria:
 - o Continuous enrollment with IEHP in the measurement year (2024) with no more than one gap of up to 45 days during the measurement year (2024).

Denominator: Members 50 years of age and older in the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who were administered the herpes zoster vaccine by meeting one of the criteria below:

1) Members who received at least one dose of the herpes live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart), any time on or after the Member's 50th birthday and before or during the measurement year (2024).

OR

2) Members who had anaphylaxis from the herpes zoster vaccine any time before or during the measurement year (2024).

| | CODES TO IDENTIFY ZOSTER VACCINE: | | | | | |
|-------------------|-----------------------------------|-------|--|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Zoster Vaccine | СРТ | 90736 | Zoster (shingles) vaccine (HZV), live, for subcutaneous injection;Includes Zostavax | | | |
| Zoster Vaccine | СРТ | 90750 | Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | | | |

Adult Pneumococcal Vaccine

Methodology: IEHP – HEDIS Modified Measure

Measure Description: The percentage of Members 66 years of age and older, who received the pneumococcal vaccine by the end of the measurement year (2024).

- The eligible population in this measure meets all of the following criteria:
 - o Continuous enrollment with IEHP in the measurement year (2024) with no more than one gap of up to 45 days during the measurement year (2024).

Denominator: Members 66 years of age, or older, in the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who were administered the pneumococcal vaccine by meeting one of the criteria below:

1) Members in the denominator who received at least one dose of an adult pneumococcal vaccine on or after the Member's 19th birthday and before or during the measurement year (2024).

<u>OR</u>

2) Members who had anaphylaxis from the pneumococcal vaccine any time before or during the measurement year (2024).

| CODES TO IDENTIFY ADULT PNEUMOCOCCAL VACCINE: | | | | | |
|---|-----------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Adult Pneumococcal Vaccine Procedure | СРТ | 90670 | Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use; Includes Prevnar 13 | | |
| Adult Pneumococcal Vaccine Procedure | СРТ | 90671 | Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use;Includes Vaxneuvance | | |
| Adult Pneumococcal Vaccine Procedure | СРТ | 90677 | Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | | |
| Adult Pneumococcal Vaccine Procedure | СРТ | 90732 | Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use; Includes Pneumovax 23 | | |
| Adult Pneumococcal Vaccine Procedure | HCPCS | G0009 | Administration of pneumococcal vaccine | | |

Adult Td/Tdap Vaccine

Methodology: IEHP – HEDIS Modified Measure

Measure Description: The percentage of Members 19 years of age and older, who received the tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap) vaccine by the end of the measurement year (2024).

- The eligible population in this measure meets all of the following criteria:
 - o Continuous enrollment with IEHP in the measurement year (2024) with no more than one gap of up to 45 days during the measurement year (2024).

Denominator: Members 19 years of age and older in the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who were administered the Td/Tdap vaccine by meeting one of the criteria below:

1) Members in the denominator who received at least one Td vaccine or one Tdap vaccine between 9 years prior to the measurement year (2015) and the end of the measurement year (2024).

<u>OR</u>

- 2) Members with a history of at least one of the following any time before or during the measurement year (2024):
 - Members who had anaphylaxis from the diphtheria, tetanus, or pertussis vaccine.
 - Members who had encephalitis due to the diphtheria, tetanus, or pertussis vaccine.

| | CODES TO IDENTIFY TD/TDAP VACCINE: | | | | | |
|-----------------|------------------------------------|-------|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Td Vaccine | СРТ | 90714 | Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use;Includes TDVAX; Includes Tenivac | | | |
| Tdap Vaccine | СРТ | 90715 | Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use;Includes Adacel; Includes Boostrix | | | |

Post Discharge Follow-Up

Methodology: IEHP-Defined Measure

Measure Description: The percentage of Members, 18 years and older who have follow-up visits with a Provider within required timeframes. For this measure, two rates are calculated and the average of both rates are used as the final score.

Rate 1: Follow-Up Visit High-Risk Members – this measure assesses the percentage of Members identified as "high-risk" who were discharged from an acute or nonacute inpatient stay during the measurement year (2024) who also had a follow-up visit with a Provider within seven days of discharge.

• Anchor Date: Assigned Provider at the end of the 7 day follow-up window.

Rate 2: Follow-Up Visit with non-High-Risk Members - this measure assesses the percentage of Members identified as "low or rising risk" who were discharged from an acute or nonacute inpatient stay during the measurement year (2024) who also had a follow-up visit with a Provider within 30 days of discharge.

• Anchor Date: Assigned Provider at the end of the 30 day follow-up window.

As part of IEHP's population health strategy, all IEHP Members are designated a risk level based on all available utilization and diagnostic data available to the plan. Members fall into one of three risk categories: High, Rising and Low Risk. IEHP employs the Chronic Illness and Disability Payment System (CDPS) and Medicaid Rx (MRx) model (CDPS+MRx), a combined diagnostic and pharmacy model, to identify high-, rising- and low-risk members. The system was developed by the University of California, San Diego, and has been adopted by the Department of Health Care Services (DHCS) of the State of California for use in its rate setting methodology with Medi-Cal Managed Care Plans (MCPs).

CDPS+MRx uses clinical and pharmaceutical data from the prior 12 months to generate predictive risk scores for the next 12 months.

The CDPS+MRx system measures the morbidity burden of patient populations based on age, gender, and diagnostic markers.


For member stratification, IEHP uses the CDPS+MRx risk scores, along with other inputs including Social Determinants of Health (SDOH) indices, and other clinical indicators to further stratify members into high, rising, and low risk tiers.

- The eligible population in this measure meets all of the following criteria:
 - 1. Members who are 18 years of age or older by December 31, 2024.
 - 2. To be eligible for this measure, IEHP Members must be enrolled with IEHP on the date of the discharge through 30 days after the discharge (31 total days).
 - 3. Discharged to home from an acute or nonacute inpatient hospital stay during the measurement year (2024).

This risk score is available for every IEHP Member on the IEHP Provider Portal and can be accessed by following these steps:

To view an IEHP Member's risk score, Providers can log into the secure IEHP Provider Portal and follow these steps:







| | | CC | DDES TO IDENTIFY FOLLOW-UP VISITS: |
|-----------------|-----------|-------|--|
| Service | Code Type | Code | Code Description |
| Office Visit | СРТ | 99202 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 15-29 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99203 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 30-44 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99204 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 45-59 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99205 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 60-74 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99211 | Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. |
| Office Visit | СРТ | 99212 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 10-19 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99213 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99214 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99215 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 40-54 minutes of total time is spent on the date of the encounter. |
| Office Visit | СРТ | 99241 | Office consultation for a new or established patient, which requires these three key components: A problem-focused history; A problem-focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family. |

| | CODES TO IDENTIFY FOLLOW-UP VISITS: | | | | | | |
|-----------------|-------------------------------------|-------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Office Visit | СРТ | 99242 | Office consultation for a new or established patient, which requires these three key components: An expanded problem-focused history; An expanded problem-focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Typically, 30 minutes are spent face-to-face with the patient and/or family. | | | | |
| Office Visit | СРТ | 99243 | Office consultation for a new or established patient, which requires these three key components: A detailed history; A detailed examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 40 minutes are spent face-to-face with the patient and/or family. | | | | |
| Office Visit | СРТ | 99244 | Office consultation for a new or established patient, which requires these three key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/ or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family. | | | | |
| Office Visit | СРТ | 99245 | Office consultation for a new or established patient, which requires these three key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 80 minutes are spent face-to-face with the patient and/or family. | | | | |
| Office Visit | СРТ | 99385 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years. | | | | |
| Office Visit | СРТ | 99386 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years. | | | | |
| Office Visit | СРТ | 99387 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older. | | | | |

| | CODES TO IDENTIFY FOLLOW-UP VISITS: | | | | | | |
|-----------------|-------------------------------------|-------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Office Visit | СРТ | 99395 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years. | | | | |
| Office Visit | СРТ | 99396 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years. | | | | |
| Office Visit | СРТ | 99397 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older. | | | | |
| Office Visit | СРТ | 99401 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes. | | | | |
| Office Visit | СРТ | 99402 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 30 minutes. | | | | |
| Office Visit | СРТ | 99403 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 45 minutes. | | | | |
| Office Visit | СРТ | 99404 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 60 minutes. | | | | |
| Office Visit | СРТ | 99411 | Preventive Medicine Counseling And/or Risk Factor Reduction Intervention(s) Provided To Individuals In A Group Setting (separate Procedure); Approximately 30 Minutes | | | | |
| Office Visit | СРТ | 99412 | Preventive Medicine Counseling And/or Risk Factor Reduction Intervention(s) Provided To Individuals In A Group Setting (separate Procedure); Approximately 60 Minutes | | | | |
| Office Visit | СРТ | 99429 | Unlisted Preventive Medicine Service | | | | |
| Office Visit | СРТ | 99455 | Work related or medical disability examination by the treating physician that includes: Completion of a medical history commensurate with the patient's condition; Performance of an examination commensurate with the patient's condition; Formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment; Development of future medical treatment plan; and Completion of necessary documentation/certificates and report. | | | | |
| Office Visit | СРТ | 99456 | Work related or medical disability examination by other than the treating physician that includes: Completion of a medical history commensurate with the patient's condition; Performance of an examination commensurate with the patient's condition; Formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment; Development of future medical treatment plan; and Completion of necessary documentation/certificates and report. | | | | |

| | CODES TO IDENTIFY FOLLOW-UP VISITS: | | | | | | |
|-----------------|-------------------------------------|--------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Office Visit | СРТ | 99483 | Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination, Medical decision making of moderate or high complexity, Functional assessment (eg, basic and instrumental activities of daily living), including decision-making capacity, Use of standardized instruments for staging of dementia (eg, functional assessment staging test [FAST], clinical dementia rating [CDR]), Medication reconciliation and review for high-risk medications, Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s), Evaluation of safety (eg, home), including motor vehicle operation, Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks, Development, updating or revision, or review of an Advance Care Plan, Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (eg, rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 60 minutes of total time is spent on the date of the encounter. | | | | |
| Office Visit | СРТ | 99495* | Transitional Care Management Services with the following required elements: Communication (direct contact, telephone, electronic) with the patient and/or caregiver within two business days of discharge Medical decision making of at least moderate complexity during the service period face-to-face visit, within 14 calendar days of discharge. | | | | |
| Office Visit | СРТ | 99496 | Transitional Care Management Services with the following required elements Communication (direct contact, telephone, electronic) with the patient and/ or caregiver within two business days of discharge medical decision making of high complexity during the service period face-to-face visit, within seven calendar days of discharge. | | | | |
| Office Visit | HCPCS | G0402 | Initial Preventive Physical Examination; Face-to-face Visit, Services Limited To New Beneficiary During The First 12 Months Of Medicare Enrollment (g0402) | | | | |
| Office Visit | HCPCS | G0438 | Annual Wellness Visit; Includes A Personalized Prevention Plan Of Service (pps), Initial Visit (g0438) | | | | |
| Office Visit | HCPCS | G0439 | Annual Wellness Visit, Includes A Personalized Prevention Plan Of Service (pps), Subsequent Visit (g0439) | | | | |
| Office Visit | HCPCS | G0463 | Hospital outpatient clinic visit for assessment and management of a patient. | | | | |
| Office Visit | HCPCS | T1015 | Clinic visit/encounter, all-inclusive. | | | | |

| | CODES TO IDENTIFY TELEPHONE VISITS: | | | | | | |
|--------------------|-------------------------------------|-------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Telephone Visit | СРТ | 98966 | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion. | | | | |
| Telephone Visit | СРТ | 98967 | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion. | | | | |
| Telephone Visit | СРТ | 98968 | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion. | | | | |
| Telephone Visit | СРТ | 99441 | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion. | | | | |
| Telephone Visit | СРТ | 99442 | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion. | | | | |
| Telephone Visit | СРТ | 99443 | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion. | | | | |

| CODES TO IDENTIFY ONLINE ASSESSMENTS: | | | | | | |
|---------------------------------------|-----------|-------|--|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Online Assessment | СРТ | 98970 | Qualified Nonphysician Health Care Professional Online Digital Assessment And Management, For An Established Patient, For Up To 7 Days, Cumulative Time During The 7 Days; 5-10 Minutes | | | |
| Online Assessment | СРТ | 98971 | Qualified Nonphysician Health Care Professional Online Digital Assessment And Management, For An Established Patient, For Up To 7 Days, Cumulative Time During The 7 Days; 11-20 Minutes | | | |
| Online Assessment | СРТ | 98972 | Qualified Nonphysician Health Care Professional Online Digital Assessment And Management, For An Established Patient, For Up To 7 Days, Cumulative Time During The 7 Days; 21 Or More Minutes | | | |
| Online Assessment | СРТ | 98980 | Remote Therapeutic Monitoring Treatment Management Services, Physician Or Other Qualified Health Care Professional Time In A Calendar Month Requiring At Least One Interactive Communication With The Patient Or Caregiver During The Calendar Month; First 20 minutes | | | |
| Online Assessment | СРТ | 98981 | Remote therapeutic monitoring treatment management services, physician or other qualified health care professional time in a calendar month requiring at least one interactive communication with the patient or caregiver during the calendar month; each additional 20 minutes | | | |
| Online Assessment | СРТ | 99421 | Online Digital Evaluation And Management Service, For An Established Patient, For Up To 7 Days, Cumulative Time During The 7 Days; 5-10 Minutes | | | |
| Online Assessment | СРТ | 99422 | Online Digital Evaluation And Management Service, For An Established Patient, For Up To 7 Days, Cumulative Time During The 7 Days; 11-20 Minutes | | | |
| Online Assessment | СРТ | 99423 | Online Digital Evaluation And Management Service, For An Established Patient, For Up To 7 Days, Cumulative Time During The 7 Days; 21 Or More Minutes | | | |
| Online Assessment | СРТ | 99457 | Remote Physiologic Monitoring Treatment Management Services, Clinical Staff/physician/other Qualified Health Care Professional Time In A Calendar Month Requiring Interactive Communication With The Patient/caregiver During The Month; First 20 Minutes | | | |
| Online Assessment | СРТ | 99458 | Remote Physiologic Monitoring Treatment Management Services, Clinical | | | |
| Online Assessment | HCPCS | G0071 | Payment for communication technology-based services for 5 minutes or more of a virtual (nonface-to-face) communication between a rural heal clinic (RHC) or federally qualified health center (FQHC) practitioner and RHC or FQHC patient, or 5 minutes or more of remote evaluation or recorded video and/or images by an RHC or FQHC practitioner, occurring lieu of an office visit; RHC or FQHC only | | | |
| Online Assessment | HCPCS | G2010 | Remote Evaluation Of Recorded Video And/or Images Submitted By An Established Patient (e.g., Store And Forward), Including Interpretation With Follow-up With The Patient Within 24 Business Hours, Not Originating From A Related E/m Service Provided Within the next 24 hours or soonest available appointment | | | |

| | CODES TO IDENTIFY ONLINE ASSESSMENTS: | | | | |
|----------------------|---------------------------------------|-------|---|--|--|
| Service | Code Type | Code | Code Description | | |
| Online Assessment | HCPCS | G2012 | Brief communication technology-based service, e.g., virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | | |
| Online Assessment | HCPCS | G2250 | Remote assessment of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment | | |
| Online Assessment | HCPCS | G2251 | Brief communication technology-based service, e.g. virtual check-in, by a qualified health care professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion | | |
| Online Assessment | HCPCS | G2252 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related EM service provided within the previous 7 days nor leading to an EM service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | | |

^{*}Code can only be applied to follow-up visits for non-high risk Members.

Note: Visits with an Urgent Care will not be accepted for the Post Discharge Follow-Up measure.

The following are excluded from the measure:

- 1. Hospice
- 2. Skilled Nursing Facility
- 3. Deliveries

Statin Therapy Received for Patients with Cardiovascular Disease (SPC)

Methodology: HEDIS®

Measure Description: The percentage of men who are 21-75 years of age and women who are 40-75 years of age during the measurement year (2024), who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Men who are 21-75 years of age as of December 31 of the measurement year (2024).
 - 2. Women who are 40-75 years of age as of December 31 of the measurement year (2024).
 - 3. Continuous enrollment with IEHP during the measurement year (2024) and the year prior (2023) with no more than one gap in continuous enrollment with IEHP of up to 45 days during each year of the continuous enrollment with IEHP period.

Denominator: Men who are 21-75 years of age and women who are 40-75 years of age who meet all criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had at least one dispensing event for high-intensity or moderate-intensity statin medication during the measurement year (2024).

| HIGH-AND MODERATE-INTENSITY STATIN MEDICATIONS: | | | | | |
|---|----------------------------------|--|--|--|--|
| Description | Prescription | | | | |
| High-intensity statin therapy | Atorvastatin 40-80 mg | | | | |
| High-intensity statin therapy | Amlodipine-atorvastatin 40-80 mg | | | | |
| High-intensity statin therapy | Rosuvastatin 20-40 mg | | | | |
| High-intensity statin therapy | Simvastatin 80 mg | | | | |
| High-intensity statin therapy | Ezetimibe-simvastatin 80 mg | | | | |
| Moderate-intensity statin therapy | Atorvastatin 10-20 mg | | | | |
| Moderate-intensity statin therapy | Amlodipine-atorvastatin 10-20 mg | | | | |
| Moderate-intensity statin therapy | Rosuvastatin 5-10 mg | | | | |
| Moderate-intensity statin therapy | Simvastatin 20-40 mg | | | | |
| Moderate-intensity statin therapy | Ezetimibe-simvastatin 20-40 mg | | | | |
| Moderate-intensity statin therapy | Pravastatin 40-80 mg | | | | |
| Moderate-intensity statin therapy | Lovastatin 40 mg | | | | |
| Moderate-intensity statin therapy | Fluvastatin 40-80 mg | | | | |
| Moderate-intensity statin therapy | Pitavastatin 1-4 mg | | | | |

Statin Therapy Received for Patients with Diabetes (SPD)

Methodology: HEDIS®

Measure Description: The percentage of Members who are 40-75 years of age during the measurement year (2024) with diabetes who did not have clinical atherosclerotic cardiovascular disease (ASCVD) who were dispensed at least one statin medication of any intensity during the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Members who 40-75 years as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) and the year prior (2023) with no more than one gap in continuous enrollment with IEHP of up to 45 days during each year of the continuous enrollment with IEHP period.

Denominator: Members who are 40-75 years of age who meet all criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had at least one dispensing event for any intensity statin medication during the measurement year (2024).

| HIGH, MODERATE AND LOW-INTENSITY STATIN MEDICATIONS | | | | |
|---|----------------------------------|--|--|--|
| Description | Prescription | | | |
| High-intensity statin therapy | Atorvastatin 40-80 mg | | | |
| High-intensity statin therapy | Amlodipine-atorvastatin 40-80 mg | | | |
| High-intensity statin therapy | Rosuvastatin 20-40 mg | | | |
| High-intensity statin therapy | Simvastatin 80 mg | | | |
| High-intensity statin therapy | Ezetimibe-simvastatin 80 mg | | | |
| Moderate-intensity statin therapy | Atorvastatin 10-20 mg | | | |
| Moderate-intensity statin therapy | Amlodipine-atorvastatin 10-20 mg | | | |
| Moderate-intensity statin therapy | Rosuvastatin 5-10 mg | | | |
| Moderate-intensity statin therapy | Simvastatin 20-40 mg | | | |
| Moderate-intensity statin therapy | Ezetimibe-simvastatin 20-40 mg | | | |
| Moderate-intensity statin therapy | Pravastatin 40-80 mg | | | |
| Moderate-intensity statin therapy | Lovastatin 40 mg | | | |
| Moderate-intensity statin therapy | Fluvastatin 40-80 mg | | | |
| Moderate-intensity statin therapy | Pitavastatin 1-4 mg | | | |
| Low-intensity statin therapy | Ezetimibe-simvastatin 10 mg | | | |
| Low-intensity statin therapy | Fluvastatin 20 mg | | | |
| Low-intensity statin therapy | Lovastatin 10-20 mg | | | |
| Low-intensity statin therapy | Pravastatin 10-20 mg | | | |
| Low-intensity statin therapy | Simvastatin 5-10 mg | | | |

Substance Use Assessment in Primary Care

Methodology: IEHP-Defined Quality Measure

Measure Description: The percentage of Members 18 years and older who were screened for substance use during the measurement year (2024).

| CODES TO IDENTIFY SUBSTANCE USE ASSESSMENT IN PRIMARY CARE: | | | | | |
|---|-----------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Substance Use Assessment in Primary Care | СРТ | 99408 | Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention (SBI) Services 15 to 30 Minutes | | |
| Substance Use Assessment in Primary Care | СРТ | 99409 | Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention (SBI) Services Greater than 30 Minutes | | |
| Substance Use Assessment in Primary Care | HCPCS | G0442 | Annual Alcohol Misuse Screening 15 Minutes | | |
| Substance Use Assessment in Primary Care | HCPCS | G0443 | Brief Face-to-face Behavioral Counseling for Alcohol Misuse, 15 Minutes | | |
| Substance Use Assessment in Primary Care | HCPCS | H0001 | Alcohol and/or Drug Assessment | | |
| Substance Use Assessment in Primary Care | HCPCS | H0049 | Alcohol and/or Drug Screening | | |
| Substance Use Assessment in Primary Care | | H0050 | Alcohol and/or Drug Service Brief Intervention Per 15 Minutes | | |

Denominator: All Members aged 18 years and older during the measurement year (2024). Member counted only once in the denominator.

• Anchor Date: December 31, 2024

Numerator: Members who were screened for substance use at least once during the measurement year (2024).

Examples of Substances Use Assessment in Primary Care screening tools include but are not limited to:

- Cut Down-Annoyed-Guilty-Eye-Opener Adapted to Include Drugs (CAGE-AID)
- Tobacco Alcohol, Prescription medication and other Substances (TAPS)
- National Institute on Drug Abuse (NIDA) Quick Screen for adults
 - o The single NIDA Quick Screen alcohol-related question can be used for alcohol use screening

- Drug Abuse Screening Test (DAST-10)
- Alcohol Use Disorders Identification Test (AUDIT-C)
- Parents, Partner, Past and Present (4Ps) for pregnant women and adolescents
- Car, Relax, Alone, Forget, Friends, Trouble (CRAFFT) for non-pregnant adolescents
- Michigan Alcoholism Screening Test Geriatric (MAST-G) alcohol screening for geriatric population

✓ Population: Adult and Adolescent

Antidepressant Medication Management (AMM)

Methodology: HEDIS®

Measure Description: The percentage of Members who are 18 years of age or older who had a diagnosis of major depression, remained on antidepressant medication treatment and who were treated with antidepressant medication.

- Two rates are reported:
 - 1. Effective Acute Phase Treatments: The percentage of Members who remained on an antidepressant medication for at least 84 days (12 weeks).
 - 2. Effective Continuation Phase Treatment: The percentage of Members who remained on antidepressant medication for at least 180 days (six months).
- Eligible population in this measure meets all of the following criteria:
 - 1. Members who are 18 years and older as of the Index Prescription Start Date (IPSD).
 - 2. Continuous enrollment with IEHP 105 days prior to the index prescription start date through 231 days after the index prescription start date.
 - 3. Filled a prescription for an antidepressant medication during the intake period (starting May 1, 2023, through April 30, 2024).
 - 4. Has at least one of the following 60 days prior and 60 days after the prescription date:
 - Diagnosis of major depression in an inpatient setting.
 - Diagnosis of major depression in an outpatient setting.
 - 5. Must have no prior prescriptions for antidepressant medications in the prior 105 days.

<u>Rate 1</u>

Denominator: Members who are 18 years of age or older who meet all criteria for the eligible population.

Anchor Date: Index prescription start date

Numerator: Members in the denominator that had at least 84 days (12 weeks) of treatment with antidepressant medication beginning on the Index Prescription Start Date (IPSD) through 114 days after the IPSD (115 total days).

Rate 2

Denominator: Members who are 18 years of age or older who meet all criteria for the eligible population.

• Anchor Date: Index prescription start date

Numerator: Members in the denominator that had at least 180 days (6 months) of treatment with antidepressant medication beginning on the Index Prescription Start Date (IPSD) through 231 days after the IPSD (232 total days).

| ANTIDEPRESSANT MEDICATION: | | | | | | |
|----------------------------------|--|---|--|--|--|--|
| Description | Prescription | | | | | |
| Miscellaneous Antidepressants | BupropionVortioxetine | Vilazodone | | | | |
| Monoamine Oxidase Inhibitors | IsocarboxazidPhenelzine | SelegilineTranylcypromine | | | | |
| Phenylpiperazine Antidepressants | Nefazdone Trazodone | | | | | |
| Psychotherapeutic Combinations | Amitriptyline-chlordiazepoxideAmitriptyline-perphenazine | Fluoxetine-olanzapine | | | | |
| SNRI Antidepressants | DesvenlafaxineDuloxetine | LevomilnacipranVenlafaxine | | | | |
| SSRI Antidepressants | Citalopram Escitalopram Fluoxetine | FluvoxamineParoxetineSetraline | | | | |
| Tetracyclic Antidepressants | Maprotiline | Mirtazapine | | | | |
| Tricyclic Antidepressants | Amitriptyline Amoxapine Clomipramine Desipramine Doxepin (>6mg) | ImipramineNortriptylineProtriptylineTrimipramine | | | | |

Screening for Clinical Depression in Primary Care

Summary of Changes to the Global Quality P4P Program Guide:

• Measure tools updated

Methodology: IEHP-Defined Quality Measure

Measure Description: The percentage of Members ages 12 and older screened for clinical depression during the measurement year (2024) with the result of the screening documented by the Provider. For this measure, two rates are calculated, and the average of both rates is used as the final score.

Rate 1: Screening for Clinical Depression - This measure assesses the percentage of Members aged 12 and older who were screened for clinical depression during a PCP visit using an age appropriate standardized tool during the measurement year (2024).

Denominator: All Members aged 12 years and older with a PCP visit in the measurement year (2024). Member counted only once in the denominator.

| PRIMARY CARE PROVIDER VISIT CODES: | | | |
|---|--------------|-------|--|
| Service | Code Type | Code | Code Description |
| Screening for Clinical Depression in Primary Care | СРТ | 99202 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 15-29 minutes of total time is spent on the date of the encounter. |
| Screening for Clinical Depression in Primary Care | СРТ | 99203 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 30-44 minutes of total time is spent on the date of the encounter. |
| Screening for Clinical Depression in Primary Care | СРТ | 99204 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 45-59 minutes of total time is spent on the date of the encounter. |

| PRIMARY CARE PROVIDER VISIT CODES: | | | | |
|---|--------------|-------|--|--|
| Service | Code Type | Code | Code Description | |
| Screening for Clinical Depression in Primary Care | СРТ | 99205 | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 60-74 minutes of total time is spent on the date of the encounter. | |
| Screening for Clinical Depression in Primary Care | СРТ | 99212 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 10-19 minutes of total time is spent on the date of the encounter. | |
| Screening for Clinical Depression in Primary Care | СРТ | 99213 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter. | |
| Screening for Clinical Depression in Primary Care | СРТ | 99214 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter. | |
| Screening for Clinical Depression in Primary Care | СРТ | 99215 | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 40-54 minutes of total time is spent on the date of the encounter. | |
| Screening for Clinical Depression in Primary Care | СРТ | 99384 | Initial comprehensive preventive medicine; evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12-17 years). | |
| Screening for Clinical Depression in Primary Care | СРТ | 99385 | Initial comprehensive preventive medicine; evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; age 18-39 years. | |
| Screening for Clinical Depression in Primary Care | СРТ | 99386 | Initial comprehensive preventive medicine; evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; age 40-64 years. | |
| Screening for Clinical Depression in Primary Care | | 99387 | Initial comprehensive preventive medicine; evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; age 65 years and older. | |

| PRIMARY CARE PROVIDER VISIT CODES: | | | | | | |
|---|--------------|-------|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99394 | Periodic comprehensive preventive medicine; re-evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12-17 years). | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99395 | Periodic comprehensive preventive medicine; re-evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; age 18-39 years. | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99396 | Periodic comprehensive preventive medicine; re-evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; age 40-64 years. | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99397 | Periodic comprehensive preventive medicine; re-evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; age 65 years and older. | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99446 | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 5-10 minutes of medical consultative discussion and review. | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99447 | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 11-20 minutes of medical consultative discussion and review. | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99448 | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 21-30 minutes of medical consultative discussion and review. | | | |
| Screening for Clinical Depression in Primary Care | СРТ | 99449 | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 31 minutes or more of medical consultative discussion and review. | | | |

| PRIMARY CARE PROVIDER VISIT CODES: | | | | | |
|---|--------------|-------|---|--|--|
| Service | Code Type | Code | Code Description | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G0402 | Initial preventive physical examination face-to-face visits services limited to new beneficiary during the first 12 months. | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G0438 | Annual wellness visit includes a personalized prevention plan of service (PPS) initial visit. | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G0439 | Annual wellness visit includes a personalized prevention plan of service (PPS) subsequent visit. | | |

| CODES TO IDENTIFY TELEPHONE VISITS: | | | | | |
|-------------------------------------|-----------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Telephone Visit | СРТ | 98966 | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion. | | |
| Telephone Visit | СРТ | 98967 | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion. | | |
| Telephone Visit | СРТ | 98968 | Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion. | | |
| Telephone Visit | СРТ | 99441 | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion. | | |
| Telephone Visit | СРТ | 99442 | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion. | | |

| CODES TO IDENTIFY TELEPHONE VISITS: | | | | | |
|-------------------------------------|-----------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Telephone Visit | СРТ | 99443 | Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion. | | |

Numerator: Members screened for clinical depression using an age appropriate standardized tool during the measurement year (2024).

| CODES TO IDENTIFY SCREENING FOR CLINICAL DEPRESSION: | | | | | | |
|--|-------------------------------------|-------|--|--|--|--|
| Service | Code Type Code Code Description | | Code Description | | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G0444 | Annual depression screening, 15 minutes. | | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G8431 | Screening for depression is documented as being positive and a follow-up plan is documented. | | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G8510 | Negative screen for clinical depression using a standardized tool patient not eligible/appropriate for follow-up plan. | | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G8511 | Screening for depression documented as positive, follow- up plan not documented, reason not given. | | | |

Rate 2: Appropriate Documentation of Depression Screening Result - This measure assesses the percent of Members in the measurement year (2024) screened for clinical depression who also had the result recorded and a follow-up plan documented, indicated on the date of the encounter. The clinical depression screening tool must be an age-appropriate standardized tool.

Denominator: Same as Rate 1.

Numerator: Members screened for clinical depression with a recorded result and follow-up plan if indicated, on the date of the encounter using an age appropriate standardized tool during the measurement year (2024).

| CODES TO IDENTIFY DOCUMENTATION OF DEPRESSION SCREENING RESULT: | | | | | |
|---|-------|-------|--|--|--|
| Service Code Type | | Code | Code Description | | |
| Screening for Clinical Depression in Primary Care | HCPCS | G8431 | Positive screen for clinical depression using a standardized tool and a follow-up plan is documented. | | |
| Screening for Clinical Depression in Primary Care | HCPCS | | Negative screen for clinical depression using a standardized tool patient not eligible/appropriate for follow-up plan. | | |

Definitions:

Screening – Completion of a clinical or diagnostic tool used to identify people at risk of developing or having a certain disease or condition, even in the absence of symptoms.

Standardized Depression Screening Tool – A normalized and validated depression screening tool developed for the Member population in which it is being utilized. The name of the age-appropriate standardized depression screening tool utilized must be documented in the medical record.

Examples of depression screening tools include:

Instruments for Adolescents <17 years of age

- Patient Health Questionnaire (PHQ-9)*
- Patient Health Questionnaire Modified for Teens (PHQ-9M)*
- Patient Health Questionnaire-2 (PHQ-2)®1
- Beck Depression Inventory-Fast Screen (BDI-FS)^{®1,2}
- Center for Epidemiologic Studies Depression Scale—Revised (CESD-R)
- Edinburgh Postnatal Depression Scale (EPDS)
- PROMIS Depression

Instruments for Adults 18 years and older

- Patient Health Questionnaire (PHQ-9)*
- Patient Health Questionnaire-2 (PHQ-2)®1
- Beck Depression Inventory-Fast Screen (BDI-FS)^{®1,2}
- Beck Depression Inventory (BDI-II)
- Center for Epidemiologic Studies Depression Scale—Revised (CESD-R)
- Duke Anxiety—Depression Scale (DUKE-AD)^{®2}
- Geriatric Depression Scale Short Form (GDS)¹
- Geriatric Depression Scale Long Form (GDS)
- Edinburgh Postnatal Depression Scale (EPDS)
- My Mood Monitor (M-3)®
- PROMIS Depression
- Clinically Useful Depression Outcome Scale (CUDOS)

Social Determinants of Health Screening Rate

Methodology: IEHP-Defined Equity Measure

Measure Description: The percentage of Members who were screened for social determinants of health during the measurement year (2024).

Eligible population in this measure meets the following criteria:

1. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in continuous enrollment with IEHP of up to 45 days during the measurement year (2024).

Denominator: All Members during the measurement year (2024).

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who were screened for social determinants of health in the measurement year (2024).

| CODES TO IDENTIFY SOCIAL DETERMINANTS OF HEALTH SCREENING: | | | | | |
|--|--------------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Social Determinants of Health | СРТ | 96160 | Administration of patient-focused health risk assessment instrument (e.g. health hazard appraisal) with scoring and documentation, per standardized instrument. | | |
| Social Determinants of Health | СРТ | 96161 | Administration of caregiver-focused health risk assessment instrument (e.g. depression inventory) for the benefit of the patient, with scoring and documentation, per standardized instrument. | | |
| Social Determinants of Health | HCPCS | G9919 | Screening performed and positive and provision of recommendations. | | |
| Social Determinants of Health | HCPCS | G9920 | Screening performed and negative. | | |

Examples of Social Determinants of Health screening instruments include but are not limited to:

| FOOD INSECURITY INSTRUMENTS: | | | | |
|--|--|--|--|--|
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool | | | | |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool | | | | |
| Health Leads Screening Panel®1 | | | | |
| Hunger Vital Sign™1 (HVS) | | | | |
| Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE]®1 | | | | |
| Safe Environment for Every Kid (SEEK)*1 | | | | |
| U.S. Household Food Security Survey [U.S. FSS] | | | | |
| U.S. Adult Food Security Survey [U.S. FSS] | | | | |
| U.S. Child Food Security Survey [U.S. FSS] | | | | |
| U.S. Household Food Security Survey–Six-Item Short Form [U.S. FSS] | | | | |
| We Care Survey | | | | |
| WellRx Questionnaire | | | | |

HOUSING INSTABILITY AND HOMELESSNESS INSTRUMENTS:

Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool

American Academy of Family Physicians (AAFP) Social Needs Screening Tool

Children's Health Watch Housing Stability Vital Signs™1

Health Leads Screening Panel®1

Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE]®1

We Care Survey

WellRx Questionnaire

Accountable Health communities (AHC) Health - Related Social Needs (HRSN Screening Tool)

American Academy and Family Physicians (AAFP) Social Needs Screening Tool

TRANSPORTATION INSECURITY INSTRUMENTS:

Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool

American Academy of Family Physicians (AAFP) Social Needs Screening Tool

Comprehensive Universal Behavior Screen (CUBS)

Health Leads Screening Panel®1

Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE]®1

PROMIS®1

WellRx Questionnaire

Social Determinants of Health Identification Rate

Methodology: IEHP-Defined Equity Measure

Measure Description: The percentage of Members who were screened for social determinants of health during the measurement year (2024) and who had at least one social determinant of health identified.

Eligible population in this measure meet the following criteria:

1. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in continuous enrollment with IEHP of up to 45 days during the measurement year (2024).

Denominator: All Members during the measurement year (2024).

Anchor Date: December 31, 2024

Numerator: Members in the denominator who were screened for social determinant in the measurement year (2024) and had a social determinant identified.

| CODES TO IDENTIFY PRIORITY SOCIAL DETERMINANTS OF HEALTH | | | | | | |
|--|-----------|---------|---|--|--|--|
| SCREENING IDENTIFICATION FACTORS: | | | | | | |
| Service | Code Type | Code | Code Description | | | |
| Social Determinants of Health | ICD10CM | Z55.0 | Illiteracy and low-level literacy | | | |
| Social Determinants of Health | ICD10CM | Z58.6 | Inadequate drinking-water supply | | | |
| Social Determinants of Health | ICD10CM | Z59.00 | Homelessness unspecified | | | |
| Social Determinants of Health | ICD10CM | Z59.01 | Sheltered homelessness | | | |
| Social Determinants of Health | ICD10CM | Z59.02 | Unsheltered homelessness | | | |
| Social Determinants of Health | ICD10CM | Z59.1 | Inadequate housing (lack of heating/space, unsatisfactory surroundings) | | | |
| Social Determinants of Health | ICD10CM | Z59.3 | Problems related to living in residential institution | | | |
| Social Determinants of Health | ICD10CM | Z59.41 | Food insecurity | | | |
| Social Determinants of Health | ICD10CM | Z59.48 | Other specified lack of adequate food | | | |
| Social Determinants of Health | ICD10CM | Z59.7 | Insufficient social insurance and welfare support | | | |
| Social Determinants of Health | ICD10CM | Z59.811 | Housing instability, housed, with risk of homelessness | | | |
| Social Determinants of Health | ICD10CM | Z59.812 | Housing instability, housed, homelessness in past 12 months | | | |
| Social Determinants of Health | ICD10CM | Z59.819 | Housing instability, housed unspecified | | | |
| Social Determinants of Health | ICD10CM | Z59.89 | Other problems related to housing and economic circumstances | | | |
| Social Determinants of Health | ICD10CM | Z60.2 | Problems related to living alone | | | |
| Social Determinants of Health | ICD10CM | Z60.4 | Social exclusion and rejection (physical appearance, illness, or behavior) | | | |
| Social Determinants of Health | ICD10CM | Z62.819 | Personal history of unspecified abuse in childhood | | | |
| Social Determinants of Health | ICD10CM | Z63.0 | Problems in relationship with spouse or partner | | | |
| Social Determinants of Health | ICD10CM | Z63.4 | Disappearance and death of family member (assumed death, bereavement) | | | |
| Social Determinants of Health | ICD10CM | Z63.5 | Disruption of family by separation and divorce (marital estrangement) | | | |
| Social Determinants of Health | ICD10CM | Z63.6 | Dependent relative needing care at home | | | |
| Social Determinants of Health | ICD10CM | Z63.72 | Alcoholism and drug addiction in family | | | |
| Social Determinants of Health | ICD10CM | Z65.1 | Imprisonment and other incarceration | | | |
| Social Determinants of Health | ICD10CM | Z65.2 | Problems related to release from prison | | | |
| Social Determinants of Health | ICD10CM | Z65.8 | Other specified problems related to psychosocial circumstances (religious or spiritual problem) | | | |

| CODES TO IDENTIFY ADDITIONAL SOCIAL DETERMINANTS OF HEALTH SCREENING IDENTIFICATION FACTORS: | | | | |
|--|---|-----------|--------|--|
| Service | Category | Code Type | Code | Code Description |
| Social Determinants of Health | | ICD10CM | Z55.0 | Illiteracy and low-level literacy |
| Social Determinants of Health | | ICD10CM | Z55.1 | Schooling unavailable and unattainable |
| Social Determinants of Health | Problems related to | ICD10CM | Z55.2 | Failed school examinations |
| Social Determinants of Health | education & literacy | ICD10CM | Z55.3 | Underachievement in school |
| Social Determinants of Health | | ICD10CM | Z55.4 | Educational maladjustment and discord with teachers and classmates |
| Social Determinants of Health | | ICD10CM | Z55.9 | Problems related to education and literacy, unspecified |
| Social Determinants of Health | | ICD10CM | Z56.0 | Unemployment, unspecified |
| Social Determinants of Health | | ICD10CM | Z56.1 | Change of job |
| Social Determinants of Health | Problems related to employment and unemployment | ICD10CM | Z56.2 | Threat of job loss |
| Social Determinants of Health | | ICD10CM | Z56.4 | Discord with boss and workmates |
| Social Determinants of Health | | ICD10CM | Z56.5 | Uncongenial work environment |
| Social Determinants of Health | | ICD10CM | Z56.6 | Other physical and mental strain related to work |
| Social Determinants of Health | | ICD10CM | Z56.81 | Sexual harassment on the job |
| Social Determinants of Health | | ICD10CM | Z56.82 | Military deployment status |
| Social Determinants of Health | | ICD10CM | Z56.9 | Unspecified problems related to employment |
| Social Determinants of Health | | ICD10CM | Z57.0 | Occupational exposure to noise |
| Social Determinants of Health | | ICD10CM | Z57.1 | Occupational exposure to radiation |
| Social Determinants of Health | Occupational exposure to risk factors | ICD10CM | Z57.2 | Occupational exposure to dust |
| Social Determinants of Health | | ICD10CM | Z57.31 | Occupational exposure to environmental tobacco smoke |
| Social Determinants of Health | | ICD10CM | Z57.39 | Occupational exposure to other air contaminants |
| Social Determinants of Health | | ICD10CM | Z57.4 | Occupational exposure to toxic agents in agriculture |

| CODES TO I | CODES TO IDENTIFY ADDITIONAL SOCIAL DETERMINANTS OF HEALTH SCREENING IDENTIFICATION FACTORS: | | | | |
|-------------------------------|--|-----------|---------|---|--|
| Service | Category | Code Type | Code | Code Description | |
| Social Determinants of Health | | ICD10CM | Z57.5 | Occupational exposure to toxic agents in other industries | |
| Social Determinants of Health | Occumational | ICD10CM | Z57.6 | Occupational exposure to extreme temperature | |
| Social Determinants of Health | Occupational exposure to risk factors | ICD10CM | Z57.7 | Occupational exposure to vibration | |
| Social Determinants of Health | 11014 1401010 | ICD10CM | Z57.8 | Occupational exposure to other risk factors | |
| Social Determinants of Health | | ICD10CM | Z57.9 | Occupational exposure to unspecified risk factor | |
| Social Determinants of Health | | ICD10CM | Z58.6 | Inadequate drinking-water supply | |
| Social Determinants of Health | | ICD10CM | Z59.00 | Homelessness unspecified | |
| Social Determinants of Health | | ICD10CM | Z59.01 | Sheltered homelessness | |
| Social Determinants of Health | | ICD10CM | Z59.02 | Unsheltered homelessness | |
| Social Determinants of Health | | ICD10CM | Z59.1 | Inadequate housing (lack of heating/space, unsatisfactory surroundings) | |
| Social Determinants of Health | | ICD10CM | Z59.2 | Discord with neighbors, lodgers and landlord | |
| Social Determinants of Health | | ICD10CM | Z59.3 | Problems related to living in residential institution | |
| Social Determinants of Health | Problems | ICD10CM | Z59.41 | Food insecurity | |
| Social Determinants of Health | related to housing and economic | ICD10CM | Z59.48 | Other specified lack of adequate food | |
| Social Determinants of Health | circumstances | ICD10CM | Z59.5 | Extreme poverty | |
| Social Determinants of Health | | ICD10CM | Z59.6 | Low income | |
| Social Determinants of Health | | ICD10CM | Z59.7 | Insufficient social insurance and welfare support | |
| Social Determinants of Health | | ICD10CM | Z59.811 | Housing instability, housed, with risk of homelessness | |
| Social Determinants of Health | | ICD10CM | Z59.812 | Housing instability, housed, homelessness in past 12 months | |
| Social Determinants of Health | | ICD10CM | Z59.819 | Housing instability, housed unspecified | |
| Social Determinants of Health | | ICD10CM | Z59.89 | Other problems related to housing and economic circumstances | |
| Social Determinants of Health | | ICD10CM | Z59.9 | Problem related to housing and economic circumstances, unspecified | |

| CODES TO IDENTIFY ADDITIONAL SOCIAL DETERMINANTS OF HEALTH SCREENING IDENTIFICATION FACTORS: | | | | |
|--|--|-----------|---------|---|
| Service | Category | Code Type | Code | Code Description |
| Social Determinants of Health | | ICD10CM | Z60.0 | Problems of adjustment to life transitions (life phase, retirement) |
| Social Determinants of Health | | ICD10CM | Z60.2 | Problems related to living alone |
| Social Determinants of Health | Dooblesse | ICD10CM | Z60.3 | Acculturation difficulty (migration, social transplantation) |
| Social Determinants of Health | Problems related to social environment | ICD10CM | Z60.4 | Social exclusion and rejection (physical appearance, illness, behavior) |
| Social Determinants of Health | Cityiroiiiiiciit | ICD10CM | Z60.5 | Target of (perceived) adverse discrimination and persecution |
| Social Determinants of Health | | ICD10CM | Z60.8 | Other problems related to social environment |
| Social Determinants of Health | | ICD10CM | Z60.9 | Problem related to social environment, unspecified |
| Social Determinants of Health | | ICD10CM | Z62.0 | Inadequate parental supervision and control |
| Social Determinants of Health | | ICD10CM | Z62.1 | Parental overprotection |
| Social Determinants of Health | | ICD10CM | Z62.21 | Child in welfare custody (non-parental family member, foster care) |
| Social Determinants of Health | | ICD10CM | Z62.22 | Institutional upbringing (orphanage or group home) |
| Social Determinants of Health | | ICD10CM | Z62.29 | Other upbringing away from parents |
| Social Determinants of Health | | ICD10CM | Z62.3 | Hostility towards and scapegoating of child |
| Social Determinants of Health | Problems related to | ICD10CM | Z62.6 | Inappropriate (excessive) parental pressure |
| Social Determinants of Health | upbringing | ICD10CM | Z62.810 | Personal history of physical and sexual abuse in childhood |
| Social Determinants of Health | | ICD10CM | Z62.811 | Personal history of psychological abuse in childhood |
| Social Determinants of Health | | ICD10CM | Z62.812 | Personal history of neglect in childhood |
| Social Determinants of Health | | ICD10CM | Z62.813 | Personal history of forced labor or sexual exploitation in childhood |
| Social Determinants of Health | | ICD10CM | Z62.819 | Personal history of unspecified abuse in childhood |
| Social Determinants of Health | | ICD10CM | Z62.820 | Parent-biological child conflict |
| Social Determinants of Health | | ICD10CM | Z62.821 | Parent-adopted child conflict |

| CODES TO IDENTIFY ADDITIONAL SOCIAL DETERMINANTS OF HEALTH SCREENING IDENTIFICATION FACTORS: | | | | |
|--|--|-----------|---------|---|
| Service | Category | Code Type | Code | Code Description |
| Social Determinants of Health | | ICD10CM | Z62.822 | Parent-foster child conflict |
| Social Determinants of Health | | ICD10CM | Z62.890 | Parent-child estrangement NEC |
| Social Determinants of Health | Problems related to | ICD10CM | Z62.891 | Sibling rivalry |
| Social Determinants of Health | upbringing | ICD10CM | Z62.898 | Other specified problems related to upbringing |
| Social Determinants of Health | | ICD10CM | Z62.9 | Problem related to upbringing, unspecified |
| Social Determinants of Health | | ICD10CM | Z72.3 | Lack of physical exercise |
| Social Determinants of Health | | ICD10CM | Z63.0 | Problems in relationship with spouse or partner |
| Social Determinants of Health | | ICD10CM | Z63.1 | Problems in relationship with in-laws |
| Social Determinants of Health | | ICD10CM | Z63.31 | Absence of family member due to military deployment |
| Social Determinants of Health | | ICD10CM | Z63.32 | Other absence of family member |
| Social Determinants of Health | Other | ICD10CM | Z63.4 | Disappearance/death of family member (assumed death, bereavement) |
| Social Determinants of Health | | ICD10CM | Z63.5 | Disruption of family by separation and divorce (marital estrangement) |
| Social Determinants of Health | problems related to | ICD10CM | Z63.6 | Dependent relative needing care at home |
| Social Determinants of Health | primary support group, including | ICD10CM | Z63.71 | Stress on family due to return of family from military deployment |
| Social Determinants of Health | family circumstances | ICD10CM | Z63.72 | Alcoholism and drug addiction in family |
| Social Determinants of Health | | ICD10CM | Z63.79 | Other stressful events affecting family/ household (ill/disturbed member) |
| Social Determinants of Health | | ICD10CM | Z63.8 | Other specified problems related to primary support group (discord or estrangement, inadequate support) |
| Social Determinants of Health | | ICD10CM | Z63.9 | Problem related to primary support group, unspecified |
| Social Determinants of Health | | ICD10CM | Z81.8 | Family history of other mental and behavioral disorders |
| Social Determinants of Health | | ICD10CM | Z91.89 | Other specified personal risk factors, not elsewhere classified |

| CODES TO IDENTIFY ADDITIONAL SOCIAL DETERMINANTS OF HEALTH SCREENING IDENTIFICATION FACTORS: | | | | |
|--|--|-----------|--------|--|
| Service | Category | Code Type | Code | Code Description |
| Social Determinants of Health | | ICD10CM | Z64.0 | Problems related to unwanted pregnancy |
| Social Determinants of Health | | ICD10CM | Z64.1 | Problems related to multiparity |
| Social Determinants of Health | | ICD10CM | Z64.4 | Discord with counselors |
| Social Determinants of Health | | ICD10CM | Z65.0 | Conviction in civil and criminal proceedings without imprisonment |
| Social Determinants of Health | | ICD10CM | Z65.1 | Imprisonment and other incarceration |
| Social Determinants of Health | Problems related to other psychosocial circumstances | ICD10CM | Z65.2 | Problems related to release from prison |
| Social Determinants of Health | | ICD10CM | Z65.3 | Problems related to other legal circumstances (arrest, custody, litigation) |
| Social Determinants of Health | | ICD10CM | Z65.4 | Victim of crime and terrorism |
| Social Determinants of Health | | ICD10CM | Z65.5 | Exposure to disaster, war and other hostilities |
| Social Determinants of Health | | ICD10CM | Z65.8 | Other specified problems related to psychosocial circumstances (religious or spiritual problem) |
| Social Determinants of Health | | ICD10CM | Z65.9 | Problem related to unspecified psychosocial circumstances |
| Social Determinants of Health | Transportation Insecurity | ICD10CM | Z59.82 | Excessive transportation time, inaccessible transportation, inadequate transportation, lack of transportation, unaffordable transportation, unreliable transportation, unsafe transportation |

Social Need Screening and Intervention (SNS-E)

Methodology: HEDIS[®]

Measure Description: The percentage of Members who were screened for social needs, at least once during the measurement year (2024), and received a corresponding intervention if the Member screened positive. Each of the following three social need indicators will be monitored below:

- Food Insecurity
- Housing Insecurity
- Transportation Insecurity

Eligible population in this measure meets the following criteria:

1. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in continuous enrollment with IEHP of up to 45 days during the measurement year (2024).

Members who meet any of the following criteria are excluded:

- 1. Members in hospice.
- 2. Members who expire at any time during the measurement year (2024).

Screening Rate:

Denominator: All Members during the measurement year (2024).

- Anchor Date: December 31, 2024.

<u>Numerator</u>: Members with documented results who were screened for food insecurity, housing insecurity, or transportation insecurity between January 1st and December 1st of the measurement year (2024).

Follow-up Rate:

<u>Denominator:</u> All Members who are positive for food insecurity, housing insecurity, or transportation insecurity between January 1st and December 1st of the measurement year (2024).

- Anchor Date: December 31, 2024.

<u>Numerator:</u> Members who are positive for food insecurity, housing insecurity, or transportation insecurity screening who received a corresponding intervention within 30-days of the positive screening.

Refer to the Social Need Intervention List on the IEHP website https://www.providerservices.iehp.org/en/provider-central/provider-incentive-programs/pay-for-performance-program.
This list includes codes that identify the Social Need Intervention.

Screening Tools:

| FOOD INSECURITY: | | | |
|---|----------------------------|---------------------------------|--|
| Food Insecurity Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes | |
| Accountable Health Communities (AHC) Health-Related | 88122-7 | LA28397-0 LA6729-3 | |
| Social Needs (HRSN) Screening Too | 88123-5 | LA28397-0 LA6729-3 | |
| American Academy of Family Physicians (AAFP) Social | 88122-7 | LA28397-0 LA6729-3 | |
| Needs Screening Tool | 88123-5 | LA28397-0 LA6729-3 | |
| American Academy of Family Physicians (AAFP) Social | 88122-7 | LA28397-0 LA6729-3 | |
| Needs Screening Tool—short form | 88123-5 | LA28397-0 LA6729-3 | |
| Health Leads Screening Panel®1 | 95251-5 | LA33-6 | |
| Hunger Vital Sign™1 (HVS) | 88124-3 | LA19952-3 | |
| Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE]*1 | 93031-3 | LA30125-1 | |
| Safe Environment for Every Kid (SEEK)®1 | 95400-8 | LA33-6 | |
| Safe Environment for Every Rid (SEER) 1 | 95399-2 | LA33-6 | |
| U.S. Household Food Security Survey [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 | |
| U.S. Adult Food Security Survey [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 | |
| U.S. Child Food Security Survey [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 | |
| U.S. Household Food Security Survey–Six-Item Short Form [U.S. FSS] | 95264-8 | LA30985-8 LA30986-6 | |
| We Care Survey | 96434-6 | LA32-8 | |
| WellRx Questionnaire | 93668-2 | LA33-6 | |

| HOUSING INSECURITY: | | | | |
|---|----------------------------|---------------------------------|--|--|
| Housing Instability and Homelessness Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes | | |
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Too | 71802-3 | LA31994-9 LA31995-6 | | |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool | 99550-6 | LA33-6 | | |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form | 71802-3 | LA31994-9 LA31995-6 | | |

| HOUSING INSECURITY: | | | | |
|--|-------------------------------|---------------------------------|--|--|
| Housing Instability and Homelessness Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes | | |
| | 98976-4 | LA33-6 | | |
| Children's Health Watch Housing Stability Vital Signs™1 | 98977-2 | ≥3 | | |
| | 98978-0 | LA33-6 | | |
| Health Leads Screening Panel®1 | 99550-6 | LA33-6 | | |
| Protocol for Responding to and Assessing Patients' Assets, | 93033-9 | LA33-6 | | |
| Risks and Experiences [PRAPARE]*1 | 71802-3 | LA30190-5 | | |
| We Care Survey | 96441-1 | LA33-6 | | |
| WellRx Questionnaire | 93669-0 | LA33-6 | | |

| HOUSING INSECURITY: | | | | |
|--|----------------------------|---|--|--|
| Housing Inadequacy Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes | | |
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool | 96778-6 | LA31996-4 LA28580-1 LA31997-2 LA31998-0 LA31999-8 | | |
| | | LA32000-4 LA32001-2 | | |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool | 96778-6 | LA32691-0 LA28580-1 LA32693-6 LA32694-4 LA32695-1 LA32696-9 LA32001-2 | | |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form | 96778-6 | LA31996-4 LA28580-1 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2 | | |
| | 99134-9 | LA33-6 | | |
| Norwalk Community Health Center Screening Tool [NCHC] | 99135-6 | LA31996-4 LA28580-1 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2 | | |

| TRANSPORTATION INSECURITY | | | | |
|---|-------------------------------|-------------------------------------|--|--|
| Transportation Insecurity Instruments | Screening Item LOINC Codes | Positive Finding LOINC Codes | | |
| Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool | 93030-5 | LA33-6 | | |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool | 99594-4 | LA33-6 | | |
| American Academy of Family Physicians (AAFP) Social Needs Screening Tool—short form | 99594-4 | LA33093-8 LA30134-3 | | |
| Comprehensive Universal Behavior Screen (CUBS) | 89569-8 | LA29232-8 LA29233-6 LA29234-4 | | |
| Health Leads Screening Panel®1 | 99553-0 | LA33-6 | | |
| Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI)—version 4.0 [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 | | |
| Outcome and assessment information set (OASIS) form—version E—Discharge from Agency [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 | | |
| Outcome and assessment information set (OASIS) form—version E—Resumption of Care [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 | | |
| Outcome and assessment information set (OASIS) form—version E—Start of Care [CMS Assessment] | 93030-5 | LA30133-5 LA30134-3 | | |
| Protocol for Responding to and Assessing Patients' Assets, Risks and Experiences [PRAPARE]*1 | 93030-5 | LA30133-5 LA30134-3 | | |
| PROMIS*1 | 92358-1 | LA30024-6 LA30026-1 LA30027-9 | | |
| WellRx Questionnaire | 93671-6 | LA33-6 | | |

Note: The Social Need Screening and Intervention measure numerator counts only screenings that utilize instruments in the measure specification as identified by the associated LOINC code(s). Allowed screening instruments and LOINC codes for each social need are listed above.

✓ Population: Women

Breast Cancer Screening (BCS)

Methodology: HEDIS®

Measure Description: The percentage of members 50-74 years of age who had a mammogram to screen for breast cancer any time on or between October 1, two years prior to the measurement year (2022) and December 31 of the measurement year (2024).

- The eligible population in the measure meets all of the following criteria:
 - 1. Members 52-74 years as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP from October 1, two years prior to the measurement year (2022), through December 31 of the measurement year (2024) with no more than one gap in enrollment of up to 45 days for each calendar year of continuous enrollment with IEHP. No gaps in enrollment are allowed from October 1, two years prior to the measurement year (2022), through December 31 two years prior to the measurement year (2022).

| | CODES USED TO IDENTIFY MAMMOGRAPHY: | | | | |
|-------------------------|-------------------------------------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Breast Cancer Screening | CPT | 77061 | Digital Breast Tomosynthesis Unilateral | | |
| Breast Cancer Screening | CPT | 77062 | Digital Breast Tomosynthesis Bilateral | | |
| Breast Cancer Screening | СРТ | 77063 | Screening Digital Breast Tomosynthesis Bilateral (list Separately In Addition To Code For Primary Procedure) | | |
| Breast Cancer Screening | СРТ | 77065 | Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral | | |
| Breast Cancer Screening | СРТ | 77066 | Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral | | |
| Breast Cancer Screening | СРТ | 77067 | Screening Mammography Bilateral (Two-view Film Study Of Each Breast Including Computer-aided Detection (CAD) | | |

- Members who meet any of the following criteria are excluded:
 - 1. Members in hospice.
 - 2. Members receiving palliative care.
 - 3. Members who expired at any time during the measurement year (2024).
 - 4. Members who had gender-affirming chest surgery with a diagnosis of gender dysphoria any time during the member's history through the end of the measurement period (2024).
 - 5. Members 66 years of age and older as of December 31 of measurement year (2024) with both frailty and advanced illness.

Denominator: Members 52-74 years of age who meet the criteria for the eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had one or more mammograms any time on or between October 1, two years prior to the measurement year (2022), and December 31 of the measurement year (2024).

Cervical Cancer Screening (CCS)

Methodology: HEDIS®

Measure Description: The percentage of members 21–64 years of age who were screened for cervical cancer using either of the following criteria:

- Members ages 21-64 who had cervical cytology performed every three years.
- Members ages 30-64 who had cervical high-risk human papillomavirus (hrHPV) testing performed every five years.
- Members ages 30-64 who had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing performed every five years.
- The eligible population in the measure meets all of the following criteria:
 - 1. Members 24-64 years of age as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in enrollment of up to 45 days.

| | CODES TO IDENTIFY CERVICAL CYTOLOGY: | | | | |
|------------------------------|--------------------------------------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Cervical Cancer Screening | СРТ | 88141 | Cytopathology Cervical Or Vaginal (any Reporting System) Requiring Interpretation By Physician (List separately in addition to code for technical service) | | |
| Cervical Cancer Screening | СРТ | 88142 | Cytopathology Cervical Or Vaginal (any Reporting System) Collected In Preservative Fluid Automated Thin Layer Preparation Manual screening under Physician supervision | | |
| Cervical Cancer Screening | СРТ | 88143 | Cytopathology Cervical Or Vaginal (any Reporting System) Collected In Preservative Fluid Automated Thin Layer Preparation; manual screening Under Physician Supervision: With manual screening and rescreening Under Physician Supervision | | |
| Cervical Cancer Screening | СРТ | 88147 | Cytopathology Smears Cervical Or Vaginal Screening By Automated System Under Physician Supervision | | |

| CODES TO IDENTIFY CERVICAL CYTOLOGY: | | | | | | | |
|--------------------------------------|-----------|-------|---|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Cervical Cancer Screening | СРТ | 88148 | Cytopathology Smears Cervical Or Vaginal Screening By Automated System With Manual Rescreening Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88150 | Cytopathology Slides Cervical Or Vaginal Manual Screening Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88152 | Cytopathology Slides Cervical Or Vaginal With Manual Screening And Computer-assisted Rescreening Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88153 | Cytopathology Slides Cervical Or Vaginal With Manual Screening And Rescreening Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88164 | Cytopathology Slides Cervical Or Vaginal (the Bethesda System) Manual Screening Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88165 | Cytopathology Slides Cervical Or Vaginal (the Bethesda System) With Manual Screening And Rescreening Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88166 | Cytopathology Slides Cervical Or Vaginal (the Bethesda System) With Manual Screening And Computer-assisted Rescreening Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88167 | Cytopathology Slides Cervical Or Vaginal (the Bethesda System) With Manual Screening And Computer-assisted Rescreening Using cell selection and review Under Physician Supervision | | | | |
| Cervical Cancer Screening | СРТ | 88174 | Cytopathology Cervical Or Vaginal (any Reporting System) Collected In Preservative Fluid Automated Thin Layer Preparation | | | | |
| Cervical Cancer Screening | СРТ | 88175 | Cytopathology Cervical Or Vaginal (any Reporting System) Collected In Preservative Fluid Screening Automated By System | | | | |
| Cervical Cancer Screening | HCPCS | G0123 | Screening Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, Screening By Cytotechnologist Under Physician Supervision | | | | |
| Cervical Cancer Screening | HCPCS | G0124 | Screening Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, Requiring Interpretation By Physician | | | | |
| Cervical Cancer Screening | HCPCS | G0141 | Screening Cytopathology Smears, Cervical Or Vaginal, Performed By Automated System, With Manual Rescreening, Requiring Interpretation By Physician | | | | |
| Cervical Cancer Screening | HCPCS | G0143 | Screening Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, With Manual Screening And Rescreening By Cytotechnologist Under Physician Supervision | | | | |
| Cervical Cancer Screening | HCPCS | G0144 | Screening Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, With Screening By Automated System, Under Physician Supervision | | | | |
| Cervical Cancer Screening | HCPCS | G0145 | Screening Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, With Screening By Automated System And Manual Rescreening Under Physician Supervision | | | | |

| CODES TO IDENTIFY CERVICAL CYTOLOGY: | | | | | | |
|--------------------------------------|-----------|-------|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Cervical Cancer Screening | HCPCS | G0147 | Screening Cytopathology Smears, Cervical Or Vaginal, Performed By Automated System Under Physician Supervision | | | |
| Cervical Cancer Screening | HCPCS | G0148 | Screening Cytopathology Smears, Cervical Or Vaginal, Performed By Automated System With Manual Rescreening | | | |
| Cervical Cancer Screening | HCPCS | P3000 | Screening Papanicolaou Smear, Cervical Or Vaginal, Up To Three Smears, By Technician Under Physician Supervision | | | |
| Cervical Cancer Screening | HCPCS | P3001 | Screening Papanicolaou Smear, Cervical Or Vaginal, Up To Three Smears, Requiring Interpretation By Physician | | | |
| Cervical Cancer Screening | HCPCS | Q0091 | Screening Papanicolaou Smear; Obtaining, Preparing And Conveyance Of Cervical Or Vaginal Smear To Laboratory | | | |

| | CODES TO IDENTIFY HPV TESTS: | | | | | |
|------------------------------|------------------------------|-------|--|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Cervical Cancer Screening | СРТ | 87624 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Human Papilloma Virus (HPV) High-risk Types (e.g. 16 18 31 33 35 39 45 51 52 56 58 59 68) | | | |
| Cervical Cancer Screening | СРТ | 87625 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Human Papilloma Virus (HPV) Types 16 And 18 Only Includes Type 45, If Performed | | | |
| Cervical Cancer Screening | HCPCS | G0476 | Infectious Agent Detection By Nucleic Acid (DNA or RNA); Human Papilloma Virus (HPV), High-risk Types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) For Cervical Cancer Screening, Must Be Performed In Addition To Pap Test (g0476) | | | |

- Members who meet any of the following criteria are excluded:
 - 1. Members in hospice.
 - 2. Members receiving palliative care.
 - 3. Members who expired at any time during the measurement year (2024).
 - 4. Members who had a hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix.

Denominator: Members 24-64 years of age who meet the criteria for eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who received a timely screening for cervical cancer.

Chlamydia Screening in Women (CHL)

Methodology: HEDIS®

Measure Description: The percentage of women 16-24 years of age who identified as sexually active and had at least one test for chlamydia during the measurement year (2024).

- The eligible population in the measure meets all of the following criteria:
 - 1. Women 16-24 years as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP during the measurement year (2024) with no more than one gap in enrollment of up to 45 days.
 - 3. There are two methods to identify sexually active women: claim/encounter data or pharmacy data.

| CODES TO IDENTIFY SEXUALLY ACTIVE WOMEN: | | | | | | |
|--|-----------|-------|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Sexually Active | СРТ | 86631 | Antibody Chlamydia | | | |
| Sexually Active | CPT | 86632 | Antibody Chlamydia Igm | | | |
| Sexually Active | СРТ | 87810 | Infectious Agent Detection By Immunoassay With Direct Optical Observation Chlamydia Trachomatis | | | |
| Sexually Active | СРТ | 87270 | Infectious Agent Antigen Detection By Immunofluorescent Technique Chlamydia Trachomatis | | | |
| Sexually Active | СРТ | 87320 | Infectious Agent Antigen Detection By Enzyme Immunoassay Technique Qualitative Or Semiquantitative Multiple Step Method Chlamydia | | | |
| Sexually Active | СРТ | 87492 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Chlamydia Trachomatis Quantification | | | |
| Sexually Active | CPT | 87110 | Culture Chlamydia Any Source | | | |
| Sexually Active | СРТ | 87490 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Chlamydia Trachomatis Direct Probe Technique | | | |
| Sexually Active | СРТ | 87491 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Chlamydia Trachomatis Amplified Probe Technique | | | |
| Sexually Active | СРТ | 87492 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Chlamydia Trachomatis Quantification | | | |

| CONTRACEPTIVE MEDICATIONS | | | |
|---------------------------|---|--|--|
| Description | Prescription | | |
| Contraceptives | Desogestrel-ethinyl estradiol Dienogest-estradiol (multiphasic) Drospirenone-ethinyl estradiol Drospirenone-ethinyl estradiol-levomefolate (biphasic) Ethinyl estradiol-ethynodiol Ethinyl estradiol-etonogestrel Ethinyl estradiol-levonorgestrel Ethinyl estradiol-norelgestromin Ethinyl estradiol-norethindrone Ethinyl estradiol-norgestimate Ethinyl estradiol-norgestrel Etonogestrel Levonorgestrel Medroxyprogesterone Norethindrone | | |
| Diaphragm | Diaphragm | | |
| Spermicide | Nonxynol 9 | | |

| | CODES TO IDENTIFY CHLAMYDIA SCREENING: | | | | |
|------------------------|--|-------|---|--|--|
| Service | Code Type | Code | Code Description | | |
| Chlamydia Screening | СРТ | 87110 | Culture Chlamydia Any Source | | |
| Chlamydia Screening | СРТ | 87270 | Infectious Agent Antigen Detection By Immunofluorescent Technique Chlamydia Trachomatis | | |
| Chlamydia Screening | СРТ | 87320 | Infectious Agent Antigen Detection By Enzyme Immunoassay Technique Qualitative Or Semiquantitative Multiple Step Method Chlamydia | | |
| Chlamydia Screening | СРТ | 87490 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Chlamydia Trachomatis Direct Probe Technique | | |
| Chlamydia Screening | СРТ | 87491 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Chlamydia Trachomatis Amplified Probe Technique | | |
| Chlamydia Screening | СРТ | 87492 | Infectious Agent Detection By Nucleic Acid (DNA or RNA) Chlamydia Trachomatis Quantification | | |
| Chlamydia Screening | СРТ | 87810 | Infectious Agent Detection By Immunoassay With Direct Optical Observation Chlamydia Trachomatis | | |
| Chlamydia Screening | СРТ | 0353U | Infectious Agent Detection By Nucleic Acid (dna), Chlamydia Trachomatis And Neisseria Gonorrhoeae, Multiplex Amplified Probe Technique, Urine, Vaginal, Pharyngeal, Or Rectal, Each Pathogen Reported As Detected Or Not Detected | | |

Denominator: Women 16-24 years of age who meet the criteria for eligible population.

• Anchor Date: December 31, 2024

Numerator: Women in the denominator who were tested at least once for chlamydia during the measurement year (2024).

✓ Population: Child

Child and Adolescent Well-Care Visits (WCV)

Methodology: HEDIS®

Measure Description: The percentage of Members ages 3-21 who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Ages 3-21 as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP throughout the measurement year (2024). No more than one gap in enrollment of up to 45 days during the measurement year (2024).

| | CODES TO IDENTIFY WELL-CARE VISITS: | | | | |
|--------------------|-------------------------------------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Well-Care Visit | СРТ | 99382 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; early childhood (age 1 through 4 years) | | |
| Well-Care Visit | СРТ | 99383 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; late childhood (age 5 through 11 years) | | |
| Well-Care Visit | СРТ | 99384 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12 through 17 years) | | |
| Well-Care Visit | СРТ | 99385 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years | | |
| Well-Care Visit | СРТ | 99392 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | | |

| | CODES TO IDENTIFY WELL-CARE VISITS: | | | | | | |
|-----------------|-------------------------------------|---------|--|--|--|--|--|
| Service | Code Type | Code | Code Description | | | | |
| Well-Care Visit | СРТ | 99393 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | | | | |
| Well-Care Visit | СРТ | 99394 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | | | | |
| Well-Care Visit | СРТ | 99395 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | | | | |
| Well-Care Visit | HCPCS | G0438 | Annual wellness visit; includes a personalized prevention plan of service (PPS), initial visit | | | | |
| Well-Care Visit | HCPCS | G0439 | Annual wellness visit, includes a personalized prevention plan of service (PPS), subsequent visit | | | | |
| Well-Care Visit | HCPCS | S0302 | Completed early periodic screening diagnosis and treatment (EPSDT) service (list in addition to code for appropriate evaluation and management service) | | | | |
| Well-Care Visit | HCPCS | S0610 | Annual gynecological examination, new patient | | | | |
| Well-Care Visit | HCPCS | S0612 | Annual gynecological examination, established patient | | | | |
| Well-Care Visit | HCPCS | S0613 | Annual gynecological examination; clinical breast examination without pelvic evaluation | | | | |
| Well-Care Visit | ICD-10 | Z00.00 | Encounter for general adult medical examination without abnormal findings | | | | |
| Well-Care Visit | ICD-10 | Z00.01 | Encounter for general adult medical examination with abnormal findings | | | | |
| Well-Care Visit | ICD-10 | Z00.121 | Encounter for routine child health examination with abnormal findings | | | | |
| Well-Care Visit | ICD-10 | Z00.129 | Encounter for routine child health examination without abnormal findings | | | | |
| Well-Care Visit | ICD-10 | Z01.411 | Encounter for gynecological examination (general) (routine) with abnormal findings | | | | |
| Well-Care Visit | ICD-10 | Z01.419 | Encounter for gynecological examination (general) (routine) without abnormal findings | | | | |
| Well-Care Visit | ICD-10 | Z00.2 | Encounter for examination for period of rapid growth in childhood | | | | |
| Well-Care Visit | ICD-10 | Z00.3 | Encounter for examination for adolescent development state | | | | |
| Well-Care Visit | ICD-10 | Z02.5 | Encounter for examination for participation in sport | | | | |
| Well-Care Visit | ICD-10 | Z76.1 | Encounter for health supervision and care of foundling | | | | |
| Well-Care Visit | ICD-10 | Z76.2 | Encounter for health supervision and care of other healthy infant and child | | | | |

Denominator: The eligible population.

• Anchor Date December 31, 2024

Numerator: Members in the denominator who had one or more well-care visits with a PCP or an OB/GYN during the measurement year (2024).



Childhood Immunizations (CIS) - Combo 10

Summary of Changes to the Global Quality P4P Program Guide:

• Update to the exclusions

Methodology: HEDIS®

Measure Description: The percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); three haemophilus influenza type B (HiB); three hepatitis B (HepB); four pneumococcal conjugate (PCV); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The percentage of children 2 years of age who had one measles, mumps and rubella (MMR); one chicken pox (VZV); and one hepatitis A (HepA) vaccines on or between the child's first and second birthdays. The measure calculates a rate for each vaccine and one combination rate.

- Combo 10 includes the timely completion of the following antigens:
 - DTaP; IPV; MMR; HiB; HepB; VZV; PCV; HepA; Rotavirus; Flu
- The eligible population in this measure meets all of the following criteria:
 - 1. Children who turn 2 during the measurement year (2024).
 - 2. Continuous enrollment with IEHP 12 months prior to the child's second birthday with no more than one gap in enrollment of up to 45 days during the 12 months prior to the child's second birthday.

| CHILDHOOD IMMUNIZATION CODE SET: | | | | | |
|----------------------------------|-----------|-------|---|--|--|
| Antigen | Code Type | Code | Code Description | | |
| DTaP | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | | |
| DTaP | СРТ | 90698 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine And Activated Poliovirus Vaccine, (DTaP-IPV/Hib), For Intramuscular Use | | |
| DTaP | СРТ | 90700 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine (DTaP) For Intramuscular Use | | |

| | CHILDHOOD IMMUNIZATION CODE SET: | | | | | |
|---------|----------------------------------|-------|---|--|--|--|
| Antigen | Code Type | Code | Code Description | | | |
| DTaP | СРТ | 90723 | Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (DTaP-HepB-IPV), For Intramuscular Use | | | |
| IPV | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | | | |
| IPV | CPT | 90698 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine and activated poliovirus vaccine, (DTaP-IPV/HiB), For Intramuscular Use | | | |
| IPV | CPT | 90713 | Poliovirus Vaccine Inactivated (IPV) For Subcutaneous Use | | | |
| IPV | СРТ | 90723 | Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (DTaP-HepB-IPV), For Intramuscular Use | | | |
| MMR | СРТ | 90707 | Measles Mumps And Rubella Virus Vaccine (MMR) Live For Subcutaneous Use | | | |
| MMR | СРТ | 90710 | Measles Mumps Rubella And Varicella Vaccine (MMRV) Live For Subcutaneous Use | | | |
| HiB | СРТ | 90644 | Meningococcal Conjugate Vaccine, Serogroups C & Y And Hemophilus Influenzae Type B Vaccine (HiB-mency), four dose schedule, when administered to children six weeks-18 months of age, for intramuscular use | | | |
| HiB | СРТ | 90647 | Hemophilus Influenza B Vaccine (HiB) Prp-omp Conjugate (Three Dose Schedule) For Intramuscular Use | | | |
| HiB | СРТ | 90648 | Hemophilus Influenza B Vaccine (HiB) prp-t Conjugate (Four Dose Schedule) For Intramuscular Use | | | |
| HiB | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | | | |
| HiB | СРТ | 90698 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine and activated poliovirus vaccine, (DTaP-IPV/HiB), for intramuscular use | | | |
| HiB | СРТ | 90748 | Hepatitis B And Hemophilus Influenza B Vaccine (HepB-HiB) For Intramuscular Use | | | |
| НерВ | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | | | |
| НерВ | СРТ | 90723 | Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (DTaP-HepB-IPV), For Intramuscular use | | | |
| НерВ | СРТ | 90740 | Hepatitis B Vaccine Dialysis Or Immunosuppressed Patient Dosage (Three Dose Schedule) For Intramuscular Use | | | |
| НерВ | СРТ | 90744 | Hepatitis B Vaccine Pediatric/adolescent Dosage (Three Dose Schedule) For Intramuscular Use | | | |
| НерВ | СРТ | 90747 | Hepatitis B Vaccine Dialysis Or Immunosuppressed Patient Dosage (Four Dose Schedule) For Intramuscular Use | | | |

| | CHILDHOOD IMMUNIZATION CODE SET: | | | | | |
|-----------------------------|----------------------------------|-------|---|--|--|--|
| Antigen | Code Type | Code | Code Description | | | |
| НерВ | СРТ | 90748 | Hepatitis B And Hemophilus Influenza B Vaccine (HepB-HiB) For Intramuscular Use | | | |
| НерВ | HCPCS | G0010 | Administration Of Hepatitis B Vaccine | | | |
| VZV | СРТ | 90710 | Measles Mumps Rubella And Varicella Vaccine (MMRV) Live For Subcutaneous Use | | | |
| VZV | CPT | 90716 | Varicella Virus Vaccine Live For Subcutaneous Use | | | |
| PCV | CPT | 90670 | Pneumococcal Conjugate Vaccine 13 Valent For Intramuscular Use | | | |
| PCV | CPT | 90671 | Pneumococcal Conjugate Vaccine, 15 Valent (pcv15), For Intramuscular Use | | | |
| PCV | CPT | 90677 | Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | | | |
| PCV | HCPCS | G0009 | Administration Of Pneumococcal Vaccine | | | |
| НерА | СРТ | 90633 | Hepatitis A Vaccine Pediatric/adolescent Dosage-2 Dose Schedule For Intramuscular Use | | | |
| Rotavirus - Two Dose* | СРТ | 90681 | Rotavirus Vaccine Human Attenuated Two Dose Schedule Live For Oral Use. | | | |
| Rotavirus - Three Dose** | СРТ | 90680 | Rotavirus Vaccine Tetravalent Live For Oral Use | | | |
| Flu | СРТ | 90655 | Influenza Virus Vaccine, Trivalent (IIV3), Split Virus, Preservative Free, 0.25ml Dosage, For Intramuscular Use | | | |
| Flu | СРТ | 90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use | | | |
| Flu | CPT | 90660 | Influenza virus vaccine, trivalent, live (LAIV3) for intranasal use | | | |
| Flu | СРТ | 90661 | Influenza Virus Vaccine Derived From Cell Cultures Subunit Preservative And Antibiotic Free For Intramuscular Use | | | |
| Flu | CPT | 90672 | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | | | |
| Flu | СРТ | 90673 | Influenza Virus Vaccine Trivalent Derived From Recombinant DNA (RIV3) Hemagglutinin (HA) Protein Only Preservative And Antibiotic | | | |
| Flu | СРТ | 90674 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | | | |
| Flu | СРТ | 90685 | Influenza Virus Vaccine Quadrivalent (II4V) Split Virus Preservative Free, 0.25 mL dosage, for Intramuscular Use | | | |
| Flu | СРТ | 90686 | Influenza Virus Vaccine Quadrivalent (II4V) Split Virus Preservative Free, 0.5 mL dosage, for Intramuscular Use | | | |
| Flu | СРТ | 90687 | Influenza Virus Vaccine Quadrivalent (II4V) Split Virus, 0.25 mL dosage, for Intramuscular Use | | | |
| Flu | СРТ | 90688 | Influenza Virus Vaccine Quadrivalent (II4V) Split Virus, 0.5 mL dosage, for Intramuscular Use | | | |
| Flu | СРТ | 90689 | Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use | | | |
| Flu | СРТ | 90756 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use | | | |
| Flu | HCPCS | G0008 | Administration Of Influenza Virus Vaccine | | | |

^{*}Rotavirus - Two Dose: At least two doses of the two-dose rotavirus vaccine on different dates of services.

^{**}Rotavirus - Three Dose: At least three doses of the three-dose rotavirus vaccine on different dates of service.

- Members who meet any of the following criteria are excluded:
 - 1. Members in hospice.
 - 2. Members who expired at any time during the measurement year (2024).
 - 3. Members who had a contraindication to a childhood vaccine on or before their second birthday.

Denominator: Children 2 years of age in the eligible population.

• Anchor Date: Child's 2nd birthday

Numerator: Members in denominator who show timely completion of all antigens in Combo10.

• All immunization series must be at least 14 days apart.



Lead Screening in Children (LSC)

Methodology: HEDIS®

Measure Description: The percentage of children who are 2 years of age and had one or more capillary or venous lead blood tests for lead poisoning, by their second birthday.

- The eligible population in this measure meets all the following criteria:
 - 1. No more than one gap in enrollment of up to 45 days during the 365 days before the child's second birthday.
 - 2. Continuous enrollment with IEHP 365 days before the child's second birthday.
- Members in hospice are excluded.
- Members who expire at any time during the measurement year (2024).

Denominator: Children who turn 2 years old during the measurement year (2024).

• Anchor Date: Child's second birthday.

Numerator: At least one lead capillary or venous blood test on or before the child's second birthday.

| CODES TO IDENTIFY LEAD SCREENING: | | | | | |
|-----------------------------------|-------------------------------------|-------|------|--|--|
| Service | Code Type Code Code Description | | | | |
| Lead Screening | CPT | 83655 | Lead | | |

Developmental Screening

Methodology: CMS Child Core Set

Measure Description: The percentage of children who are screened for the risk of developmental, behavioral and social delays using a standardized screening tool, in the 12 months before or on their first, second or third birthday in the measurement year (2024).

- Eligible population in this measure meets all of the following criteria:
 - 1. Children turning ages 1-3 as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP for 12 months prior to the child's first, second or third birthday with no more than one gap in enrollment of up to 45 days during the 12 months prior to the child's first, second or third birthday.

Denominator: Children who turn ages 1, 2 or 3 by December 31 of the measurement year (2024).

• Anchor Date: Child's birthday in the measurement year

Numerator: Children who were screened for risk of developmental, behavioral and social delays on or before the child's first, second or third birthday.

Examples of developmental screening tools include but are not limited to:

- Ages and Stages Questionnaire 3rd Edition (ASQ-3)
- Parents' Evaluation of Developmental Status (PEDS)
- Parents' Evaluation of Developmental Status Developmental Milestones (PEDS-DM)
- Survey of Well-Being in Young Children (SWYC)

| CODES TO IDENTIFY DEVELOPMENTAL SCREENING: | | | | |
|--|-----------|-------|---|--|
| Service | Code Type | Code | Code Description | |
| Developmental Screening | СРТ | 96110 | Developmental screening (e.g. developmental milestone survey, speech and language delay screen) with scoring and documentation, per standardized instrument | |

QUAUTY BONUS BERVICE

Immunizations for Adolescents (IMA) - Combo 2

Methodology: HEDIS®

Measure Description: The percentage of adolescents 13 years of age who had one dose of meningococcal conjugate; one tetanus, diphtheria toxoids and acellular pertussis (Tdap); and two or three doses of the human papillomavirus (HPV) vaccine on or before their 13th birthday. The measure calculates a rate for each vaccine and a combination rate.

- At least one dose of meningococcal conjugate vaccine on or between the Member's 11th and 13th birthdays.
- At least one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine on or between the Member's 10th and 13th birthdays.
- At least two HPV vaccines, with different dates of service on or between the Member's 9th and 13th birthdays.
 - There must be at least 146 days between the first and second dose of the HPV vaccine. For example, if the service date for the first vaccine was March 1, then the service date for the second vaccine must be on or after July 25.

OR

At least three HPV vaccines, with different dates of service on or between the Member's 9th and 13th birthdays.

- The eligible population in this measure meets all of the following criteria:
 - 1. Adolescents who turn 13 years of age during the measurement year (2024).
 - 2. Continuous enrollment with IEHP 12 months prior to the Member's 13th birthday with no more than one gap in enrollment of up to 45 days during the 12 months prior to the 13th birthdays.

| | CODES TO IDENTIFY MENINGOCOCAL: | | | | |
|----------------------------|---------------------------------|-------|---|--|--|
| Antigen | Code Type Code | | Code Description | | |
| Meningococcal Conjugate | СРТ | 90619 | Meningococcal Conjugate Vaccine, Serogroups A, C, W, Y, quadrivalent tetanus toxoid carrier (MenACWY-TT), For Intramuscular Use | | |
| Meningococcal Conjugate | СРТ | 90733 | Meningococcal Polysaccharide Vaccine, Serogroups A, C, Y, W-135, quadrivalent (MPSV4), For Subcutaneous Use | | |
| Meningococcal Conjugate | СРТ | 90734 | Meningococcal Conjugate Vaccine Serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), For Intramuscular Use | | |

| CODE TO IDENTIFY TDAP: | | | |
|------------------------|-----------|-------|---|
| Antigen | Code Type | Code | Code Description |
| Tdap | СРТ | 90715 | Tetanus Diphtheria Toxoids And Acellular Pertussis Vaccine (Tdap) When Administered To Individuals Seven Years Or Older For Intramuscular Use |

| | CODES TO IDENTIFY HPV: | | | | |
|---------|------------------------|-------|---|--|--|
| Antigen | Code Type Code | | Code Description | | |
| HPV | СРТ | 90649 | Human Papilloma Virus (HPV) Vaccine Types 6 11 16 18 Quadrivalent (4vHPV), two or three Dose Schedule, For Intramuscular Use | | |
| HPV | СРТ | 90650 | Human Papilloma Virus (HPV) Vaccine Types 16, 18 bivalent (2vHPV) two or three Dose Schedule, For Intramuscular Use | | |
| HPV | СРТ | 90651 | Human Papilloma Virus Vaccine 6 11 16 18 31 33 45 52 58, nonavalent (9vHPV) two or three Dose Schedule, For Intramuscular Use | | |

- Members who meet the following criteria are excluded:
 - 1. Members in hospice.
 - 2. Members who expired at any time during the measurement year (2024).

Denominator: Adolescents 13 years of age who meet all the criteria for eligible population.

• Anchor Date: Child's 13th birthday

Numerator: Members in the denominator who had one dose of meningococcal conjugate vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday during the measurement year (2024).

• All immunization series must be at least 14 days apart.

Substance Use Assessment in Primary Care for Adolescents

Methodology: IEHP-Defined Quality Measure

Measure Description: The percentage of Members 11-17.99 years of age who were screened for substance use during the measurement year (2024).

Denominator: All Members 11-17.99 years of age during the measurement year (2024). Member counted only once in the denominator.

• Anchor Date: December 31, 2024

Numerator: Members who were screened for substance use at least once during the measurement year (2024).

| CODES TO IDE | CODES TO IDENTIFY SUBSTANCE USE ASSESSMENT IN PRIMARY CARE: | | | | |
|--|---|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Substance Use Assessment in Primary Care | СРТ | 99408 | Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention (SBI) Services 15 to 30 Minutes | | |
| Substance Use Assessment in Primary Care | СРТ | 99409 | Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention (SBI) Services Greater than 30 Minutes | | |
| Substance Use Assessment in Primary Care | HCPCS | G0442 | Annual Alcohol Misuse Screening 15 Minutes | | |
| Substance Use Assessment in Primary Care | HCPCS | G0443 | Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes | | |
| Substance Use Assessment in Primary Care | HCPCS | H0001 | Alcohol and/or Drug Assessment | | |
| Substance Use Assessment in Primary Care | HCPCS | H0049 | Alcohol and/or Drug Screening | | |
| Substance Use Assessment in Primary Care | HCPCS | H0050 | Alcohol and/or Drug Service Brief Intervention Per 15 Minutes | | |

Examples of Substances Use Assessment in Primary Care for Adolescents screening tools include but are not limited to:

- Cut Down-Annoyed-Guilty-Eye-Opener Adapted to Include Drugs (CAGE-AID)
- Tobacco, Alcohol, Prescription medication and other Substances (TAPS)
- National Institute on Drug Abuse (NIDA) Quick Screen for adults
 - o The single NIDA Quick Screen alcohol-related question can be used for alcohol use screening
- Drug Abuse Screening Test (DAST-10)

- Alcohol Use Disorders Identification Test (AUDIT-C)
- Parents, Partner, Past and Present (4Ps) for pregnant women and adolescents
- Car, Relax, Alone, Forget, Friends, Trouble (CRAFFT) for non-pregnant adolescents
- Michigan Alcoholism Screening Test Geriatric (MAST-G) alcohol screening for geriatric population

Well-Child Visits in the First 15 Months of Life (W30)

Methodology: HEDIS®

Measure Description: The percentage of Members who turned 15 months old during the measurement year (2024) and had six or more well-child visits.

- The eligible population in this measure meets all of the following criteria:
 - 1. Children who turn 15 months old during the measurement year (2024).
 - 2. Member must be enrolled with IEHP by 31 days after birth and maintain continuous enrollment between 31 days and 15 months of age with no more than one gap in enrollment of up to 45 days.

Denominator: Members who turned 15 months old during the measurement year (2024) who meet all criteria for eligible population.

• Anchor Date: Child's 15th month birthday

Numerator: Members who received six or more well-child visits on or before the child's 15th month birthday. The well-child visit must occur with a PCP, but the PCP does not have to be the Practitioner assigned to the child.

• All visits must be at least 14 days apart.

| CODES TO IDENTIFY WELL-CARE VISITS: | | | | |
|-------------------------------------|-----------|-------|---|--|
| Service | Code Type | Code | Code Description | |
| Well-Care Visit | СРТ | 99381 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year) | |
| Well-Care Visit | СРТ | 99382 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; early childhood (age 1 through 4 years) | |

| | CODES TO IDENTIFY WELL-CARE VISITS: | | | | |
|-----------------|-------------------------------------|---------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Well-Care Visit | СРТ | 99391 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | | |
| Well-Care Visit | СРТ | 99392 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | | |
| Well-Care Visit | СРТ | 99461 | Initial care, per day, for evaluation and management of normal newborn infant seen in other than hospital or birthing center | | |
| Well-Care Visit | ICD10CM | Z00.110 | Health Examination For Newborn Under 8 Days Old | | |
| Well-Care Visit | ICD10CM | Z00.111 | Health Examination For Newborn 8 To 28 Days Old | | |
| Well-Care Visit | ICD10CM | Z00.121 | Encounter For Routine Child Health Examination With Abnormal Findings (Health check (routine) for child over 28 days old) | | |
| Well-Care Visit | ICD10CM | Z00.129 | Encounter For Routine Child Health Examination Without Abnormal Findings (Health check (routine) for child over 28 days old) | | |
| Well-Care Visit | ICD10CM | Z76.1 | Encounter For Health Supervision And Care Of Foundling | | |
| Well-Care Visit | ICD10CM | Z76.2 | Encounter For Health Supervision And Care Of Other Healthy Infant And Child | | |

Well-Child Visits in the First 30 Months of Life (W30)

Methodology: HEDIS®

Measure Description: The percentage of children who turned 30 months old during the measurement year (2024) and had two or more well-child visits with a PCP within the 15-30 months of life.

- Eligible population in this measure meets all of the following criteria:
 - 1. Children who turn 30 months old during the measurement year (2024).
 - 2. Member must be enrolled with IEHP by 15 months after birth and maintain continuous enrollment between 15 months and 30 months of age with no more than one gap in enrollment of up to 45 days.

Denominator: Members who turn 30 months old during the measurement year (2024) who meet all criteria for eligible population.

 Anchor Date: Child's 30th month birthday (Calculate the 30th-month birthday as the second birthday plus 180 days). **Numerator:** Members in the denominator who received two or more well-child visits between the child's 15 month plus 1 day and 30 months of life. The well-child visit must occur with a PCP, but the PCP does not have to be the Practitioner assigned to the child.

• All visits must be at least 14 days apart.

| | CODES TO IDENTIFY WELL-CARE VISITS: | | | | |
|---|-------------------------------------|---------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Well-Child Visits in the First 30 Months of Life | СРТ | 99381 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year) | | |
| Well-Child Visits in the First 30 Months of Life | СРТ | 99382 | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; early childhood (age 1 through 4 years) | | |
| Well-Child Visits in the First 30 Months of Life | СРТ | 99391 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | | |
| Well-Child Visits in the First 30 Months of Life | СРТ | 99392 | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | | |
| Well-Child Visits in the First 30 Months of Life | ICD10CM | Z00.121 | Encounter For Routine Child Health Examination With Abnormal Findings | | |
| Well-Child Visits in the First 30 Months of Life | ICD10CM | Z00.129 | Encounter For Routine Child Health Examination Without Abnormal Findings | | |
| Well-Child Visits in the First 30 Months of Life | ICD10CM | Z00.2 | Encounter For Examination For Period Of Rapid Growth In Childhood | | |
| Well-Child Visits in the First 30 Months of Life | ICD10CM | Z76.1 | Encounter For Health Supervision And Care Of Foundling | | |
| Well-Child Visits in the First 30 Months of Life | ICD10CM | Z76.2 | Encounter For Health Supervision And Care Of Other Healthy Infant And Child | | |

Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents (WCC)

Methodology: HEDIS®

Measure Description: The percentage of Members 3-17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year (2024). Report each of the three indicators below:

- BMI percentile documentation*
- Counseling for nutrition
- Counseling for physical activity
- The eligible population in this measure meets all of the following criteria:
 - 1. Members who are 3-17 years of age as of December 31 of the measurement year (2024).
 - 2. Continuous enrollment with IEHP in the measurement year (2024) with no more than one gap up to 45 days.
 - 3. An outpatient visit with a PCP or an OB/GYN during the measurement year (2024).

^{*} Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value.

| | CODES TO IDENTIFY BMI PERCENTILE: | | | | | |
|--------|-----------------------------------|---|--|--|--|--|
| Code | Code Type | Description | | | | |
| Z68.51 | ICD10 | Body Mass Index (BMI) Pediatric, Less Than 5th Percentile For Age | | | | |
| Z68.52 | ICD10 | Body Mass Index (BMI) Pediatric, 5th Percentile To Less Than 85th Percentile For Age | | | | |
| Z68.53 | ICD10 | Body Mass Index (BMI) Pediatric, 85th Percentile To Less Than 95th Percentile For Age | | | | |
| Z68.54 | ICD10 | Body Mass Index (BMI) Pediatric, Greater Than Or Equal To 95th Percentile For Age | | | | |

| | CODES TO IDENTIFY COUNSELING FOR PHYSICAL ACTIVITY: | | | | | |
|--------|---|--|--|--|--|--|
| Code | Code Type | Description | | | | |
| G0447 | HCPCS | Face-to-face Behavioral Counseling For Obesity, 15 Minutes | | | | |
| S9451 | HCPCS | Exercise Classes, Non-Physician Provider, Per Session | | | | |
| Z02.5 | ICD10 | Encounter For Examination For Participation In Sport | | | | |
| Z71.82 | ICD10 | Exercise Counseling | | | | |

| | CODES TO IDENTIFY COUNSELING FOR NUTRITION: | | | | | |
|-------|---|---|--|--|--|--|
| Code | Code Type | Description | | | | |
| 97802 | СРТ | Medical Nutrition Therapy Initial Assessment And Intervention Individual Face-to-face With The Patient Each 15 Minutes | | | | |
| 97803 | СРТ | Medical Nutrition Therapy Reassessment And Intervention Individual Face-to-face With The Patient Each 15 Minutes | | | | |
| 97804 | CPT | Medical Nutrition Therapy Group (Two Or More Individual(s) Each 30 Minutes | | | | |
| G0270 | HCPCS | Medical Nutrition Therapy; Reassessment And Subsequent Intervention(s) Following Second Referral In Same Year For Change In Diagnosis, Medical Condition Or Treatment Regimen (including Additional Hours Needed For Renal Disease), Individual, Face-to-face | | | | |
| G0271 | HCPCS | Medical Nutrition Therapy, Reassessment And Subsequent Intervention(s) Following Second Referral In Same Year For Change In Diagnosis, Medical Condition, Or Treatment Regimen (including Additional Hours Needed For Renal Disease), Group (Two Or More Individuals) | | | | |
| G0447 | HCPCS | Face-to-face Behavioral Counseling For Obesity, 15 Minutes (G0447) | | | | |
| S9449 | HCPCS | Weight Management Classes, Non-Physician Provider, Per Session (S9449) | | | | |
| S9452 | HCPCS | Nutrition Classes, Non-Physician Provider, Per Session (S9452) | | | | |
| S9470 | HCPCS | Nutritional Counseling, Dietitian Visit (S9470) | | | | |
| Z71.3 | ICD10 | Dietary Counseling And Surveillance | | | | |

Members who meet any of the following criteria are excluded:

- 1. Members in hospice.
- 2. Members who have a diagnosis of pregnancy any time during the measurement year (2024).
- 3. Members who expired at any time during the measurement year (2024).

Denominator: Members 3-17 years of age who meet all the criteria for eligible population.

• Anchor Date: December 31, 2024

Numerator: Members in the denominator who had evidence of BMI percentile, counseling of nutrition or physical activity during the measurement year (2024).

✓ Population: All

Initial Health Appointment (IHA)

Methodology: IEHP-Defined Quality Measure

Measure Description: The IHA is a comprehensive assessment that is completed during the Member's initial encounter with a PCP, appropriate medical specialist, or Non-Physician Medical Provider, and it must be documented in the Member's medical record. The IHA enables the Member's PCP to assess and manage the acute, chronic and preventive health needs of the Member.

IEHP provides PCPs with a monthly detailed Member roster on the secure IEHP Provider Portal for all newly enrolled IEHP Members who are due for an IHA at 120 days of enrollment.

- The eligible population is newly assigned Members with an IEHP effective enrollment date of January 1, 2024 through December 31, 2024. The IHA must be provided within 120 days of enrollment (e.g., Member enrolled in December 2024 must be seen by April 2025 and PCP must submit encounter by May 2025).
- IHA visits completed during the 11 months prior to enrollment with IEHP count towards numerator compliance.

An IHA must include all of the following:

- A history of the Member's physical and mental health
- An identification of risks
- An assessment of need for preventive screens or services
- Health education
- The diagnosis and plan for treatment of any diseases

| | CODES TO IDENTIFY IHA VISITS: | | | | | |
|-------|-------------------------------|--|--|--|--|--|
| Code | Code Type | Description | | | | |
| 96160 | СРТ | Administration of patient-focused health risk assessment instrument (e.g., health hazard appraisal) with scoring and documentation, per standardized instrument. | | | | |
| 96161 | СРТ | Administration of caregiver-focused health risk assessment instrument (e.g., depression inventory) for the benefit of the patient, with scoring and documentation, per standardized instrument. | | | | |
| 99202 | СРТ | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 15-29 minutes of total time is spent on the date of the encounter. | | | | |

| CODES TO IDENTIFY IHA VISITS: | | | | |
|-------------------------------|-----------|--|--|--|
| Code | Code Type | Description | | |
| 99203 | СРТ | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 30-44 minutes of total time is spent on the date of the encounter. | | |
| 99204 | СРТ | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 45-59 minutes of total time is spent on the date of the encounter. | | |
| 99205 | СРТ | Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 60-74 minutes of total time is spent on the date of the encounter. | | |
| 99211 | СРТ | Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. | | |
| 99212 | СРТ | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 10-19 minutes of total time is spent on the date of the encounter. | | |
| 99213 | СРТ | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter. | | |
| 99214 | СРТ | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter. | | |
| 99215 | СРТ | Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 40-54 minutes of total time is spent on the date of the encounter. | | |
| 99241 | СРТ | Office consultation for a new or established patient, which requires these three key components: A problem-focused history; A problem-focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family. | | |
| 99242 | СРТ | Office consultation for a new or established patient, which requires these three key components: An expanded problem-focused history; An expanded problem-focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Typically, 30 minutes are spent face-to-face with the patient and/or family. | | |

| CODES TO IDENTIFY IHA VISITS: | | | | |
|-------------------------------|-----------|--|--|--|
| Code | Code Type | Description | | |
| 99243 | СРТ | Office consultation for a new or established patient, which requires these three key components: A detailed history; A detailed examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 40 minutes are spent face-to-face with the patient and/or family. | | |
| 99244 | СРТ | Office consultation for a new or established patient, which requires these three key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family. | | |
| 99245 | СРТ | Office consultation for a new or established patient, which requires these three key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 80 minutes are spent face-to-face with the patient and/or family. | | |
| 99354 | СРТ | Prolonged service(s) in the outpatient setting requiring direct patient contact beyond the time of the usual service; first hour (List separately in addition to code for outpatient Evaluation and Management or psychotherapy service, except with office or other outpatient services [99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215]). | | |
| 99355 | СРТ | Prolonged service(s) in the outpatient setting requiring direct patient contact beyond the time of the usual service; each additional 30 minutes (List separately in addition to code for prolonged service). | | |
| 99381 | СРТ | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year). | | |
| 99382 | СРТ | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; early childhood (age 1 through 4 years). | | |
| 99383 | СРТ | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; late childhood (age 5 through 11 years). | | |

| CODES TO IDENTIFY IHA VISITS: | | | | |
|-------------------------------|-----------|---|--|--|
| Code | Code Type | Description | | |
| 99384 | СРТ | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12 through 17 years). | | |
| 99385 | СРТ | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years. | | |
| 99386 | СРТ | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years. | | |
| 99387 | СРТ | Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older. | | |
| 99391 | СРТ | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year). | | |
| 99392 | СРТ | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years). | | |
| 99393 | СРТ | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years). | | |
| 99394 | СРТ | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years). | | |
| 99395 | СРТ | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years. | | |
| 99396 | СРТ | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years. | | |

| CODES TO IDENTIFY IHA VISITS: | | | | |
|-------------------------------|-----------|---|--|--|
| Code | Code Type | Description | | |
| 99397 | СРТ | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older. | | |
| 99401 | СРТ | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes. | | |
| 99402 | СРТ | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 30 minutes. | | |
| 99403 | СРТ | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 45 minutes. | | |
| 99404 | СРТ | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 60 minutes. | | |
| 99411 | СРТ | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 30 minutes. | | |
| 99412 | СРТ | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 60 minutes. | | |
| 99429 | CPT | Unlisted Preven Meds Serv. | | |
| 99444 | СРТ | Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous seven days, using the Internet or similar electronic communications network. | | |
| 99446 | СРТ | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 5-10 minutes of medical consultative discussion and review. | | |
| 99447 | СРТ | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 11-20 minutes of medical consultative discussion and review. | | |
| 99448 | СРТ | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 21-30 minutes of medical consultative discussion and review. | | |
| 99449 | СРТ | Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 31 minutes or more of medical consultative discussion and review. | | |
| 99450 | СРТ | Basic life and/or disability examination that includes: Measurement of height, weight, and blood pressure; Completion of a medical history following a life insurance pro forma; Collection of blood sample and/or urinalysis complying with "chain of custody" protocols; and Completion of necessary documentation/certificates. | | |

| CODES TO IDENTIFY IHA VISITS: | | | | |
|-------------------------------|-----------|--|--|--|
| Code | Code Type | Description | | |
| 99455 | СРТ | Work-related or medical disability examination by the treating physician that includes: Completion of a medical history commensurate with the patient's condition; Performance of an examination commensurate with the patient's condition; Formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment; Development of future medical treatment plan; and Completion of necessary documentation/certificates and report. | | |
| 99456 | СРТ | Work-related or medical disability examination by other than the treating physician that includes: Completion of a medical history commensurate with the patient's condition; Performance of an examination commensurate with the patient's condition; Formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment; Development of future medical treatment plan; and Completion of necessary documentation/certificates and report. | | |
| G0402 | HCPCS | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of Medicare enrollment. | | |
| G0438 | HCPCS | Annual wellness visit; includes a personalized prevention plan of service (PPS), initial visit. | | |
| G0439 | HCPCS | Annual wellness visit, includes a personalized prevention plan of service (PPS), subsequent visit. | | |
| G0463 | HCPCS | Hospital outpatient clinic visit for assessment and management of a patient. | | |
| T1015 | HCPCS | Clinic visit/encounter, all-inclusive. | | |
| Z00.00 | ICD10CM | Encounter for general adult medical examination without abnormal findings. | | |
| Z00.01 | ICD10CM | Encounter for general adult medical examination with abnormal findings. | | |
| Z00.121 | ICD10CM | Encounter for routine child health examination with abnormal findings. | | |
| Z00.129 | ICD10CM | Encounter for routine child health examination without abnormal findings. | | |
| Z02.5 | ICD10CM | Encounter for examination for participation in sport. | | |

After Hours Availability On-Call Physician Access

Methodology: IEHP-Defined Provider Access After Hours Survey

Measure Description: The Provider After Hours measure assesses Provider office call handling protocols for after hours access. IEHP conducts a one-time annual call campaign to assess Provider network compliance. Provider offices are compliant if during the call, they followed the protocol below:

• The caller was provided with instructions on how to connect to a Doctor, on-call physician or covering nurse after hours OR was connected directly to a Doctor, on-call physician or covering nurse.

Measure Support: The Provider Access After Hours call campaign is conducted annually to assess the after hours accessibility of Providers within the IEHP network. Specifically, the calls assess the after hours call handling protocol of contracted Primary Care Providers.

This measure is used to monitor Provider compliance with IEHP's Access Standards in Policy 9A, ensuring that IEHP Members have appropriate guidance and access if care is needed from their Providers after office hours.

After Hours Availability Emergency Calls

Methodology: IEHP-Defined Provider Access After Hours Survey

Measure Description: The Provider After Hours measure assesses Provider office call handling protocols for life-threatening emergency calls. IEHP conducts a one-time annual call campaign to assess Provider network compliance. Provider offices are compliant if during the call, they followed the protocol below:

• The caller was instructed to dial 9-1-1 OR instructed to go to the nearest Emergency Room.

Measure Support: The Provider Access After Hours call campaign is conducted annually to assess the after hours accessibility of Providers within the IEHP network. Specifically, the calls assess the after hours call handling protocol of contracted Primary Care Providers.

This measure is used to monitor Provider compliance with IEHP's Access Standards in Policy 9A, ensuring that IEHP Members have appropriate guidance and access if care is needed from their Providers after office hours.

Appointment Availability – Urgent Visits

Methodology: Department of Managed Health Care (DMHC) Model Provider Appointment Availability Survey (PAAS)

Measure Description: The type of appointment and the acceptable time frames to access care are listed below. A Provider is compliant if they meet the following Appointment Access timeframe:

PCP Appointment

• Urgent: \leq 48 Hours

Measure Support: The purpose of the Appointment Availability measure is to assess the appointment access for Primary Care Providers.

Appointment Availability – Routine Visits

Methodology: Department of Managed Health Care (DMHC) Model Provider Appointment Availability Survey (PAAS)

Measure Description: The type of appointment and the acceptable time frames to access care are listed below. A Provider is compliant if they meet the following Appointment Access timeframe:

PCP Appointment

• Routine: ≤ 10 days

Measure Support: The purpose of the Appointment Availability measure is to assess the appointment access for Primary Care Providers.

Access to Care Needed Right Away

Methodology: IEHP's Monthly Member Satisfaction Survey

Measure Description: In the last six months, when you needed care right away, how often did you get care as soon as you needed?

- Valid response: never, sometimes, usually, always
- Target response: usually, always

Measure Support: To help identify opportunities to improve customer service, IEHP conducts a monthly Member Satisfaction Survey between June-December annually. Member survey responses are analyzed and shared at the PCP and IPA level.

Coordination of Care

Methodology: IEHP's Monthly Member Satisfaction Survey

Measure Description: In the last six months, how often did your Personal Doctor seem informed and up-to-date about the care you received from these Doctors or other health Providers?

- Valid response: never, sometimes, usually, always
- Target response: usually, always

Measure Support: To help identify opportunities to improve customer service, IEHP conducts a monthly Member Satisfaction Survey between June-December annually. Member Survey responses are analyzed and shared at the PCP and IPA level.

Medical Assistance with Smoking and Tobacco Use Cessation (MSC) - Advising Smokers to Quit

Methodology: IEHP's Monthly Member Satisfaction Survey

Measure Description: The percentage of Members 18 years of age and older who are current smokers or tobacco users and who received advice to quit during the measurement year.

Do you currently use tobacco? This includes smoking, vaping or using chewing tobacco.

Valid response: Yes, No Target Response: Yes

In the last six months, how often were you advised to quit smoking or using tobacco by a Doctor or other health Provider in your plan?

Valid response: Never, Sometimes, Usually, Always

• Target Response: Usually, Always

Measure Support: To help identify opportunities to advise smokers and tobacco users to quit, IEHP conducts a monthly Member Satisfaction Survey between June-December annually. Member survey responses are analyzed and shared at the PCP level.

Rating of Personal Doctor

Methodology: IEHP's Monthly Member Satisfaction Survey

Measure Description: Using any number from 0 to 10, where 0 is the worst Personal Doctor possible and 10 is the best Personal Doctor possible, what number would you use to rate your Personal Doctor?

Valid response: 0-10Target response: 9 or 10

Measure Support: Each year, to help identify opportunities to improve customer service, IEHP conducts a monthly Member Satisfaction Survey between June-December annually. Member Survey responses are analyzed and shared at the PCP level.

Potentially Avoidable Emergency Department (ED) Visits

Methodology: IEHP has developed this measure in accordance with the New York University (NYU) research conducted on classifying emergency department utilization (https://wagner.nyu.edu/community/faculty) and the California Department of Healthcare Services (DHCS) methodology for determining Low-acuity non-emergent (LANE) visits.

Measure Description: Low-acuity non-emergent (LANE) visits are visits to an emergency department (ED) in which the condition could be treated by a physician or other health care provider in a non-emergency setting or conditions that are potentially preventable or ambulatory care sensitive.

The following steps are used to determine potentially preventable emergency room visits:

Step 1: Identify all Emergency Department (ED) visits that contain potentially preventable diagnosis codes on both the facility and professional claims in the measurement year (2024).

Step 2: The following criteria is assessed to exclude ED visits:

- ED visits that resulted in an inpatient admission or observation stay
- Members under the age of 4 or over the age of 65 on the date of service
- ED visits with evaluation & management codes 99284 and 99285

Step 3: Using the primary diagnosis code on the facility component of the ED visit, preventable percentages are assigned to each ED event to account for external factors that can influence and impact variation in ED use. These "preventable percentages" for each ED visit are summed to create a final "count" of preventable ED visits based on the primary diagnosis code on the facility component of the ED visit. The attached worksheet contains the diagnosis codes and preventable percentages assigned to each code (https://www.providerservices.iehp.org/en/provider-central/provider-incentive-programs/pay-for-performance-program#potentially-avoidable-emergency-department).

Denominator: All assigned Medi-Cal and Covered California Members each month of the measurement year (2024). All monthly assigned Members are summed to create a denominator. This is also called Member Months.

Numerator: The sum of the output from Step 3 noted above for Members assigned to the PCP on the date of service. This is the final count of preventable ED visits.

Rate: (Numerator / Denominator) x 12,000



PROCESS MEASURES

✓ Process Measures

Process measures allow Providers to earn additional dollars based on performance in process metrics. IEHP is committed to reward Providers who have high performance in quality metrics that assist in providing quality care to IEHP Members.

For the 2024 program year, Providers can earn an additional PMPM* up to \$1.50 PMPM for the process measures listed below, for meeting the process measure goals. Please see Appendix 3 below for details.

APPENDIX 3: 2024 PCP Global Quality Process Measures

| 2024 GLOBAL QUALITY PCP PROCESS MEASURE LIST: | | | | | | |
|---|--|--|--|--|--|--|
| Measure Name | Goal | Incentive Amount (PMPM*) | | | | |
| Manifest MedEx (MX) Connectivity | Five (5) Milestones are included in the Manifest MedEx (MX) Connectivity measure: - Milestone (1) Get Connected - Milestone (2) Stay Connected - Milestone (3) Improve Data Quality - Minimum Data Requirements - Milestone (4) Improve Data Quality - Clinical Data Elements - Milestone (5) Improve Data Quality - Behavioral Health Data Elements (Monitor Only) | Milestone (1) \$0.25 Milestone (2) \$0.25 Milestone (3) \$0.25 Milestone (4) \$0.50 Milestone (5) Monitoring Only | | | | |
| Provider Diversity Equity Inclusion Survey | Provider timely response to Diversity Equity Inclusion Survey Spring 2024. | \$0.25 | | | | |

*PMPM: Per Member Per Month



APPENDIX 4: Process Measures Overview

Manifest MedEx (MX) Connectivity

Methodology: IEHP-Defined Process Measure

Measure Description: Providers are encouraged to participate in the Manifest MedEx (MX) Connectivity efforts that will help IEHP increase PCP connections with an aim to improve patient care and coordination.

Five (5) milestones are included in the Manifest MedEx (MX) Connectivity measure:

| | 2024 PCP INCENTIVES FOR MX- MEASURE MILESTONES: | | | | |
|------------|---|--|--------------------|--|--|
| Milestone* | Milestone Category | Description | Payment | | |
| 1 | Get Connected | An opportunity for PCPs to connect with Manifest MedEx (MX) if PCP did not establish a connection with MX in the 2022 or 2023 performance years. | \$0.25 | | |
| 2 | Stay Connected | For PCPs who successfully connected to MX in the 2023 performance year: • Must continue to report data throughout the year. • Must participate in data validation activities, as directed. | \$0.25 | | |
| 3 | Improve Data Quality — Minimum Data Requirements | Ensure reporting of core data elements:Patient ID, Provider NPI, Location NPI, Date of Service, Service/Procedure Codes | \$0.25 | | |
| 4 | Improve Data Quality - Clinical Data Elements | Ensure reporting of clinical data elements: Blood Pressure Results — systolic / diastolic, member, date of service | \$0.50 | | |
| 5 | Improve Data Quality - Behavioral Health (BH) Data Elements | Monitor ability to report BH data elements: • Depression Screening, results and follow up - PHQ-9 assessments and results, member, date of service — July 1 reporting to begin - monitoring only for 2024 | Monitoring Only | | |

^{*}Providers eligible for milestone 1 cannot participate in milestones 2-5 for the 2024 performance year. Providers who established their MX connection in the 2022 or 2023 performance years are eligible for milestones 2-5. Provider must document all data elements in the Electronic Medical Record (EMR). Documents scanned into the chart will not count as compliant for this measure.

For Providers that have not set up a connection with Manifest MedEx, the following two items will need to be completed:

- 1. Sign a participation agreement with MX by June 1, 2024.
- 2. Establish data connections with MX with routine reporting of Consolidated Clinical Document Architecture (CCDA) by the established deadline.
 - Providers must pass primary source verification (PSV) with MX.
 - Once PSV is completed, active data sharing must be confirmed by MX.
 - Deadline will be set based on the volume of PCPs who sign up.

Goal is by December 2024, may extend out further, based on MX connectivity capability.

As part of the PSV process, Providers will be required to pass the following elements in order to meet the data quality requirement of this measure.

All EHR printouts must meet the "Golden Rule" and be considered a "Robust" case. Any documentation missing this information is considered incomplete and will fail PSV for this measure.

Golden Rule:

- Patient Name
- Date of Birth
- Facility Name
- Provider Name
- Target Date of Service (DOS)
- Time of Service (TOS) If applicable

Robust Case:

- Patient Race / Ethnicity
- Problem List containing all PX codes and/or Descriptions
- Procedures Codes and/or Description
- Vitals
- Immunizations
- Labs (when applicable)

| MANIFEST MEDEX CONNECTED ELECTRONIC HEALTH RECORDS (EHRs)*: | | | | | | |
|---|------------------------------|----------------------|--------------------|--|--|--|
| AdvancedMD | DeVero | Harris Flex | Netsmart myInsight | | | |
| Allscripts | DrChrono | iKnowMed Gen2 | NextGen Healthcare | | | |
| Amazing Charts | eClinicalWorks | InSync | Office Ally | | | |
| Aprima | eMDs | Kareo | Office Practicum | | | |
| AthenaHealth | Epic | McKesson | Practice Fusion | | | |
| Avatar | GE Centricity | MatrixCare | Practice Partner | | | |
| Cerner | Greenway Health-Intergy | MEDITECH | Prime Clinical | | | |
| CPSI-Evident-Thrive | Greenway Health - Primesuite | Modernizing Medicine | PrognoCIS | | | |

^{*}other EHR connections may be added

Provider Diversity Equity Inclusion Survey

Methodology: IEHP – Defined Process Measure

Measure Description: IEHP encourages Primary Care Physicians (PCPs) to complete the Diversity Equity Inclusion (DEI) Survey timely, Spring 2024. The purpose of this survey is to assess the IEHP PCP networks comfort in diversity, equity, and inclusion topics.

Goal: Provider offices will be required to respond, timely, to the DEI survey. Provider responses to the DEI survey must be submitted by survey deadline May 30, 2024, to be eligible for this incentive.

✓ Bonus Bundles

The bonus bundle measures allow Providers the opportunity to obtain additional P4P incentive earnings towards their monthly Quality PMPM. Providers can earn up to two (2) bonus bundles! All goals within the bundle must be met in order to earn incentive. Providers can earn up to an additional \$1.00 PMPM per bonus bundle for meeting all the bonus bundle goals.



APPENDIX 5: 2024 PCP Global Quality Bonus Bundles

| | 2024 GLOBAL QUALITY PCP BONUS BUNDLES: | | | | | | |
|-----------------------|--|------------------------------------|----------------|--|--|--|--|
| Bundle Name | Includes | Goal | Value | | | | |
| Adolescent* | Well-Care Visits – Ages 12-17 Immunizations for Adolescents Combo 2 Depression Screening and Follow-Up Plan – Ages 12-17 Chlamydia Screening – Ages 16-20 | 51% 41% 56% 62% | \$1.00 PMPM | | | | |
| Cancer Screening | Breast Cancer Screening Cervical Cancer Screening Colorectal Cancer Screening | 59% 64% 46% | \$1.00 PMPM | | | | |
| Cardiovascular | Controlling High Blood Pressure Statin Therapy for Patients with Cardiovascular Disease – Received Statin Therapy for Patients with Cardiovascular Disease – Adherence | 61% 83% 86% | \$1.00 PMPM | | | | |
| Diabetes | Glycemic Status Assessment for Patients with Diabetes Diabetes Care – Blood Pressure Control <140/90 Diabetes Care – Kidney Health Evaluation Statin Therapy for Patients with Diabetes – Received | 52% 64% 47% 72% | \$1.00 PMPM | | | | |
| Early Childhood | Childhood Immunizations Combo 10 Well-Child Visits First 15 Months of Life Well-Child Visits First 15-30 Months of Life Developmental Screening in the First 3 years of Life | 31% 58% 67% 44% | \$1.00 PMPM | | | | |
| Patient Experience | Rating of Personal Doctor After Hours Availability – On-Call Physician Access Appointment Availability – Urgent Customer Service Grievance | 85% Pass Pass ≤ 3.0 PTMPY | \$1.00 PMPM | | | | |

^{*}Three (3) of the four (4) Adolescent Bundle measures must be met to qualify for the Adolescent Bundle incentive earning.



QUALITY BONUS SERVICES

Global Quality P4P Quality Bonus Services (for PCPs)

The 2024 Global Quality P4P (GQ P4P) Program includes the Quality Bonus Services. The services included in this domain are linked to key quality measures that are low performing and were previously covered under the DHCS Value-Based Payments Program. Appendix 6 references the payment amounts per Quality Bonus Service, and Appendix 7 provides service details, including service requirements for payment.

Eligibility and Participation

To be eligible for the Quality Bonus Services, Providers must be contracted with IEHP as a Medi-Cal Primary Care Physician (PCP) participating in the 2024 Global Quality P4P Program. NOTE: Federally Qualified Health Centers (FQHCs), Indian Health Facilities (IHFs) and Rural Health Clinics (RHCs) are not eligible to receive the Quality Bonus Service payments.

▼ Financial Overview

All quality bonus services must be captured through normal reporting channels with the Providers assigned IPA. The quality bonus services will be paid following the Quality Bonus Payment Schedule.

| 2024 GLOBAL QUALITY P4P – QUALITY BONUS SERVICES PAYMENT SCHEDULE | | | | | |
|--|---------------------|---------------|--|--|--|
| Date of Service: | Encounter Received: | Payment Date: | | | |
| 1/1/2024 - 1/31/2024 | 2/15/2024 | 3/20/2024 | | | |
| 1/1/2024 - 2/28/2024 | 3/15/2024 | 4/20/2024 | | | |
| 1/1/2024 - 3/31/2024 | 4/15/2024 | 5/20/2024 | | | |
| 1/1/2024 - 4/30/2024 | 5/15/2024 | 6/20/2024 | | | |
| 1/1/2024 - 5/31/2024 | 6/15/2024 | 7/20/2024 | | | |
| 1/1/2024 - 6/30/2024 | 7/15/2024 | 8/20/2024 | | | |
| 1/1/2024 - 7/31/2024 | 8/15/2024 | 9/20/2024 | | | |
| 1/1/2024 - 8/31/2024 | 9/15/2024 | 10/20/2024 | | | |
| 1/1/2024 - 9/30/2024 | 10/15/2024 | 11/20/2024 | | | |
| 1/1/2024 - 10/31/2024 | 11/15/2024 | 12/20/2024 | | | |
| 1/1/2024 - 11/30/2024 | 12/15/2024 | 1/20/2025 | | | |
| 1/1/2024 - 12/31/2024 | 1/15/2025 | 2/20/2025 | | | |
| 1/1/2024 - 12/31/2024 | 2/15/2025 | 3/20/2025 | | | |
| 1/1/2024 - 12/31/2024 | 3/15/2025 | 4/20/2025 | | | |



| QUALITY BONUS SERVICE - PAYMENT PER SERVICE | | | | | |
|---|---------|--|--|--|--|
| Service | Amount | | | | |
| Pediatric Immunizations Administration | \$18.00 | | | | |
| Adult Influenza Vaccine Administration | \$25.00 | | | | |
| Lead Screening | \$25.00 | | | | |
| Dental Fluoride Varnish | \$25.00 | | | | |
| Tobacco Use Screening | \$25.00 | | | | |



APPENDIX 7: Quality Bonus Services Overview

Pediatric Immunizations Administration (\$18)

Service Description: Quality bonus payment to a Provider for each pediatric immunization administered for Members 0-18 years of age for antigens included in the Childhood Immunization Combo 10 (CIS) or Immunizations for Adolescents (IMA) measure.

- Payment based on antigen administered
- Payment to each rendering Provider who administered the pediatric immunization
- Effective for dates of service 1/1/2024-12/31/2024
- Payment eligible for all antigens included in the CIS or IMA measures
- One payment per Member per antigen per date of service allowed
- Members must be between ages 0-18 at the time of the shot administration
- Provider must bill the antigen code for the antigen being administered

| | PEDIATRIC IMMUNIZATION CODE SET: | | | | |
|---------|----------------------------------|-------|---|--|--|
| Service | Code Type | Code | Code Description | | |
| DTaP | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | | |
| DTaP | СРТ | 90698 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine And Activated Poliovirus Vaccine, (DTaP-IPV/Hib), For Intramuscular Use DTaP CPT 90700 Diphtheria Tetanus Toxoids And Acellular | | |

119

| | PEDIATRIC IMMUNIZATION CODE SET: | | | | | |
|---------|----------------------------------|--|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| DTaP | СРТ | 90700 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine (DTaP) For Intramuscular Use | | | |
| DTaP | СРТ | 90723 | Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (DTaP-HepB-IPV), For Intramuscular Use | | | |
| IPV | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), foi intramuscular use | | | |
| IPV | СРТ | 90698 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine and activated poliovirus vaccine, (DTaP-IPV/HiB), For Intramuscular Use | | | |
| IPV | CPT | 90713 | Poliovirus Vaccine Inactivated (IPV) For Subcutaneous Use | | | |
| IPV | СРТ | 90723 | Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (DTaP-HepB-IPV), For Intramuscular Use | | | |
| MMR | СРТ | 90707 | Measles Mumps And Rubella Virus Vaccine (MMR) Live For Subcutaneous Use | | | |
| MMR | СРТ | 90710 | 90710 Measles Mumps Rubella And Varicella Vaccine (MMRV) Live For Subcutaneous Use | | | |
| HiB | СРТ | Meningococcal Conjugate Vaccine, Serogroups C & Y And Hemophilus Influenzae Type B Vaccine (HiB-mency), four dose schedule, when administered to children six weeks-18 months of a for intramuscular use | | | | |
| HiB | СРТ | 90647 | Hemophilus Influenza B Vaccine (HiB) Prp-omp Conjugate (Three Dose Schedule) For Intramuscular Use | | | |
| HiB | СРТ | 90648 | Hemophilus Influenza B Vaccine (HiB) prp-t Conjugate (Four Dose Schedule) For Intramuscular Use | | | |
| HiB | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | | | |
| HiB | СРТ | 90698 | Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine and activated poliovirus vaccine, (DTaP-IPV/HiB), for intramuscular use | | | |
| HiB | СРТ | 90748 | Hepatitis B And Hemophilus Influenza B Vaccine (HepB-HiB) For Intramuscular Use | | | |
| НерВ | СРТ | 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | | | |
| НерВ | СРТ | 90723 | Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis | | | |

| PEDIATRIC IMMUNIZATION CODE SET: | | | | | |
|----------------------------------|-----------|--|---|--|--|
| Service | Code Type | Code | Code Description | | |
| НерВ | СРТ | 90740 | Hepatitis B Vaccine Dialysis Or Immunosuppressed Patient Dosage (Three Dose Schedule) For Intramuscular Use | | |
| НерВ | СРТ | 90744 | Hepatitis B Vaccine Pediatric/adolescent Dosage (Three Dose Schedule) For Intramuscular Use | | |
| НерВ | СРТ | 90747 | Hepatitis B Vaccine Dialysis Or Immunosuppressed Patient Dosage (Four Dose Schedule) For Intramuscular Use | | |
| НерВ | СРТ | 90748 | Hepatitis B And Hemophilus Influenza B Vaccine (HepB-HiB) For Intramuscular Use | | |
| НерВ | HCPCS | G0010 | Administration Of Hepatitis B Vaccine | | |
| VZV | СРТ | 90710 | Measles Mumps Rubella And Varicella Vaccine (MMRV) Live For Subcutaneous Use | | |
| VZV | CPT | 90716 | Varicella Virus Vaccine Live For Subcutaneous Use | | |
| PCV | CPT | 90670 | Pneumococcal Conjucate Vaccine 13 Valent For Intramuscular Use | | |
| PCV | СРТ | 90671 | Pneumococcal Conjugate Vaccine, 15 Valent (pcv15), For Intramuscular Use | | |
| PCV | СРТ | 90677 | Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | | |
| PCV | HCPCS | G0009 | Administration Of Pneumococcal Vaccine | | |
| НерА | СРТ | 90633 | Henatitis A Vaccine Pediatric/adolescent Dosage-2 Dose Schedule I | | |
| Rotavirus - Two Dose | СРТ | 90681 | Rotavirus Vaccine Human Attenuated Two Dose Schedule Live For Oral Use. | | |
| Rotavirus - Three Dose | СРТ | 90680 | Rotavirus Vaccine Tetravalent Live For Oral Use | | |
| Flu | СРТ | 90655 | Influenza Virus Vaccine, Trivalent (IIV3), Split Virus, Preservative Free, 0.25ml Dosage, For Intramuscular Use | | |
| Flu | СРТ | 90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use | | |
| Flu | CPT | 90660 | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use | | |
| Flu | СРТ | 90661 | Influenza Virus Vaccine Derived From Cell Cultures Subunit Preservative And Antibiotic Free For Intramuscular Use | | |
| Flu | CPT | 90672 | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | | |
| Flu | СРТ | 90673 | Influenza Virus Vaccine Trivalent Derived From Recombinant DNA (RIV3) Hemagglutinin (HA) Protein Only Preservative And Antibiotic | | |
| Flu | СРТ | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, fo intramuscular use | | | |
| Flu | СРТ | 90685 | Influenza Virus Vaccine Quadrivalent (II4V) Split Virus Preservative Free, 0.25 mL dosage, for Intramuscular Use | | |
| Flu | СРТ | 90686 | Influenza Virus Vaccine Quadrivalent (IIAV) Split Virus Preservative | | |
| Flu | СРТ | 90687 | Influenza Virus Vaccine Quadrivalent (II4V) Split Virus, 0.25 mL dosage, for Intramuscular Use | | |

| PEDIATRIC IMMUNIZATION CODE SET: | | | | | |
|----------------------------------|-----------|---|---|--|--|
| Service | Code Type | Code Description | | | |
| Flu | СРТ | 90688 | Influenza Virus Vaccine Quadrivalent (II4V) Split Virus, 0.5 mL dosage, for Intramuscular Use | | |
| Flu | СРТ | 90689 | Influenza virus vaccine quadrivalent (IIVA) inactivated adjuvanted | | |
| Flu | СРТ | 90756 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use | | |
| Flu | HCPCS | G0008 | Administration Of Influenza Virus Vaccine | | |
| Meningococcal Conjugate | СРТ | 90619 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent tetanus toxoid carrier (MenACWY-TT), for intramuscular use | | |
| Meningococcal Conjugate | СРТ | 90733 Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use | | | |
| Meningococcal Conjugate | СРТ | 90734 | Meningococcal Conjugate Vaccine Serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), For Intramuscular Use | | |
| Tdap | СРТ | 90715 | Tetanus Diphtheria Toxoids And Acellular Pertussis Vaccine (Tdap) When Administered To Individuals 7 Years Or Older For Intramuscular Use | | |
| HPV | СРТ | 90649 | Human Papilloma Virus (HPV) Vaccine Types 6 11 16 18 Quadrivalent (4vHPV), two or three Dose Schedule, For Intramuscular Use | | |
| HPV | СРТ | 90650 | Human Papilloma Virus (HPV) Vaccine Types 16, 18 bivalent (2vHPV) two or three Dose Schedule, For Intramuscular Use | | |
| HPV | СРТ | 90651 | Human Papilloma Virus Vaccine 6 11 16 18 31 33 45 52 58, nonavalent (9vHPV) two or three Dose Schedule, For Intramuscular Use | | |

Adult Influenza Vaccine Administration (\$25)

Service Description: Quality bonus payment to a Provider for each adult influenza vaccine administered for Members 19 years of age and older.

- Payment based on antigen administered
- Payment to each rendering Provider who administered the adult influenza vaccine
- Effective dates of service 1/1/2024-12/31/2024
- One payment per Member per flu season (January through June and July through December)
- One payment per Member per date of service allowed
- Provider must bill the antigen code for the antigen being administered

| ADULT INFLUENZA VACCINE CODE SET: | | | | | | |
|-----------------------------------|--------------|-------|---|--|--|--|
| Service | Code Type | Code | Code Description | | | |
| Flu Vaccine | СРТ | 90630 | Influenza Virus Vaccine, Quadrivalent (Iiv4), Split Virus, Preservative Free, For Intradermal Use | | | |
| Flu Vaccine | CPT | 90653 | Influenza Vaccine, Inactivated (Iiv), Subunit, Adjuvanted, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90654 | Influenza Virus Vaccine, Trivalent (Iiv3), Split Virus, Preservative-Free, For Intradermal Use | | | |
| Flu Vaccine | СРТ | 90656 | Influenza Virus Vaccine, Trivalent (Iiv3), Split Virus, Preservative Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90658 | Influenza Virus Vaccine, Trivalent (Iiv3), Split Virus, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | CPT | 90660 | Influenza Virus Vaccine, Trivalent, Live (Laiv3), For Intranasal Use | | | |
| Flu Vaccine | СРТ | 90661 | Influenza Virus Vaccine, Trivalent (Cciiv3), Derived From Cell Cultures, Subunit, Preservative And Antibiotic Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90662 | Influenza Virus Vaccine (Iiv), Split Virus, Preservative Free, Enhanced Immunogenicity Via Increased Antigen Content, For Intramuscular Use | | | |
| Flu Vaccine | CPT | 90672 | Influenza Virus Vaccine, Quadrivalent, Live (Laiv4), For Intranasal Use | | | |
| Flu Vaccine | СРТ | 90673 | Influenza Virus Vaccine, Trivalent (Riv3), Derived From Recombinant Dna, Hemagglutinin (Ha) Protein Only, Preservative And Antibiotic Free, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90674 | Influenza Virus Vaccine, Quadrivalent (Cciiv4), Derived From Cell Cultures, Subunit, Preservative And Antibiotic Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90682 | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use | | | |
| Flu Vaccine | СРТ | 90686 | Influenza Virus Vaccine, Quadrivalent (Iiv4), Split Virus, Preservative Free, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90688 | Influenza Virus Vaccine, Quadrivalent (Iiv4), Split Virus, 0.5 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90689 | Influenza Virus Vaccine Quadrivalent (Iiv4), Inactivated, Adjuvanted, Preservative Free, 0.25 Ml Dosage, For Intramuscular Use | | | |
| Flu Vaccine | СРТ | 90694 | Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use | | | |
| Flu Vaccine | СРТ | 90756 | Influenza Virus Vaccine, Quadrivalent (Cciiv4), Derived From Cell Cultures, Subunit, Antibiotic Free, 0.5ml Dosage, For Intramuscular Use | | | |

Blood Lead Screening (\$25)

Service Description: Quality bonus payment to a Provider for completing a blood lead service screening in their office for children up to 2 years of age.

- Payment to each rendering Provider for each blood lead screening on or before the Member's second birthday
- Effective dates of service 1/1/2024-12/31/2024
- One payment per Member per date of service allowed
- Blood lead tests will not be excluded if a child is diagnosed with lead toxicity
- Provider must bill blood lead screening code

| BLOOD LEAD SCREENING CODE: | | | | | |
|---|-----|-------|------|--|--|
| Service Code Type Code Code Description | | | | | |
| Blood Lead Screening | СРТ | 83655 | Lead | | |

Dental Fluoride Varnish (\$25)

Service Description: Quality bonus payment to a Provider when oral fluoride varnish application is rendered to children 6 months through 5 years of age (6 months-5.99 years of age).

- Payment to each rendering Provider for each occurrence of dental fluoride application
- Effective dates of service 1/1/2024-12/31/2024
- Up to four payments per Member per Provider per year
- One payment per Member per date of service allowed
- Provider must bill one fluoride varnish code

| DENTAL FLUORIDE VARNISH CODES: | | | | | |
|--------------------------------|-----------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Fluoride Varnish | СРТ | 99188 | Application of topical fluoride varnish by a physician or other qualified health care professional | | |
| Fluoride Varnish | CDT | D1206 | Topical fluoride varnish; therapeutic application for moderate to high caries risk patients | | |
| Fluoride Varnish | CDT | D1208 | Topical Application of fluoride – excluding varnish | | |

Tobacco Use Screening (\$25)

Service Description: Quality bonus payment to a Provider for tobacco use screening and counseling provided to Members 12 years of age and older.

- Payment to Provider who renders tobacco use screening to Members
- Effective dates of service 1/1/2024-12/31/2024
- One payment per Member per Provider per year allowed
- Provider must bill one tobacco use screening code

| TOBACCO USE SCREENING CODES: | | | | | |
|------------------------------|------------|-------|--|--|--|
| Service | Code Type | Code | Code Description | | |
| Tobacco Use Screening | СРТ | 99406 | Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes | | |
| Tobacco Use Screening | СРТ | 99407 | Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes | | |
| Tobacco Use Screening | CPT-CAT-II | 4004F | Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD) | | |
| Tobacco Use Screening | CPT-CAT-II | 1036F | Current tobacco non-user (CAD, CAP, COPD, PV) (DM) (IBD) | | |



PENALTY MEASURES

Penalty Measures

Provider payment models have been evolving away from traditional fee-for-service and moving toward payments for quality and value. Frameworks supporting alternative payment models have been developed by the Centers for Medicare and Medicaid Services (CMS) and the Department of Healthcare Services (DHCS). IEHP is committed to investing in alternative payment models that pay for quality and provide value. In the spirit of evolving our alternative payment models, IEHP includes "risk" as a component in the Global Quality P4P Program. This movement will focus on measures that:

- Are within a Provider's scope of care and influence
- Are within a Provider's control and influence
- Bring value to the organization

IEHP will be including two penalty measures in the Global Quality P4P Program for 2024:

- PCP Encounter Data Rate
- Customer Service Grievance

Both measures represent processes within the PCP practice that are within the control of the Provider. These measures will be structured in a way that a Provider's performance will be compared to a pre-determined target for the measurement period. Provider performance that meets or exceeds the target will result in no penalty or "risk". Alternatively, Provider performance that falls below the established target will result in a financial penalty. The financial penalty will be taken from the Provider's incentive earnings for the same measurement period. Financial penalties will not exceed the value of the incentive earnings within the measurement period.

Financial penalties for the 2024 program year will be capped at no more than \$0.50 PMPM. Please see Appendix 8 for penalty details.

APPENDIX 8: 2024 PCP Global Quality P4P Quality Penalty Measures

| 2024 GQ P4P PCP PENALTY MEASURE LIST | | | | |
|--------------------------------------|-----|-------|--|--|
| Measure Name Population Goal | | | | |
| PCP Encounter Data Rate - SPD* | All | 3 | | |
| PCP Encounter Data Rate - Non-SPD* | All | 2.5 | | |
| Customer Service Grievance | All | ≤ 3.0 | | |

*SPD: Seniors and Persons with Disabilities; Non-SPD: Non-Seniors and Persons with Disabilities

PCP Encounter Data Rate

Methodology: IEHP-Defined Risk Measure

Measure Description: Percentage of complete, timely and accurate encounter data submitted through standard reporting channels for all PCP services rendered to IEHP Members in the measurement year (2024).

Denominator: All assigned Medi-Cal Members each month of the measurement year (2024). All monthly assigned Members are summed to create the denominator.

Numerator: The sum of all unique PCP encounters (e.g., unique Member, Provider, date of service) in the measurement year (2024) for all assigned Members in the denominator.

Rate: A Per Member Per Year (PMPY) rate is calculated following this formula:

(Total Unique PCP Encounters/Total Member Months) x 12 = PMPY

Measure Support: The purpose of the IEHP PCP Encounter Data Rate measure is to ensure IEHP receives adequate PCP encounter data from IEHP-contracted Medi-Cal Providers. Encounter data is important to performance scoring and is essential to the success of the GQ P4P Program.

Customer Service Grievance

Methodology: IEHP – Defined Risk Measure

Measure Description: IEHP strives to improve and maintain customer satisfaction for IEHP Members as defined in the IEHP Member Handbook under Member's Rights and Responsibilities: "Be treated with respect, fairness, and courtesy. IEHP recognizes your dignity and right to privacy" (Ma_22A). This measure will assess the rate of IEHPs Member dissatisfaction with their assigned Primary Care Provider (PCP) office in the measurement year (2024). The following criteria will define the Member's dissatisfaction:

Member Dissatisfaction: Member is not happy with the service received from their assigned PCP, and/or the office staff, that is not related to dissatisfaction regarding the quality of care/medical treatment received. This includes, but is not limited to:

- Tone and manner that information is presented to the Member by the assigned PCP office staff.
- Negative verbal interactions between a Member and the assigned IEHP PCP and/or office staff.

Denominator: Total Membership in the measurement year (2024).

Numerator: Count of customer service grievances in the measurement year (2024) against the PCP and/or PCP office staff.


Exclusion Criteria: Reference to dirty carpet, color of the walls, office décor and/or anything not related to Provider/office staff and Member interaction.

Goal: Customer service grievance rate of \leq 3.0 PTMPY



APPENDIX 10: Historical Data Form

The IEHP Historical (Hx) Data Form is located in the secure Provider Portal. Providers seeking to submit medical records to close quality gaps in care can enter Member information and upload documentation via an online process. As a reminder, this process should be utilized for the submission of visits, procedures, or services that cannot be submitted via claims or encounters (e.g., services received prior to IEHP Membership, historical surgical procedures, etc.). Please see below for more details.



NOTE: All Historical Data submissions for the 2024 performance year must be submitted to IEHP no later than December 31, 2024.



APPENDIX 11: Member Satisfaction Survey



IEHP 2024 MEDI-CAL ADULT MEMBER SATISFACTION SURVEY

| SU | RVEY INSTRUCTIONS | 5. | In the last 6 months, how often did your | |
|--|--|----|---|--|
| • A | Answer each question by marking the box to ne left of your answer. | | personal doctor spend enough time with you? | |
| ◆ You are sometimes told to skip over some questions in this survey. When this happens you will see an arrow with a note that tells you what question to answer next, like this: | | | NeverSometimesUsuallyAlways | |
| | | 6. | In the last 6 months, how often did you and your personal doctor talk about all the prescribed medicines you take? | |
| YO | UR PERSONAL DOCTOR | | ☐ Never | |
| ; | A personal doctor is the one you would see if you need a check-up, want advice about a health problem, or get sick or hurt. Do you have a personal doctor? | | ☐ Sometimes☐ Usually☐ Always | |
| | ☐ Yes ☐ No → If No, Go to Question 14 | 7. | In the last 6 months, when you had a scheduled visit with your doctor, did he or she have your health records or other | |
| ı | In the last 6 months, how often did your personal doctor explain things in a way that was easy to understand? | | facts about your care? Never Sometimes | |
| | NeverSometimesUsuallyAlways | | ☐ Usually ☐ Always | |
| | | 8. | In the last 6 months, did your doctor order a blood test, x-ray or other test for you? | |
| | In the last 6 months, how often did your personal doctor listen carefully to you? | | ☐ Yes ☐ No → If No, Go to Question 10 | |
| | ☐ Never☐ Sometimes☐ Usually☐ Always | | In the last 6 months, when your doctor ordered a blood test, x-ray or other test for you, how often did someone from your doctor's office give you those results? | |
| ı | In the last 6 months, how often did your personal doctor show respect for what you had to say? | | □ Never □ Sometimes □ Usually | |
| | NeverSometimesUsually□ Always | | Always | |



APPENDIX 11: Member Satisfaction Survey (continued)

| 10. | 10. Would you send a friend to see your doctor? | | When you answer the next questions, include the care you got in person, by phone, or by video. Do not include dental visits or care you got when you | | |
|-----|---|-----|---|--|--|
| 11. | ☐ Yes ☐ No 11. Using any number from 0 to 10, where 0 is the worst personal doctor possible and 10 is the best personal doctor possible, what number would you use to rate your "personal doctor"? Worst personal Best personal doctor possible | | | | |
| | | | Specialists are doctors like surgeons, heart doctors, allergy doctors, skin doctors, and other doctors who specialize in one area of health care. In the last 6 months, did you make any | | |
| | 0 1 2 3 4 5 6 7 8 9 10 | | appointments with a specialist? ☐ Yes ☐ No → If No, Go to Question 18 | | |
| Y | LERKS AND RECEPTIONISTS AT DUR PERSONAL DOCTOR'S OFFICE In the last 6 months, how often were | 15. | In the last 6 months, how often did you get an appointment with a specialist as soon as you needed? | | |
| | clerks and receptionists at your personal doctor's office as helpful as you thought they should be? | | □ Never □ Sometimes □ Usually | | |
| | □ Never □ Sometimes □ Usually | 16. | ☐ Always How many specialists have you talked to in the last 6 months? | | |
| 13. | Always 3. In the last 6 months, how often did clerks and receptionists at your personal doctor's office treat you with courtesy and respect? | | None → If None, Go to Question 18 1 specialist 2 3 | | |
| | ☐ Never ☐ Sometimes | | 4 5 or more specialists | | |
| | Usually Always | 17. | We want to know your rating of the specialist you talked to most often in the last 6 months. Using any number from 0 to 10, where 0 is the worst specialist possible and 10 is the best specialist possible, what number would you use to rate that specialist? | | |
| | | | Worst specialist possible Best specialist possible | | |
| | | | 0 1 2 3 4 5 6 7 8 9 10 | | |

YOUR ACCESS TO CARE IN THE LAST 6 MONTHS

| These questions ask about your own health care. Do <u>not</u> include care you got when you stayed overnight in a hospital. Do <u>not</u> include the times you went for dental care visits. | | | ☐ Never☐ Sometimes☐ Usually | |
|---|--|-----|--|--|
| 18. | In the last 6 months, did you have an illness, injury, or condition that <u>needed</u> <u>care right away</u> in a clinic, emergency room, or doctor's office? | 24. | Always In the last 6 months, when you needed after-hours care, what did you do? | |
| | ☐ Yes☐ No → If No, Go to Question 20 | | ☐ Called IEHP Nurse Advice Line☐ Called my personal doctor's office☐ Went to the Urgent Care | |
| 19. | In the last 6 months, when you needed care right away, how often did you get care as soon as you needed? | | | |
| | ☐ Never ☐ Sometimes | 25. | In the last 6 months, did you take any prescribed medicine? | |
| | ☐ Usually ☐ Always | | ☐ Yes ☐ No. Go to Question 28 | |
| 20. | In the last 6 months, did you make any appointments for a <u>check-up or routine</u> <u>care</u> at a doctor's office or clinic? | 26. | In the last 6 months, how often was it easy to get your prescribed medicine? | |
| | ☐ Yes ☐ No → If No, Go to Question 22 | | ☐ Never ☐ Sometimes | |
| 21. | In the last 6 months, how often did you get an appointment for a check-up or routine care at a doctor's office or clinic as soon as you needed? | | ☐ Usually ☐ Always | |
| | | 27. | In the last 6 months, how often were your prescriptions not ready for you at the | |
| | ☐ Never ☐ Sometimes | | pharmacy due to an issue with IEHP's Prior Authorization process? | |
| | Usually Always | | ☐ Never ☐ Sometimes | |
| 22. | In the last 6 months, did you need care after normal office hours? | | ☐ Usually ☐ Always ☐ Don't know | |
| | ☐ Yes☐ No → If No, Go to Question 25 | 28. | In the last 6 months, did you try to get information or help about prescriptions from IEHP's customer service? | |
| | | | □ Yes | |

23. In the last 6 months, how often was it easy to get the after-hours care you

☐ No → If No, Go to Question 31

thought you needed?



APPENDIX 11: Member Satisfaction Survey (continued)

| 29. | In the last 6 months, how often did IEHP's customer service give you the information or help you needed about prescription drugs? | | Using any number from 0 to 10, where 0 is the worst health care possible and 10 is the best health care possible, what number would you use to rate all your health care in the last 6 months? |
|-----|---|-----------------------|--|
| | NeverSometimesUsuallyAlways | | Worst health care possible care possible 0 1 2 3 4 5 6 7 8 9 10 |
| 30. | In the last 6 months, how often did IEHP's customer service staff treat you with courtesy and respect when you tried to get information or help about prescription drugs? | INL | UR HEALTH PLAN: AND EMPIRE HEALTH PLAN (IEHP) next questions ask about your experience with |
| | NeverSometimesUsuallyAlways | your I 35 . | In the last 6 months, did you get information or help from IEHP's customer service? |
| 31. | In the last 6 months, did you get care from a doctor or other health provider besides your personal doctor? | | ☐ Yes ☐ No → If No, Go to Question 38 |
| | ☐ Yes ☐ No → If No, Go to Question 33 | | In the last 6 months, how often did IEHP's customer service give you the information or help you needed? |
| 32. | In the last 6 months, how often did your personal doctor seem informed and upto-date about the care you got from these doctors or other health providers? | | NeverSometimesUsuallyAlways |
| | NeverSometimesUsually | 37. | In the last 6 months, how often did IEHP's customer service staff treat you with courtesy and respect? |
| 33. | In the last 6 months, how often was it easy to get the care, tests, or treatment you needed? | | NeverSometimesUsuallyAlways |
| | NeverSometimesUsuallyAlways | | Using any number from 0 to 10, where 0 is the worst health plan possible and 10 is the best health plan possible, what number would you use to rate your health plan? |
| | | | Worst health Best health plan possible 0 1 2 3 4 5 6 7 8 9 10 |

| AE | BOUT YOU | 45. | What is your current gender identity? |
|----------------|--|-----|---|
| 39. 40. | In general, how would you rate your overall health? Excellent Very good Good Fair Poor In general, how would you rate your overall mental or emotional health? Excellent | | ☐ Female ☐ Transgender Female/Transgender ☐ Girl/Transgender Woman/Male-to-Female (MTF) ☐ Male ☐ Transgender Male/Transgender Boy/Transgender Man/Female-to-Male (FTM) ☐ Non-binary ☐ Other: Prefer to self-describe: |
| | ☐ Very good | | Prefer not to say |
| | ☐ Good ☐ Fair | | What is the highest grade or level of school that you have completed? |
| 41. | ☐ Poor Have you had either a flu shot or flu spray in the nose in the past 12 months? | | 8th grade or less Some high school, but did not graduate High school graduate or GED |
| | ☐ Yes ☐ No ☐ Don't Know | | ☐ Some college or 2-year degree ☐ 4-year college graduate ☐ More than 4-year college degree |
| 42. | includes smoking, vaping, or using | 47. | Are you of Hispanic or Latino origin or descent? |
| | chewing tobacco. ☐ Yes | | ☐ Yes, Hispanic or Latino☐ No, Not Hispanic or Latino |
| | ☐ No → If No, Go to Question 45 | | What is your race? Mark one or more. |
| 43. | In the last 6 months, how often were you advised to quit smoking or using tobacco by a doctor or other health provider in your plan? Never Sometimes Usually Always | 49. | White Black or African-American Asian Native Hawaiian or other Pacific Islander American Indian or Alaska Native Other How would you like to get health |
| 44. | Are you planning to quit using tobacco? | | information from your health plan about how to stay healthy? Select all that apply. |
| | ☐ Yes ☐ No | | ☐ Email ☐ Text ☐ Mobile application ☐ Website ☐ Social media (e.g., Facebook, |



APPENDIX 11: Member Satisfaction Survey (continued)

| 50. | Some health plans help with nonmedical concerns, like housing, food, financial, and social isolation issues. In the last 6 months, did you talk with your personal doctor or someone from your health plan about getting help for any of these issues? | | | | | |
|--|--|--|--|--|--|--|
| | ☐ Yes ☐ No | | | | | |
| 51. | Did someone help you complete this survey? | | | | | |
| | ☐ Yes ☐ No → Thank you. Please return the completed survey in the postage-paid envelope. | | | | | |
| 52. | How did that person help you? (Mark one or more) | | | | | |
| | ☐ Read the questions to me ☐ Wrote down the answers I gave ☐ Answered the questions for me ☐ Translated the questions into my language ☐ Helped in some other way | | | | | |
| Thank you for participating in our survey! Please mail the survey back in the enclosed postage-paid, self-addressed reply envelope or send to: Press Ganey • P.O. Box 7315 South Bend, IN 46699-0488 | | | | | | |
| | If you have any questions, please call 1-888-797-3605. | | | | | |



PROVIDER RELATIONS TEAM

(909) 890-2054 Monday-Friday, 8am-5pm

Follow us:

